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ABSTRACT 
 
EMILY B. ASKEW: Mechanisms that Regulate Androgen Receptor Transcriptional Activity 
(Under the direction of Elizabeth M. Wilson, Ph.D.) 
 
 
Testosterone (T) and dihydrotestosterone (DHT) are natural ligands for the androgen 
receptor (AR), an intracellular transcription factor and nuclear receptor. DHT is a more 
potent androgen than T in vivo. In this study, the mechanistic basis for the differential effects 
of T and DHT on AR activity was investigated. Dissociation kinetics, motif binding affinity 
and activation function 2 (AF2) transactivation measurements reveal that the slow 
dissociation of DHT relative to T from AR results from weaker T-induced AR FXXLF motif 
binding to the AF2 site. T acquires DHT-like activity when the AR ligand binding domain 
(LBD) contains the H874Y somatic prostate cancer mutation that results in the formation of 
direct hydrogen bonds between external and core helices 4 and 5, improving AF2 motif 
binding. The studies reveal that DHT better stabilizes the AR LBD core from the ligand 
binding pocket to the AF2 surface for maximal AR transactivation. 
To further define the mechanisms whereby the AR specific coregulator melanoma 
antigen gene protein-A11 (MAGE-11) modulates AR activity, we pursued observations that 
MAGE-11 increases AR transcriptional activity independent of AF2. We sought to 
characterize the effects of MAGE-11 and the coactivators transcription intermediary factor 2 
(TIF2) and p300 on AR transcriptional activity. The site of interaction in MAGE-11 that 
binds the AR FXXLF motif is an F-box within the MAGE homology domain. MAGE-11 Ser-
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174 is phosphorylated by MAP kinase which influences the interaction of the MAGE-11 F-
box with AR. MAGE-11 forms a complex with TIF2 and p300 to modulate AR 
transactivation independent of AF2. This research provides evidence for a novel function for 
an F-box protein in which F-box/FXXLF like motif interactions modulate AR transcriptional 
activity in the absence and presence of ligand.  
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CHAPTER 1 
 
INTRODUCTION  
 
The Androgen Receptor 
 
Molecular Structure and Androgen Receptor (AR) N/C Interaction-The AR is a 
ligand activated transcription factor and member of the steroid and nuclear receptor 
superfamily (1). The AR gene is located at Xq11-12 (2), is more than 90 kb (3) and codes for 
a 919 amino acid protein. As with other nuclear receptor family members, the AR has a 
multi-domain structure composed of an NH2-terminal transactivation domain, central DNA 
binding domain (DBD), linker hinge region and carboxyl-terminal ligand binding domain 
(LBD) (4) (Fig.1-1). AR is expressed in androgen target tissues including the prostate, 
skeletal muscle, central nervous system and liver, with highest levels in prostate, adrenal 
gland and epididymis (5).   
Androgen-induced transcriptional activity depends on activation function 1 (AF1) 
within the unstructured NH2-terminal region (4), and the activation function 2 (AF2) 
hydrophobic interface in the LBD that is stabilized by androgen binding (6). AR is unique 
among other family members based on the presence of a strong androgen-dependent AR 
NH2-and carboxyl-terminal AR (N/C) interaction between the AR 
23
FQNLF
27
 FXXLF motif 
within the AR NH2-terminal domain and AF2 in the LBD (6-10). The AR N/C interaction is 
required for AR transactivation of certain androgen-regulated genes, including prostate-
specific antigen (PSA) and probasin (11-14).  
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Agonist potency at low physiological androgen concentrations is facilitated by the 
AR N/C interaction, which was previously shown through transcription, dimerization and 
DNA binding assays (15). The androgen-dependent AR N/C interaction slows dissociation of 
bound androgen (16) and stabilizes AR binding of androgen response element DNA (9). The 
functional significance of the AR N/C interaction is demonstrated by patients with the 
androgen insensitivity syndrome, in which defects in AR residues that modulate the AR N/C 
interaction result in incomplete masculinization despite normal androgen binding kinetics 
(8,10,17-19). 
Androgen Receptor Activation by Testosterone (T) and Dihydrotestosterone (DHT)-T 
is synthesized from cholesterol in the Leydig cells of the testis in response to luteinizing 
hormone secretion from the anterior pituitary gland. T is the major male circulating hormone 
and, unlike DHT, has a double bond in ring A between carbons four and five. On average, 
adult men produce 3-10 mg of T daily and have circulating levels ranging from 300-700 
ng/dL (5). In the prostate, approximately 90% of free T within cells is irreversibly converted 
to DHT by the 5α-reductase type 2 enzyme (Fig. 1-2) (20). 
Male organ development is modulated by T and DHT binding to AR. During 
embryogenesis, T mediates the development and differentiation of the Wolffian ducts into 
seminal vesicles, epididymis and vas deferens (21), while DHT is required for the 
differentiation of the urogenital sinus into the prostate, urethra, penis and scrotum (22). Post-
natally, T is the major androgen in muscle (23) while DHT is primarily responsible for 
androgen-mediated events of male sexual maturation at puberty, including growth of facial 
and body hair and maturation of the external genitalia (24). The physiological importance of 
DHT is evident in patients with steroid 5α-reductase deficiency in which affected males 
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present with external female genitalia at birth due to the decreased ability to convert T to 
DHT (21,22,24). 
In contrast to other steroid hormone receptors, AR binds both T and DHT with 
similar equilibrium binding affinity (25). High affinity binding of T and DHT to AR depends 
on hydrophobic and electrostatic interactions as well as hydrogen bonds to critical residues in 
the AR ligand binding pocket (6,26), and results in approximately a 6-fold increase in AR 
stability (27). T dissociates three times faster from AR than DHT (25). Furthermore, there is 
no evidence that T and DHT activate different gene targets. In support of this, previously 
published studies report that T is as effective as DHT in regulating AR gene mediated 
transcription when present at high concentrations. In particular, Grino et al. showed that a 10 
fold higher concentration of T than DHT results in AR mediated transactivation in fibroblasts 
derived from a patient with 5α-reductase deficiency (28). Additionally, Deslypere et al. found 
that both T and DHT increased AR induced mouse mammary tumor virus chloramphenicol 
acetyltransferase (MMTV-CAT) activity in Chinese hamster ovary cells unable to convert T 
to DHT. DHT was 10 fold more potent than T (23).   
Androgen Action in Castration-Recurrent Prostate Cancer-Androgens are required 
for growth of the prostate and have a role in the pathogenesis of prostate cancer (29), the 
second most common form of cancer in American men. The mainstay treatment for prostate 
cancer is androgen deprivation therapy that removes testicular androgens through physical or 
chemical castration, leading to the regression of the prostate cancer tumor (20). Prostate 
cancer recurs within 18-20 months despite aggressive treatment in a majority of cases (30).   
AR signaling remains a growth-promoting pathway in castration-recurrent prostate 
cancer, and data indicate the presence of residual androgens in castration-recurrent prostate 
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cancer specimens. Belanger et al. reported that intraprostatic DHT levels remain at 40% after 
the removal of testicular androgen (31), while another report found that DHT levels in 
prostate of cancer patients that had previously undergone androgen deprivation therapy 
remained at 25% of their original concentration before treatment (32). The level of DHT 
required for growth stimulation of recurrent prostate cancer is four orders of magnitude lower 
than required by androgen-dependent prostate carcinoma cells (33,34), suggesting that DHT-
mediated stimulation of the AR contributes to the progression and growth of castration-
recurrent prostate cancer.   
T levels persist in castration-recurrent prostate cancer tissue at concentrations similar 
to benign prostatic hyperplasia (35), potentially contributing to the growth of recurrent 
prostate cancer cells that undergo recurrent growth after androgen withdrawal therapy. AR 
prostate cancer somatic mutations that slow the dissociation rate of T may also facilitate 
growth of castration-recurrent prostate cancer through AR-associated mechanisms including 
increased AR stability, increased retention time of bound androgen and increased FXXLF and 
LXXLL motif binding to AR AF2 (36).   
It is of clinical importance to elucidate the molecular determinants for the differential 
effects of T and DHT in normal prostate and prostate carcinoma in order to develop more 
targeted drug therapies to combat prostate cancer development and post castration-
recurrence.    
Regulation of AR AF2 Activity-AR AF2 is a hydrophobic cleft in the LBD formed by 
helices 3, 3’, 4, and 12 (1) that was first recognized as a coactivator binding site in the 
thyroid hormone receptor using scanning surface mutagenesis by Feng et al. (37). This study 
was later supported by observations of AF2 in crystal structures of the glucocorticoid 
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receptor LBD bound to dexamethasone and LXXLL coactivator motif peptide, as well as the 
peroxisome proliferator-activated receptor-γ LBD bound to rosiglitazone and LXXLL motif 
peptide (38,39). In the AR, androgen binding stabilizes helix 12 to complete the AF2 
hydrophobic cleft that interacts with LXXLL-related motifs (1,36,40).   
AR FXXLF and SRC/p160 coactivator LXXLL motifs bind the same AR AF2 site (6). 
AR FXXLF motif binding to AF2 in the AR N/C interaction competitively inhibits the 
interaction of AF2 with the LXXLL motifs of SRC/p160 coactivators (27). The interaction of 
the AR FXXLF motif with AF2 involves the binding of a conserved α-amphipathic helix with 
the hydrophobic surface of AF2 in a similar fashion to the interaction of the LXXLL motifs of 
SRC/p160 coactivators with the AR AF2 docking surface. Charge patches bordering AF2 
align with oppositely charged residues flanking the FXXLF or LXXLL motif sequences (1). 
AR FXXLF motif hydrogen bonds to AR charge clamp residues Glu-897 and Lys-720 while 
the LXXLL motifs of SRC/p160 coactivators lack the charge clamp bond to AR residue Glu-
897 but retain the hydrogen bond to AR charge clamp residue Lys-720 (1). 
Transcriptional activity from AR AF2 is influenced not only by androgen binding and 
the AR N/C interaction, but also by cofactors that are often expressed at high levels in 
cancer. For example, the amplified in breast cancer-1 coactivator (AIB1) is overexpressed 
and interacts with the estrogen receptor, leading to increased estrogen regulated gene 
transcription in breast cancer (41). A majority of recurrent prostate cancer tissue specimens 
express high levels of TIF2 and steroid receptor coactivator-1 (SRC1) (42) while the AR 
coactivator ARA-70 enhances transcription of androgen-responsive genes in the DU145 
metastatic prostate cancer cell line (43). In agreement with these findings, Linja et al. 
reported that the SRC1 gene is amplified in the LuCaP70 prostate cancer xenograft 
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established from a hormone-refractory prostate carcinoma (44). Furthermore, the AR specific 
coregulator, melanoma antigen gene protein-A11 (MAGE-11) of the MAGEA gene 
subfamily, increases ligand mediated AF2 activity and is expressed in AR positive prostate 
cancer cell lines (45). LXXLL motif interactions are enhanced at the AF2 interaction surface 
upon androgen binding when MAGE-11 binds the AR FXXLF motif and inhibits the 
formation of the AR N/C interaction (45,46).   
Somatic AR Prostate Cancer Mutations- Prostate cancer accounts for approximately 
10% of cancer-related deaths in men (47). The American Cancer Society estimates that there 
were approximately 192,280 new cases of prostate cancer in the United States in 2009 and 
27,360 deaths. In initial and intermediate stages, androgen-dependent prostatic tumors are 
treated with androgen ablation therapy, which ceases to be effective over time, leading to 
castration-recurrent prostate cancer.   
Evidence suggests that the AR plays a role in mediating castration-recurrent growth 
of prostate cancer. AR protein levels are similar in androgen-dependent and castration-
recurrent prostate cancer, in association with the expression of AR-regulated genes in 
castration-recurrent prostate cancer (48). AR mutation or overexpression (49,50), altered 
expression or activity of coregulators (42) and growth factor signaling leading to AR 
phosphorylation (34) can also influence AR activity in castration-recurrent prostate cancer 
cells. 
AR AF2 motif interactions are altered by somatic AR prostate cancer mutations 
which affect communication with the ligand binding pocket (36). Somatic AR mutations in 
prostate cancer are most often functional, suggesting positive selection for prostate tumor cell 
survival. AR is more sensitive to low levels of physiologic ligand and/or activated by an 
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increased number of ligands that bind to the AR ligand binding pocket (20,51-54). For 
example, the prostate cancer somatic mutant AR-V730M increases AF2 binding of SRC1 
(6,36), while the castration-recurrent prostate cancer mutation V715M increases AR 
transactivation in the presence of TIF2 without modifying androgen equilibrium binding 
affinity (36).  
Another prostate cancer somatic mutation is the AR histidine to tyrosine mutation at 
amino acid 874. His-874 is located in AR helix 10 above rings C and D of the bound 
androgen, proximal to the ligand binding pocket and AF2. The AR-H874Y recurrent prostate 
cancer mutation was identified in the human prostate cancer CWR22 xenograft isolated from 
a patient with a bone marrow metastases who was treated with flutamide and a luteinizing 
hormone releasing hormone agonist (55). This CWR22 mutant AR is responsive to the 
antiandrogen hydroxyflutamide, dehydroepiandrosterone, estradiol and progesterone (55), 
while retaining similar binding affinities for T and DHT (36,54-56). The synthetic androgen 
R1881 has a two-fold slower dissociation rate from AR-H874Y than from wild-type AR (36).  
AR-H874Y increases AR functional activity which likely favors prostate cancer cell survival 
and expansion through mechanisms including increased retention time of bound androgen, 
SRC/p160 coactivator recruitment, AR stability and AR AF2 activity.   
It is critical to determine the mechanism whereby residues proximal to the ligand 
binding pocket and AF2 regulate hormone binding, AR activity and AF2 motif binding in 
both normal prostate and castration-recurrent prostate cancer in order to develop new drug 
therapies that disrupt AR-mediated gene signaling in cancer development and progression.  
Effect of Endocrine-Disrupting Chemicals on AR Transcriptional Activity-Since 
evidence from epidemiological studies, animal studies and in vitro analysis indicates that 
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endocrine-disrupting compounds can influence AR activity (57), it is critical to understand 
the molecular basis for AR regulated gene expression. In fact, risk assessment for endocrine 
disrupting chemicals includes several key areas, such as biological half-life and exposure 
levels in addition to the activity and binding kinetics for AR (58). Thus, an in depth 
characterization into the mechanisms underlying AR transcriptional activity which focus on 
hormone binding and coregulator interactions is critical for the complete understanding of the 
molecular effects of xenobiotics on AR. Therefore, the studies presented here in this 
dissertation may provide a framework for exploring how endocrine active substances in the 
environment affect health in humans and animals by altering AR structure and function in 
normal physiology and disease.  
Vinclozolin is a fungicide whose two metabolites, M1 and M2, have antiandrogenic 
properties and compete with T and DHT for binding of the AR and block AR mediated gene 
activation in males, resulting in physical abnormalities (59-62). Gray et al. showed that 
perinatal exposure of rodents to vinclozolin caused impaired ejaculation, hypospadias and 
ectopic scrotum (63). While the pesticide 1,1,1-trichloro-2,2-bis (p-chlorophenyl) ethane 
(DDT) is known to be an environmental estrogen that binds to estrogen receptor α and β (64), 
its major metabolite, 1,1-dichloro-2,2-bis(p-chlorophenyl) ethylene (DDE) (65), has 
antiandrogen properties (59,64). DDE inhibits AR binding of androgen as indicated by 
competitive binding assays, and androgen-induced AR transactivation is blocked by DDE 
(64).  
 One source of an endocrine active substance in the environment is the synthetic 
androgen trenbolone acetate excreted from cattle given anabolic steroids to improve beef 
production (66,67). Trenbolone acetate was found to have a potency similar to DHT and the 
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synthetic androgen R1881 (66). Whole-water samples obtained from feedlot runoff, which 
contain the trenbolone acetate metabolites 17α- and 17β-trenbolone, elicited an androgenic 
response (67). In the environment, exposure of female mosquitofish to 17β-trenbolone 
resulted in masculinization (68), while masculinization of female mosquitofish downstream 
of paper mill effluent correlated with the presence of the androgen precursor progesterone, 
which is naturally present in the loblolly pine (69).   
 Diadzein is another potential environmental contaminant with androgenic properties. 
Diadzein is an isoflavone, and was previously found to have activity for the rat estrogen 
receptor α and β (70). Chen et al. found that even though it is a known phytoestrogen, 
diadzein can also elicit androgen effects in PC-3 and LNCaP prostate cancer cells transfected 
AR and/or the AR coactivators ARA55 and ARA70 (71).   
Overall, research directed at understanding the basic mechanisms underlying the 
fundamental key processes and target molecules in AR gene mediated reproduction and 
development is vital since the reproductive system is affected by androgenic and 
antiandrogenic factors present in the environment.   
The Androgen Receptor Coregulator MAGE-11 
MAGE Gene Superfamily-van der Bruggen et al. first reported the discovery of 
MAGE-A1 based on its ability to induce the expression of the tumor antigen MZ2-E in the 
human melanoma cell line, MZ2-MEL3.0 (72-74). Since this original report, MAGE-A1 has 
been detected in specimens of small cell lung cancer, bronchial squamous cell cancer, colon 
carcinoma and chronic and acute myeloid leukemia, yet undetectable in normal tissues of the 
liver, muscle, skin, lung, brain and kidney (72). MAGE-A1 was later discovered to be 1 of 12 
members of the human MAGE-A gene subfamily, from which the other 11 members were 
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identified by using MAGE-A1 sequence to probe cosmid libraries (75,76). The MAGE-A 
gene family is encoded by a 3.5-Mb segment of DNA located at position Xq28 on the X 
chromosome, is found in human and primates (76), and is expressed in tumors, testis and 
placenta (75,77). Additional MAGE gene subfamilies, including MAGE-B, and MAGE-C, 
are also located on the X chromosome at positions Xp21 and Xq26-27, respectively 
(73,74,78). Similar to the MAGE-A subfamily, expression of MAGE-B and MAGE-C is 
absent in normal tissues except for male germ cells and placenta (73,74,78). The remaining 
MAGE gene family members are positioned on chromosomes 3 and 15 in addition to the X 
chromosome, and are part of the MAGE gene subfamilies (73,74).  
To date, a total of 52 known members of the MAGE gene superfamily have been 
identified (73). Analysis of the protein sequence of the MAGE family of proteins highlights a 
region of high homology within the carboxyl-terminus, referred to as the MAGE homology 
domain. Since MAGE genes share sequence similarity within this region, it has been 
suggested that the gene family has undergone rapid evolution, and are products of 
retropositioning and gene duplication (73).  
MAGE-11-AR transcriptional activity at androgen-regulated gene promoters requiring 
the AR N/C interaction is enhanced by the increased expression of the SRC/p160 coactivator 
TIF2 (11). Studies to understand what factors modulate the AR N/C interaction and the 
accessibility of AF2 led to the identification of MAGE-11 as an AR cofactor. MAGE-11 is a 
member of the MAGE-A gene subfamily encoded on the human X chromosome (45).  
MAGE-11 was originally described by De Plaen et al. in cosmid libraries (75), and 
later isolated from human epithelial cervical carcinoma (HeLa) cells by Jurk et al. (79). Even 
though Junk and coworkers reported that MAGE-11 was a 319 residue, 48 kDa protein 
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localized primarily to the nucleus, MAGE-11 is in fact 60-65 kDa (45). MAGE-11 contains 3 
additional upstream exons that code for an additional 110 NH2-terminal residues and has a 
nuclear localization signal that is located within this extended NH2-terminal region, between 
residues 14 and 23 (Fig. 1-3) (45,46,80). The MAGE-11 gene is located on the X 
chromosome at position Xq28 downstream of the AR (45,73-75). The full-length MAGE-11 
gene includes 5 exons, 4 of which are coding exons for a 429 amino acid protein (45). 
MAGE-11 contains the MAGE homology domain between residues 222 and 421 (Fig. 1-3). 
MAGE-11 is an AR specific coregulator expressed in tissues of the human male and 
female reproductive tracts, including testis, ovary, prostate, breast and adrenal gland (45). 
MAGE-11 is expressed in glandular epithelial cell nuclei of the endometrium during the 
window of implantation (81). MAGE-11 mRNA was observed in several cell lines, including 
HeLa, ovarian cancer cells, and prostate cancer cell lines (45).  
The MAGE-11 – AR Interaction and Effect on AR Transcriptional Activity-MAGE-11 
binds the AR NH2-terminal FXXLF motif and relieves repression of AF2 caused by the 
agonist-induced AR N/C interaction, leading to increased accessibility of AF2 to coactivator 
binding (45). Mutational analysis and two-hybrid assays have revealed that the interaction of 
MAGE-11 with the AR 
23
FONLF
27
 FXXLF motif requires AR resides 16-36; however, AF2 
binding of the AR FXXLF motif is dependent on AR residues 20-30 (45). This finding 
suggests this extended region is required for MAGE-11 to effectively compete with AR AF2 
for binding of the AR FXXLF motif in the presence of androgen (45).  
Immunohistochemical evidence reveals that MAGE-11 interacts and stabilizes AR in 
the cytoplasm in the absence of androgen. In the presence of androgen, both proteins 
colocalize to the nucleus (45). Post-translational modification of MAGE-11 induced by 
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epidermal growth factor (EGF) results in the cell cycle checkpoint kinase 1 (Chk1)-
dependent phosphorylation of MAGE-11 Thr-360. Phosphorylation of MAGE-11 at Thr-360 
stimulates the monoubiquitinylation of MAGE-11 residues Lys-240 and 245 that is required 
for the interaction of MAGE-11 with the AR FXXLF motif (46).  
The EGF-induced stabilization of the MAGE-11 – AR – DHT requires 7-10 hours 
exposure of cultured cells to EGF (46). This results in the inhibition of the AR N/C 
interaction, increased recruitment of SRC/p160 coactivators to the AF2 surface and enhanced 
AF2 activity (45,46). MAGE-11 phosphorylation and ubiquitinylation sites are conserved 
throughout the MAGE gene family, allowing one to postulate that the observed regulatory 
mechanism modulating the MAGE-11 – AR FXXLF motif interaction may apply to other 
members of the MAGE superfamily.  
MAGE-11 in Castration-Recurrent Prostate Cancer-AR AF2 function in prostate 
cancer is selectively regulated through several mechanisms, including coactivator binding. 
Castration-recurrent prostate cancer tissue specimens express high levels of TIF2 and SRC1 
which bind to the AF2 site (42). MAGE-11 increases ligand mediated AF2 activity, and 
evidence reveals that MAGE-11 mRNA is found in prostate cancer cell lines that express AR 
(45,46).  
MAGE-11 levels increase during prostate cancer progression in the CWR22 human 
prostate cancer xenograft after androgen deprivation therapy and in approximately 30% of 
castration-recurrent prostate cancer patients, suggesting that MAGE-11 increases AR 
signaling and drives prostate cancer growth (82). AR mRNA levels also increase in the 
CWR22 tumor after castration, albeit to a lesser extent than MAGE-11 (82). MAGE-11 is 
upregulated in prostate cancer xenografts, clinical specimens, and prostate cancer cell lines 
13 
 
by hypomethylation of CpG islands near the MAGE-11 transcription start site (82). Overall, 
the MAGE-11 interaction with AR and its coregulators provides a mechanism for increased 
AR action in castration-recurrent prostate cancer. Thus, it is important to further elucidate the 
MAGE-11 dependent increases in AR transcriptional activity.   
Dissertation Research Objectives 
 The first objective of my dissertation was to elucidate the basis for the differences in 
the ability of T and DHT to increase AR activity through biochemical and crystal structure 
analysis of wild-type AR and a prostate cancer somatic mutant AR-H874Y LBD bound to T. 
An additional research objective was to define the mechanisms whereby MAGE-11 
contributes to ligand-dependent and independent AR transcriptional activity, pursuing 
observations that MAGE-11 increases the constitutive activity of an AR NH2-terminal 
fragment. The effects of MAGE-11 and TIF2 on AR transcriptional activity were 
characterized and the AR FXXLF motif binding site in the MAGE-11 carboxyl-terminal 
region defined.   
 Sequence homology exists between MAGE-11 and the adenovirus early region 
protein 1A (E1A), which binds to the nuclear receptor coactivator and histone 
acetyltransferase p300.  Thus, a further goal was to elucidate the mechanisms of increased 
AR transcriptional activation by MAGE-11 and p300, define and characterize the interaction 
regions within MAGE-11 and p300, and to understand the post-translational modifications by 
p300 which influence AR transcriptional activity.   
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Figure 1-1. Schematic of AR Functional Domains. Diagram of human 919 amino acid 
residues comprised of the NH2-terminal FXXLF motif (
23
FQNLF
27
), activation function 1 
(AF1) (residues 142-337), DNA binding domain (DBD) (residues 559-623) and activation 
function 2 (AF2) in the ligand binding domain (LBD) (residues 671-919).  
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 1-2. Testosterone (T) and Dihydrotestosterone (DHT). AR mediated gene 
expression is controlled by binding of the androgens, T and DHT. T has a double bond at the 
4-5 carbons not present in DHT, the 5α-reducutase metabolite of T.   
 
 
 
                                                                  
 
                                                                 5α-reductase           
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Figure 1-3. MAGE-11 Gene Structure and Protein.  The MAGE-11 gene is on the long 
arm of the human X-chromosome (blue) at Xq28 and includes 5 exons, 4 of which are coding 
exons (green). The MAGE-11 gene translates into a 429 amino acid MAGE-11 protein 
(orange). Within the C-terminal region of MAGE-11 is the conserved MAGE homology 
Domain (MHD) (amino acids 222-421). MAGE also has an NH2-terminal nuclear 
localization signal (NLS).   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 2  
 
MODULATION OF ANDROGEN RECEPTOR ACTIVATION FUNCTION 2 BY 
TESTOSTERONE AND DIHYDROTESTOSTERONE 
 
Abstract 
The androgen receptor (AR) is transcriptionally activated by high affinity binding of 
testosterone (T) or its 5α-reduced metabolite, dihydrotestosterone (DHT), a more potent 
androgen required for male reproductive tract development. The molecular basis for the 
weaker activity of T was investigated by determining T-bound ligand binding domain crystal 
structures of wild-type AR and a prostate cancer somatic mutant complexed with the AR 
FXXLF or coactivator LXXLL peptide. Nearly identical interactions of T and DHT in the AR 
ligand binding pocket correlate with similar rates of dissociation from an AR fragment 
containing the ligand binding domain. However, T induces weaker AR FXXLF and 
coactivator LXXLL motif interactions at activation function 2 (AF2). Less effective FXXLF 
motif binding to AF2 accounts for faster T dissociation from full-length AR. T can 
nevertheless acquire DHT-like activity through an AR helix-10 H874Y prostate cancer 
mutation. The Tyr-874 mutant side chain mediates a new hydrogen bonding scheme from 
exterior helix-10 to backbone protein core helix-4 residue Tyr-739 to rescue T-induced AR 
activity by improving AF2 binding of FXXLF and LXXLL motifs. Greater AR AF2 activity 
by improved core helix interactions is supported by the effects of melanoma antigen gene 
protein-11, an AR coregulator that binds the AR FXXLF motif and targets AF2 for activation. 
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We conclude that T is a weaker androgen than DHT because of less favorable T-
dependent AR FXXLF and coactivator LXXLL motif interactions at AF2. 
Introduction 
 
The androgen receptor (AR) is a member of the nuclear receptor superfamily of 
ligand-activated transcription factors. Androgen activation of AR regulates prostate growth, 
bone and muscle mass, and spermatogenesis, and is a predisposing factor in prostate cancer. 
AR mediates transcriptional activity in response to two biologically active androgens that 
bind AR with similar high affinity (1). Testosterone (T) is the major circulating androgen 
secreted by the testis and the active androgen in muscle. Dihydrotestosterone (DHT), the 5α-
reduced metabolite of T, is a more potent androgen required for male reproductive tract 
development.  
AR has a modular structure comprised of an NH2-terminal transactivation domain, 
central DNA binding domain, linker hinge region and carboxyl-terminal ligand binding 
domain (LBD) (2). Like other nuclear receptor family members (3), AR has two major 
activation domains. Androgen induced AR transcriptional activity depends on activation 
function 1 in the largely un-structured NH2-terminal region (2), and activation function 2 
(AF2), a highly ordered hydrophobic surface in the LBD that requires androgen binding for 
its structural integrity (4). 
The degree to which AF2 contributes to overall AR activity depends on multiple 
competing factors. Unlike other nuclear receptors, AR AF2 binds a number of LXXLL-
related motifs. Important among these is the AR NH2-terminal FXXLF motif 
23
FQNLF
27
 that 
binds AF2 in an androgen dependent and specific manner. AR FXXLF motif binding to AF2 
is the basis for the AR NH2- and carboxyl-terminal N/C interaction (5-7) that contributes to 
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AR dimerization (8, 9) and is critical for AR regulation of androgen dependent genes (10-
12). The functional significance of the AR N/C interaction in vivo is supported by the effects 
of several naturally occurring mutations that disrupt AR FXXLF motif binding and cause 
resistance to androgen without diminishing high affinity androgen binding (13-16). The 
androgen insensitivity syndrome results in varying degrees of incomplete masculinization of 
the external genitalia in genetic males depending on the extent to which the mutation disrupts 
AR function (17).  
In addition to the AR FXXLF motif, multiple related motifs bind the AR AF2 site 
with relatively high affinity (18). FXXLF motifs are present in a number of putative AR 
coregulatory proteins and interact at AF2 (19, 20). Within the AR NH2-terminal domain is a 
WXXLF motif that interacts with the AR AF2 site in the presence of androgen but with 
weaker affinity than the AR FXXLF motif (5, 10). Similar to other nuclear receptors, AR AF2 
serves as the binding site for steroid receptor coactivator (SRC)/p160 coactivator LXXLL 
motifs. Crystal structures demonstrate overlapping binding sites for AR FXXLF and 
coactivator LXXLL motifs (4, 18). Based on peptide display screening (18, 20, 21) and 
binding affinity measurements (4), AR AF2 preferentially binds FXXLF motifs compared to 
coactivator LXXLL motifs. In addition, we have shown that androgen dependent AR FXXLF 
motif binding to AF2 in the AR N/C interaction competitively inhibits coactivator LXXLL 
motif binding (19).  
The contribution of AF2 to AR transcriptional activity is also influenced by cell and 
tissue specific coactivators, some of which selectively increase accessibility of AF2 to 
coactivator recruitment. One mechanism proposed to increase AR AF2 activity in prostate 
cancer is higher levels of SRC/p160 coactivators that compete for the AR N/C interaction 
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and increase AR transcriptional activity through AF2 (10, 22). The AR coregulator 
melanoma antigen gene protein-11 (MAGE-11) of the MAGEA gene family binds the AR 
FXXLF motif to expose AF2 and increase coactivator recruitment (23). Naturally occurring 
AR somatic mutations in prostate cancer can increase AR activity by enhancing SRC/p160 
coactivator recruitment to AF2 (7). The relative binding affinities and competitive 
relationships at the AF2 site suggest that high affinity androgen binding triggers sequential 
interactions of multiple coregulatory proteins.  
In this report we provide biochemical and structural evidence that T is a less effective 
androgen than DHT because of weaker T dependent FXXLF and LXXLL motif binding at the 
AR AF2 surface. This conclusion is supported by a prostate cancer somatic mutation AR-
H874Y that increases the transcriptional response to T in association with improved FXXLF 
and LXXLL motif binding at AF2. Crystal structure determination of T bound WT and 
H874Y AR LBD provided some insight into the possible differential molecular effects of T 
versus DHT. Receptor bound with T appears to induce isolated conformational heterogeneity 
at the AF2 surface. The AR H874Y mutation creates new direct hydrogen (H) bonds between 
core helix residues that probably contribute to the molecular basis for the described 
functional rescue by this prostate cancer mutant. 
Materials and Methods 
Plasmids–pCMVhAR vectors expressing full-length human AR with H874Y, E897K 
and K720A mutations (6, 14, 24) and AR507-919 which lacks the NH2-terminal region (2) 
were described. Coding sequences for AR-(663-919) and AR-(663-919)-H874Y were 
inserted at the NdeI and BamHI sites of the pET-15b bacterial expression vector by PCR 
amplification of corresponding pCMVhAR mutant plasmids. GAL-AR-(658-919) and 
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H874Y, E897K and K720A mutants were created by PCR amplification of respective 
pCMVhAR plasmids and subcloning into Tth111I and XbaI digested pGAL0. GAL-AR-
(640-919) was created by PCR amplifying the fragment from pCMVhAR and subcloning 
into NdeI and XbaI digested pGAL0. VP-AR-(1-660) (13), VP-TIF2-(624-1287) (VP-
TIF2.1) (25), GAL-AR-(624-919) and H874Y, E897K and K720A mutants (7), prostate 
specific antigen-enhancer-luciferase (PSA-Enh-Luc) (26), mouse mammary tumor virus 
(MMTV)-Luc, 5XGAL4Luc3 (10) and pSG5-MAGE-11 coding for full-length MAGE-11 
residues 1 to 429 (23) were described. All PCR amplified regions were verified by DNA 
sequencing.  
Reporter Gene Assays–The CWR-R1 prostate cancer cell line derived from the 
CWR22 recurrent human prostate cancer xenograft (24, 27) was plated at 1.6 or 2 x 10
5
 
cells/well in 12 well plates in prostate cell growth medium containing Richter’s improved 
minimal essential medium (Gibco) or Dulbecco’s modified Eagle’s medium (Gibco) 
supplemented with 5 ng/ml selenium, 10 mM nicotinamide, 5 µg/ml insulin, 5 µg/ml 
transferrin and 2% fetal bovine serum, and transfected using Effectene (Qiagen). Endogenous 
CWR-R1 cell AR-H874Y transcriptional activity was detected using 0.1 µg/well MMTV-
Luc reporter vector. AR AF2 activity was determined in CWR-R1 cells by transfecting 0.1 
µg WT or mutant GAL-AR-(624-919) or GAL-AR-(658-919) and 0.25 µg 5XGAL4Luc3. 
For two-hybrid interaction assays, CWR-R1 cells were transfected with 50 ng VP-TIF2-(624-
1287), WT or mutant GAL-AR-(624-919) and 0.1 µg 5XGAL4Luc3. For 12 well plates, 
DNA was combined with (per well) 45 µl transfection buffer (Qiagen) and 1 µl Enhancer, 
vortexed and incubated for 5 min at room temperature. Effectene (1 µl/well) was added, 
vortexed for 10 s, and incubated for 10 min at room temperature. Prostate cell growth 
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medium (0.2 ml) was added and vortexed, and 220 µl DNA solution added to each well 
containing 1 ml of medium. The next day cells were washed with phosphate-buffered saline 
(PBS) and 1 ml phenol red-free, serum-free basic prostate medium containing Improved 
minimal essential Zinc Option medium (Invitrogen), and the indicated steroids were added 
per well. Cells were incubated at 37°C overnight, washed with PBS, and harvested in 0.25 ml 
lysis buffer containing 1% Triton X-100, 2 mM EDTA, and 25 mM Tris phosphate, pH 7.8. 
Cells were rocked at room temperature for 30 min in lysis buffer, and 0.1 ml cell lysate 
analyzed for luciferase activity using a Lumistar Galaxy (BMG Labtech) automated 
multiwell plate reader luminometer. 
Human epithelial cervical carcinoma HeLa cells were maintained in Eagle’s 
minimum essential medium supplemented with 10% fetal bovine serum (Gemini or 
HyClone), penicillin, streptomycin and 2 mM L-glutamine. For reporter gene assays, HeLa 
cells were plated at 5 x 10
4
 cells/well in 12 well plates and 24 h later transfected using 
FuGENE-6 Transfection Reagent (Roche Applied Science) with 10 ng pCMVhAR or H874Y 
mutant and 0.25 µg PSA-Enh-Luc reporter vector to determine androgen-induced AR 
transactivation. To measure AR AF2 activity, HeLa cells were transfected with 0.1 µg GAL-
AR-(658-919) and the H874Y mutant and 0.25 µg 5XGAL4Luc3. For two-hybrid interaction 
assays, HeLa cells were transfected with 0.1 µg 5XGAL4Luc3, 50 ng VP-AR-(1-660) or VP-
TIF2-(624-1287), and 50 ng GAL-AR-(624-919), -(640-919), -(658-919), or GAL-AR-(624-
919)-H874Y. DNA was added to 43 µl serum-free medium and 0.6 µL of FuGENE-6 reagent 
per well. After a 15 min incubation, 40 µl of FuGENE/DNA mixture was added to each well 
containing 1 ml medium. The next day cells were washed with PBS, and 1 ml/well serum-
free medium lacking phenol red containing the indicated steroids was added and incubated 
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overnight at 37°C. Twenty four hours later cells were washed with PBS and assayed for 
luciferase activity after harvesting in 0.25 ml lysis buffer as described above.  
Monkey kidney CV1 cells were maintained in Dulbecco’s modified Eagle’s medium 
containing 10% bovine calf serum (HyClone), 2 mM ʟ-glutamine, penicillin, streptomycin, 
and 20 mM Hepes, pH 7.2. Cells (4.2 x 10
5
/6 cm dish) were plated in medium containing 5% 
bovine calf serum and 24 h later transfected using calcium phosphate DNA precipitation 
(28). The effect of TIF2 on AR AF2 activity was determined by transfecting 5 µg 
5XGAL4Luc3 and 0.1 µg GAL-AR-(624-919), GAL-AR-(658-919), or the H874Y mutants 
in the absence and presence of 2 µg pSG5-TIF2. The effect of MAGE-11 on AR 
transcriptional activity was determined by transfecting 0.1 µg of pCMVhAR or pCMVhAR-
H874Y and 5 µg PSA-Enh-Luc in the absence and presence of 2 µg pSG5-MAGE-11 and 2 
µg pSG5-TIF2. Cells were incubated overnight with and without the indicated androgens and 
the next day placed in serum-free medium in the absence and presence of androgen. After 24 
h cells were washed with PBS, harvested in 0.25 ml lysis buffer, and assayed for luciferase 
activity as described. 
Immunoblots–Relative expression levels of WT and mutant GAL-AR-(624-919), 
GAL-AR-(658-919), pCMVhAR, and pCMVhAR-(507-919) were determined by 
immunoblot analysis. COS-1 cells were plated at 2 x 10
6
 cells/10 cm dish in 10% bovine calf 
serum (HyClone) in Dulbecco’s modified Eagle’s medium containing penicillin, 
streptomycin, 2 mM ʟ-glutamine, and 20 mM Hepes, pH 7.2 and transfected using DEAE 
dextran (28). After 24 h, medium containing 1 µM MG132 (Sigma), a proteosome inhibitor, 
was added to cells expressing GAL-AR-(624-919) and GAL-AR-(658-919) and readded after 
an overnight incubation and incubated for 1 h. Cells were washed with 8 ml cold PBS, 
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harvested in 1 ml PBS, and solubilized in 0.1 ml RIPA buffer containing 1% Nonidet P-40, 
0.5% sodium deoxycholate, 0.1% SDS, 1 mM dithiothreitol, 1 mM phenylmethylsulfonyl 
fluoride, and complete protease inhibitor mixture (Roche Applied Science). Protein 
concentrations were determined using the BioRad assay with bovine serum albumin as 
standard. Protein extracts were separated on a 10% acrylamide gel containing SDS and 
analyzed by immunoblot. GAL4 fusion proteins were detected using rabbit polyclonal anti-
GAL antibody (Santa Cruz Biotechnology) at 1:500 dilution. AR was detected using rabbit 
polyclonal AR52 immunoglobulin G (29) at 2 µg/ml. Incubations with primary antibody 
were for 1 h at room temperature. Anti-rabbit horseradish peroxidase-conjugated secondary 
IgG antibody (Amersham Biosciences) was used at 1:10,000 dilution for 1 h at room 
temperature. Signals were detected using chemiluminescence (SuperSignal West Dura 
Extended Duration Substrate, Pierce).  
Androgen Dissociation Rate Assays–Ligand dissociation rate studies were performed 
at 37ºC in whole cell binding assays by plating 4 x 10
5
 COS cells/well of 6-well plates and 
transfecting 1 or 2 µg pCMVhAR, pCMVhAR-(507-919), or H874Y mutant per well using 
DEAE-dextran (28). Transfected cells were incubated for 2 h at 37ºC in 0.6 ml serum-free 
medium lacking phenol red and containing 5 nM [1,2,6,7-
3
H]T (78.5 Ci/mmol) or 3 nM 
[1,2,4,5,6,7-
3
H]DHT (124 Ci/mmol). Nonspecific binding was determined in parallel wells 
by adding 100 fold molar excess of unlabeled androgen. Timed dissociation rates were 
determined by amending to 50 µM T or 17α-methyltrienolone (R1881) (PerkinElmer Life 
Sciences) to the labeling media added in 0.1 ml of medium. Cultured cell incubations at 37ºC 
were terminated at different times and cells were washed with PBS, harvested in 0.5 ml lysis 
buffer containing 2% SDS, 10% glycerol and 20 mM Tris, pH 6.8, and radioactivity was 
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determined by scintillation counting. Dissociation half-times were determined as the mean ± 
S.E. time required to reduce specific androgen binding by 50%. 
Protein Preparation–Crystallography grade AR LBD (human AR residues 663-919) 
and AR-H874Y LBD with an NH2-terminal His6 tag and thrombin cleavage site were 
expressed from pET-15b in BL-21 DE3 Escherichia coli. Cells were grown overnight at 
18ºC in 2X YT bacterial growth medium (16 g/liter Tryptone-B, 10 g/liter yeast extract-B, 5 
g/liter NaCl2, Bio101 Systems, Q-Biogene) containing 0.1 g/liter carbenecillin (Sigma), 1 
mM isopropyl thiogalactopyranoside, and 0.5 mM T added from a 347 mM stock in dimethyl 
sulfoxide. Cells resuspended in urea extraction buffer (50 ml of 25 mM Tris, pH 8.0, 0.3 M 
NaCl2, and 2 M urea per 10 g cells) were lysed with an APV LAB 1000 homogenizer and 
centrifuged at 40,000 rpm for 45 min at 4°C. The supernatant was loaded onto a Ni
2+
-charged 
immobilized nickel metal affinity Sepharose column (ProBond, Invitrogen) equilibrated with 
25 mM Tris, pH 8.0, 0.3 M NaCl2, and 50 mM imidazole. A linear gradient to 1 M imidazole 
with 25 mM Tris, pH 8.0, and 0.3 M NaCl2 was used to elute the AR LBD. Pooled fractions 
were amended with thrombin (5 NIH units/mg protein, Sigma) and NaCl2 to ~0.4 M and 
dialyzed (15,000 molecular weight cut off, Spectra/Por membrane) overnight at 4°C against a 
buffer containing 10 µM T, 25 mM Tris, pH 8.0, 0.4 M NaCl2, 5 mM DTT, 2 mM EDTA, 
and 10% glycerol. The digested AR LBD was diluted 8-fold with 25 mM Hepes, pH 7.5, 50 
mM NaCl2, 5 mM DTT, 2 mM EDTA, and 10% glycerol and immediately loaded onto a 5 ml 
HiTrap SP-HP-Sepharose ion exchange column, washed with dilution buffer and eluted using 
a linear gradient to 1 M NaCl2 with 25 mM Hepes, pH 7.5, 5 mM DTT, 2 mM EDTA, and 
10% glycerol. Samples containing AR LBD were combined, amended to 10 µM T and 0.5 M 
NaCl2, and concentrated with a Centriprep centrifugal filter unit (Amicon) to <10 ml. Size 
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exclusion chromatography was performed on the concentrated pooled ion exchange 
chromatography purified fractions using a HiLoad Superdex S75 (26/60) size exclusion 
column (GE Healthcare). Purified AR LBD was eluted with buffer containing 10 µM T, 25 
mM Hepes, pH 7.5, 0.15 M Li2SO4, 10 mM DTT, 0.5 mM EDTA, and 10% glycerol and 
concentrated to 2-4 mg/ml using a Centriprep centrifugal filter unit. The final sample buffer 
contained 10 µM T, 25 mM HEPES, pH 7.5, 0.15 M Li2SO4, 10 mM DTT, 0.5 mM EDTA, 
10% glycerol, and 0.05% β-n-octoglucoside. 
Fluorescence Polarization Measurements of Peptide Binding Affinity–Fluorescence 
binding studies were performed using WT AR LBD and AR-H874Y LBD expressed in E. 
coli in the presence of 0.5 mM T or 50 µM DHT. Protein was purified as described above 
except AR LBD–DHT thrombin digestion and overnight dialysis were not performed, and 
DHT was not readded during purification. Protein was concentrated to 0.6-3 mg/ml using 
Centriprep centrifugal filter units in buffer containing 10 µM T or DHT, 0.15 M Li2SO4, 10 
mM DTT, 0.5 mM EDTA, 10% glycerol, 0.05% β-n-octoglucoside, and 25 mM HEPES, pH 
7.5. AR FXXLF and TIF2 LXXLL peptide binding affinities were determined by fluorescence 
polarization at room temperature for 1 h using 5-40 µM AR LBD and AR-H874Y LBD 
purified in the presence of 10 µM ligand and assayed with and without addition to 40 µM 
DHT or T and 10 nM AR-20-30 fluorescein-RGAFQNLFQSV or TIF2 third LXXLL motif 
732-756 fluorescein-QEPVSPKKKENALLRYLLDKDDTKD (Synpep, Dublin, CA). As a 
control, human estrogen receptor-β (ERβ) LBD (residues 257-530) was analyzed in parallel 
in the presence of 40 µM estradiol (E2). Fluorescence polarization values were determined 
using an Envision (PerkinElmer Life Sciences) fluorescence plate reader with 485 nm 
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excitation and 520 nm emission filters. Binding isotherms were constructed and KD values 
determined by nonlinear least-squares fit based on a 1:1 interaction (30). 
Crystallization and Data Analysis–Concentrated solutions of purified AR-H874Y 
LBD and AR LBD complexed with T and amended with 2-3 M excess of AR-(20-30) 
FXXLF motif peptide RGAFQNLFQSV or TIF2-(740-753) LXXLL-III motif peptide 
KENALLRYLLDKDD were used to obtain diffraction grade crystals. Vapor diffused 
hanging drops at 22°C with a 1:1 (v/v) ratio of the AR complex and the precipitant solution 
produced ~150-200 µm crystals within 3-15 days. Salt solutions containing 0.6 M sodium-
potassium tartrate and Bistris propane, pH 7.0 or Tris, pH 8.5, were used as precipitants. 
Prior to flash freezing in liquid N2, crystals were transiently mixed with a cryoprotectant 
solvent consisting of precipitant solution amended to 20% glycerol. X-ray diffraction data 
were collected at 100 K with an ADSC 210 detector at the IMCA-CAT, sector 17ID, or a 
MAR225 CCD detector at the SER-CAT, sector 22BM at the Advanced Photon Source 
synchrotron. Diffraction data were integrated and scaled with HKL2000 (31). 
Structure Determination and Refinement–An initial model for the T-bound AR-
H874Y LBD with AR-(20-30) peptide data was determined by molecular replacement with 
MolRep (32, 33) and the AR LBD coordinates from the AR–DHT structure (34) (Protein 
Data bank access code 1I37). The convincing solution contained a single AR LBD complex 
in the asymmetric unit that had excellent quality 1.8Å resolution electron density for T and 
the respective peptide. Multiple cycles of manual model building with COOT (35) and 
maximum likelihood restrained refinement with all hydrogens was performed with Refmac 
(36) in all cases. Initial models for the remaining data sets were determined and refined in a 
similar manner. Table 2-3 summarizes the crystallographic and refinement statistics. 
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Coordinate files with hydrogens were generated with MolProbity (37). To eliminate possible 
slight differences arising from variation in AF2 helix position, backbone heavy atoms for AR 
chain A LBD residues 680-890 were used for structure superimposition and performed with 
the CCP4i LSQAB utility using coordinates without hydrogens. Reported interatomic 
distances are between heavy atoms unless specified, and the angles with protons when 
necessary were measured with COOT or PyMol. Structure figures were generated with 
PyMol from Delano Scientific. 
Results 
AF2 Activation by T and DHT–To investigate the differential effects of T and DHT 
on AR AF2 activity, we performed studies using WT AR and a prostate cancer somatic 
mutant AR-H874Y that has an increased transcriptional response to T (7, 24). To optimize 
detection of AR AF2 activity, we varied the length of the hinge region of several AR LBD–
GAL4-DNA binding domain fusion proteins expressed in several cell lines (Fig. 2-1A). In 
CV1 cells, T and DHT increased TIF2-dependent GAL-AR-(658-919) activity to a greater 
extent than GAL-AR-(624-919), indicating inhibition by hinge residues that include the AR 
nuclear targeting signal (38) (Fig. 2-1C). The H874Y mutation increased androgen sensitivity 
and overall transcriptional activity but remained dependent on ligand and coexpression of 
TIF2 (Fig. 2-1C).  
Transcriptional activity of GAL-AR-(624-919), -(640-919) and –(658-919) was also 
low in HeLa cells without coexpression of TIF2 (Fig. 2-1D). In two-hybrid assays, GAL-AR-
(640-919) and GAL-AR-(658-919) interacted to a greater extent than GAL-AR-(624-919) 
with VP-AR-(1-660) indicative of the AR N/C interaction and with VP-TIF2-(624-1287) 
reflecting coactivator LXXLL motif binding to AF2 (Fig. 2-1D) (4-8).  
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Androgen-dependent AF2 activity of GAL-AR-(658-919) was stronger in the CWR-
R1 prostate cancer cell line and was detected independent of coexpressed TIF2 (Fig. 2-1E). 
Activity of GAL-AR-(658-919) was greater than GAL-AR-(624-919), and the H874Y 
mutation increased the response to T. Differences in transcriptional activity did not result 
from differences in protein expression (Fig. 2-1B) and was AF2-dependent since charge 
clamp mutants K720A and E897K eliminated the response (Fig. 2-1F). 
Thus, differential effects of T and DHT on WT and H874Y AR AF2 activity were 
evident in CWR-R1 cells using GAL-AR-(658-919), which avoided the inhibitory effects of 
AR hinge residues 
624
MTLGARKLKKLGNLKL
639
 (39) (AR nuclear targeting signal 
underlined) (38).  
Increased AR-H874Y AF2 Activation by T and Adrenal Androgens–The magnitude 
and dose response of GAL-AR-(658-919)-H874Y AF2 activity by T in CWR-R1 cells were 
similar to DHT but less than the WT with T (Figs. 2-1E and 2-2A). GAL-AR-(658-919)-
H874Y activity was also greater with 4-androstene-3,17-dione compared to WT. 
Androstanediol activated WT and H874Y GAL-AR-(658-919) equivalent to WT with T.  
In HeLa cells, the predominant effect of the H874Y mutation was also increased 
sensitivity to T (Fig. 2-2B), whereas GAL-AR-(658-919) and the H874Y mutant responded 
similarly to DHT. We noted a lack of transcriptional response by GAL-AR-(658-919) to 
androstanediol in HeLa cells, which contrasted equivalent activity by androstanediol and T in 
CWR-R1 cells. Two-hybrid studies suggested that the greater activity by androstanediol in 
CWR-R1 cells resulted from metabolism to an active androgen (data not shown).  
Full-length endogenous AR-H874Y in CWR-R1 cells does not activate the PSA-Luc 
reporter (40) but activates MMTV-luciferase in response to T and DHT and higher 
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concentrations of androstenedione and androstanediol (Fig. 2-3A). Transiently expressed AR 
and AR-H874Y in CWR-R1 cells activate PSA-Luc in response to T and DHT, and adrenal 
androgens were more effective with AR-H874Y (data now shown). In HeLa cells, AR-
H874Y lacked constitutive activity but increased the response to T with less differential 
effects by DHT, androstenedione, and androstanediol (Fig. 2-3B). 
The results in both CWR-R1 and HeLa cell lines suggest that the predominant effect 
of the H874Y mutation is to increase the AF2 response to T. Our ability to detect AR AF2 
activity in CWR-R1 cells but not HeLa or CV1 cells without coexpression of TIF2 likely 
reflects higher endogenous SRC/p160 coactivator levels in CWR-R1 cells that endogenously 
express the AR-H874Y mutant (40).  
Preferential AF2 Activation by MAGE-11–MAGE-11 is an AR coregulator expressed 
in prostate cancer cell lines and in normal tissues of the human male and female reproductive 
tracts (23). MAGE-11 binds the AR NH2-terminal FXXLF motif and increases AF2 by 
inhibiting the AR N/C interaction. To gain further evidence that AR-H874Y increases AF2 
activity in response to T, we determined the effect of MAGE-11 with and without 
coexpression of TIF2 using a PSA-luciferase reporter.  
Coexpression of TIF2 had minimal effects on AR and AR-H874Y activity (Fig. 2-4) 
in agreement with the inhibitory effects of the AR N/C interaction on coactivator recruitment 
by AF2 (28). Coexpression of MAGE-11 with and without TIF2 preferentially increased AR-
H874Y activity in response to T compared to WT AR and AR-H874Y with DHT. AR-
H874Y activity induced by T and DHT was nearly equal in the presence of MAGE-11 with 
or without TIF2. This contrasts WT AR where DHT induced greater activity than T in the 
presence of MAGE-11 with or without TIF2. Coexpression of MAGE-11 also increased 
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ligand independent activity of AR-H874Y more than WT AR. Differences in transcriptional 
activity were independent of differences in protein expression levels based on immunoblot 
analysis (see Fig. 2-6B). The preferential effects of MAGE-11 on T dependent AR-H874Y 
activity suggest that H874Y imparts DHT-like activity to T by increasing coactivator 
recruitment to AF2.  
FXXLF and LXXLL Motif Binding Affinities–Binding isotherms calculated by 
fluorescence polarization indicate WT AR LBD–DHT binds the AR FXXLF peptide with ~2-
fold higher affinity than WT AR LBD–T with no significant change by the H874Y mutation 
(Fig. 2-5; Table 2-1). Similar results were observed for the TIF2 LXXLL peptide except 
overall binding affinities were weaker than the FXXLF peptide. ERβ LBD–E2 bound the TIF2 
LXXLL peptide with higher affinity than the FXXLF peptide as reported previously (4). The 
data suggest a direct differential effect of T and DHT on AF2 motif binding affinity that is 
not altered by the H874Y mutation.  
T and DHT Dissociation Kinetics–The prostate cancer mutation H874Y slows the 
dissociation rate of synthetic androgen R1881 from AR and AR-(507-919), a carboxyl-
terminal fragment that lacks the AR NH2-terminal domain (7). To investigate the similar AR-
H874Y AF2 activity induced by T and DHT, we determined androgen dissociation half-times 
from WT and H874Y full-length AR and AR-(507-919) containing the DNA binding domain 
and LBD, which expressed similarly on immunoblots (Fig. 2-6B).  
T dissociates 3-4 times faster than DHT from full-length WT AR (Fig. 2-6A; Table 2-
2) (1) but with a similar rate as DHT from AR-(507-919) (Table 2-2), suggesting similar 
steroid contacts in the ligand binding pocket. T dissociates 3-4 times slower from AR-H874Y 
than from WT AR at a rate similar to DHT dissociation from AR and AR-H874Y. The 
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dissociation rate of T and DHT from AR-(507-919)-H874Y was ~2 fold slower than from 
WT AR-(507-919).  
The data indicate that slow dissociation of DHT from full-length WT AR results 
predominantly from interactions outside the ligand binding pocket, and H874Y has effects 
inside and outside the binding pocket. The similar half-time of T dissociation from AR-
H874Y to DHT from AR and AR-H874Y parallel AF2 transcriptional activities (see Figs. 2-
1 and 2-2) and provide further evidence that H874Y imparts DHT-like activity to T by 
increasing the transcriptional activity of AF2.  
T-bound WT AR LBD and AR-H874Y LBD Structures–We determined the crystal 
structures of WT and H874Y AR LBD bound with T in the presence of the AR-(20-30) NH2-
terminal FXXLF motif peptide or TIF2 coactivator peptide TIF2-(740-753) third LXXLL 
motif. Crystallographic refinement data are provided in Table 2-3. Globally, all four 
structures conform to the canonical nuclear receptor LBD fold (Figs. 2-7A and 2-7B) and 
when superimposed are nearly identical based on r.m.s.d. statistics for the xyz displacement 
relative to the WT AR LBD–T–FXXLF coordinates (0.26Å for WT AR LBD–T–LXXLL, 
0.14Å for AR-H874Y LBD–T–FXXLF, and 0.27Å for AR-H874Y LBD–T–LXXLL). 
Globally, the structures concur with previously reported structures for WT AR LBD bound to 
DHT and R1881 and prostate cancer mutants AR-T877A LBD and AR-W741L LBD bound 
to steroid and nonsteroid ligands (4, 18, 34, 41-45). Our WT AR LBD–T structures with AR 
FXXLF (Protein Data Base access code 2Q7I) or TIF2 LXXLL (Protein Data Base 2Q7J) 
peptide superimpose to the DHT-bound structures with FXXLF (Protein Data Base 1TR7) or 
LXXLL (Protein Data Base 1T63) peptide (see Fig. 2-9) with an r.m.s.d. of 0.27Å and 0.3Å 
and to WT AR LBD–S-1 (Protein Data Base 2AXA) and AR-W741L LBD–bicalutamide 
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(Protein Data Base 1Z95) with an r.m.s.d. of 0.37Å and 0.31Å, respectively. Consistent with 
the AR LBD–R1881 (4) and DHT peptide bound structures (18, 42), the LXXLL motif in the 
T-bound structures is carboxyl-terminally shifted along the helical axis relative to the FXXLF 
peptide, and Leu-745 and Leu-749 lie in register with Phe-23 and Phe-27 (Fig. 2-7A). The 
AR-(20-30) FXXLF peptide H-bonds to conserved charge clamp residues Glu-897 and Lys-
720 required for AR AF2 activity (6). The NH2-terminus of the LXXLL peptide fails to H-
bond with Glu-897 and maintains the carboxyl-terminal shift, motif registry, and interaction 
to Lys-720 as shown for the AR LBD bound to R1881 (4) (Figs. 2-7A, 2-7B and 2-7C). The 
T-bound ligand binding pockets are essentially identical to each other and nearly identical to 
the DHT-bound AR LBD structures (34, 42) (Figs. 2-7C and 2-7D, and Table 2-4). 
WT AR LBD–T–FXXLF and LXXLL–There were no major structural differences to 
thoroughly account for the noted physiologic differences between T and DHT. For both, the 
steroid A-ring lies near the side chain of Arg-752, a conserved helix-5 residue required for 
ligand binding (Fig. 2-8) (41, 43, 44). In the T-bound WT AR LBD–FXXLF structure, we 
observed a 3.0Å interatomic distance between the steroid 3-keto O and Arg-752 side chain 
atom N-ε2 and measured a 126o angle subtended by atoms Arg-752 N-ε2, H- ε22 and the T 
3-keto O (Fig. 2-8A and Table 2-4). Although the 3.0Å distance supports the presence of a 
direct H-bond with Arg-752, the angular displacement is less than the optimal 180
o
 angle and 
only slightly more favorable than the 110°, 3.0Å H-bond of DHT-AR LBD (Protein Data 
Base 1T63) (Figs. 2-8B and 2-8C).  
Also located near the steroid A-ring is conserved structural water HOH1, which 
ideally could mediate up to 4 local H-bonds. However, 3 possible H-bond donors are side 
chain protons bonded to Arg-752 (N-ε1 and N-ε2) and Gln-711-A (N-ε2). Three possible H-
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bond acceptors are Gln-711 (A) (O-ε1), the backbone carbonyl oxygen of Met-745 and the 3-
keto O (Fig. 2-8A). Of these 6 atoms, the Arg-752 N-ε2, Gln-711 N-ε2 and Met-745 
backbone carbonyl oxygen align closest to 3 of 4 angles dictated by the tetrahedral geometry 
of water and leaves open the possibility for HOH1 to donate an H-bond to the T 3-keto O. 
The likelihood of an HOH1 to 3-keto O H-bond is indicated by the reduced interatomic 
distance of 3.2Å compared to 3.5Å in DHT-bound structures (Protein Data Base 1T63 and 
1I37), the planar ∆4,5 double bond of T which positions the 3-keto O closer to HOH1, and 
the more negative charge character to the 3-keto O than the nonpolar neutral 3-keto O of 
DHT. The HOH1 to 3-keto O C3 vector of 117º is nearly colinear to 120º sp
2
 electrons on the 
3-keto O in favor of the HOH1 O-H vector. Although invoking an HOH1 to T 3-keto O H-
bond forms a narrow 80º angle between the 3-keto O, HOH1 O, and Met-745 carbonyl 
oxygen atoms that violates the ideal tetrahedral water geometry, the superior hydrophilic 
properties of the T A-ring relative to DHT increase the propensity of T to accept this second 
H-bond through the fourth coordination of HOH1. Better H-bonding by T appears to also 
slightly reduce the distance between HOH1 and the Met-745 backbone carbonyl (2.7Å) 
relative to DHT (2.9Å).  
On the D-ring of T, the 17β-hydroxyl group accepts an H-bond from the helix-10 
Thr-877 side chain and donates an H-bond to helix-3 Asn-705 O-δ1 (Figs. 2-7C and 2-9) as 
reported for DHT and R1881 (4, 34). The Asn-705 side chain amine in turn H-bonds to the 
backbone carbonyl of Glu-890 in the linker between helix-11 and 12 (not shown). In the 
vicinity of the A-B-ring juncture, the C-19 bridgehead methyl group of T divides the 
hydrophobic space between Met-745 and Trp-741 as in the AR LBD–DHT structures and 
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maintains the Trp-741 indole ring nitrogen rotated toward the conserved structural water 
(HOH3 in our WT AR structures) and residue 874. 
Summarized here are amino acid residues in our T-bound structures where positive 
3ζFo-Fc electron density warranted the addition of a second side chain conformation or a 
sulfate ion. Occupancy for the A and B side chain conformers was to ~50% each, except for 
Gln-711, which was estimated as 80% A and 20% B at best: WT–T–FXXLF-Leu-712, Ser-
740, Cys-806, Met-807, Ser-814, Ile-815, Met-895 and two sulfates; WT–T–LXXLL-Glu-
678, Gln-711, Leu-712, Asn-727, Met-780, Cys-806, Ile-841, Met-895,, and one sulfate; 
H874Y–T–FXXLF-Gln-711, Leu-712, Met-780, Cys-806, Ile-841, Met-895 and two sulfates; 
H874Y–T–LXXLL-Glu-678, Glu-709, Leu-712, Arg-726, Cys-806 and Met-895. Most 
notable among these is helix-3 Gln-711 near HOH1, the next sequential residue to Leu-712 
which contacts i+1 of the bound peptide motif, and helix-12 Met-895 which lies proximal to 
Leu-712 but more distal to the i+1 residue of the bound peptide and the steroid A-ring (Fig. 
2-10). We also observed in each structure, but do not illustrate, a glycerol that derives from 
the protein buffer solution that binds above the Gln-711 side chain. It is unclear whether 
these alternate conformers are crystallization artifacts, or as for Gln-711, arise from the 
presence of glycerol. Others such as Leu-712 or Met-895 may represent conformational 
freedom arising from a protein- or ligand mediated mechanism.  
AR H874Y LBD–T–FXXLF and LXXLL–We noted a more definitive structural change 
in our analysis of the AR-H874Y mutant LBD bound to T and AR FXXLF (Protein Data 
Base access code 2Q7K) or TIF2 LXXLL (Protein Data Base 2Q7L) peptide. Side chains of 
exterior helix-10 WT residue His-874 (Fig. 2-10A) and H874Y mutant residue Tyr-874 (Fig. 
2-10B) occupy space in a second shell of residues that surround Met-742, a first shell interior 
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helix-5 residue that contributes to the hydrophobic core and whose side chain lies adjacent to 
the steroid C-ring in the binding pocket. Side chains for Met-742 and third shell AF2 helix 
residues Val-903, Ile-906, and Leu-907 located above residue 874 are virtually superimposed 
atom for atom in the WT and H874Y structures (Fig. 2-10D), and the Met-742 side chain 
clearly conforms to a single orientation for WT and H874Y AR. This overall WT AR 
configuration allows structural HOH3 to mediate an H-bond network from the His-874 side 
chain (N-ɛ2) to the Met-742 backbone carbonyl and continues through HOH4 to the helix-4 
Tyr-739 backbone carbonyl (Fig. 2-10A).  
Despite the bulkier phenyl hydroxyl group, Tyr-874 in the H874Y mutant appears 
easily accommodated with no major rearrangement of neighboring helices or side chains 
(Figs. 2-10B and 2-10C). Tyr-874 supplies a larger side chain that extends more than 2Å 
further towards helix-5 and displaces HOH3 with its phenolic hydroxyl group and presents a 
definitive change in H-bonding scheme. The helix-10 Tyr-874 phenolic oxygen can accept a 
direct 3.4Å H-bond from the backbone amide of helix-5 Met-742 at a favorable angle of 120
o
 
(Tyr-874 C-δ, O-ε to Met-742 N) that closely aligns the Met-745 amide N-H bond vector to 
the assumed 120º sp
2
 electrons of the Tyr-874 O-ε atom. In turn the Tyr-874 hydroxyl proton 
donates a 2.8Å direct H-bond to the backbone carbonyl of helix-4 Tyr-739 at a favorable 
angle of 121
o
 (Tyr-874 O-ε to Tyr-739 O, C) that closely aligns with the assumed 120º sp2 
electrons of the Tyr-739 carbonyl O atom. It is noteworthy that helix-4 residue Tyr-739 is 
adjacent to Gln-738, a residue whose side chain lies adjacent to the i+1 residue and displays 
different conformations with induced fit binding to the FXXLF or LXXLL motif and can 
participate in an H-bond network that links the helix-4 Met-734 CO to Lys-905 through the 
Gln-738 and Gln-902 side chains (Fig. 2-10D). The Tyr-874 phenyl presents more favorable 
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side chain chemistry to engage C-δ2 and C-ɛ1 in hydrophobic interactions with Val-903 C-γ2 
(3.5Å) and Ile-906 C-δ1 (3.4Å) than the heterocyclic imidazole ring of WT His-874 (4.0Å 
from C-δ2 to Val-903 C-γ2 and 3.7Å from C-ɛ1 to Ile-906 C-δ1) (Fig. 2-10D). The nearly 
identical T-bound crystal structures reveal that restored activation by T-bound AR-H874Y is 
not directly ligand mediated or accompanied by T-induced structural rearrangement and must 
be driven by the H874Y mutation. 
Discussion 
AR activation by T and DHT–AR is unique among the family of steroid hormone 
receptors by having two biologically active high affinity hormones that differ in 
physiological potency. DHT is a morphogen required for male sexual developmental, 
whereas T is the major androgen in muscle and is anabolic at puberty. Normal levels of T 
without conversion to DHT fail to stimulate complete male genital development of the 
human fetus. This is evident from the human 5α-reductase syndrome caused by a genetic 
defect in the enzyme that converts T to DHT (46). Activity differences between T and DHT 
cannot be explained by differences in transcription targets since there is no compelling 
evidence for differentially regulated gene sets, nor are they explained by the often reported 
different AR binding affinities for T and DHT. True equilibrium binding conditions may not 
be uniformly established, because the ligand-free AR and AR bound to T are more 
susceptible to degradation than AR bound to DHT leading to over-estimation of T binding 
affinity. By measuring association and dissociation rate constants and accounting for AR 
instability in the absence and presence of ligand, T and DHT equilibrium binding affinities 
are similar (1). Nevertheless, a ~10 fold higher concentration of T is required to achieve the 
AR mediated transcriptional effects of DHT (47). A DHT-like transcriptional response by 
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higher concentrations of T is supported by the 5α-reductase gene knockout mouse where a 
compensatory rise in circulating T levels results in masculinization at birth (48). 
Masculinization in humans with 5α-reductase deficiency occurs at puberty when circulating 
T levels increase (49).  
In this study we sought to elucidate the molecular basis for the different activities of 
T and DHT. Our biochemical data show that relative to DHT, T is a less potent androgen 
because of weaker FXXLF and LXXLL motif interactions at AF2 which are increased by the 
H874Y mutation. T and DHT dissociate with similar rates from AR-(507-919) but T 
dissociates ~3 times faster than DHT from WT AR and considerably slower from AR-H87Y. 
These results indicate that weaker AR FXXLF motif binding to AF2 results in the more rapid 
dissociation of T. Conversely, stronger AR FXXLF motif binding slows DHT dissociation 
from WT AR and T and DHT dissociation from AR-H874Y. Weaker interactions at AF2 
thus appear to explain the reduced androgenic activity of T.  
The similar LBD crystal structures of T-bound WT AR LBD with AR FXXLF or 
TIF2 LXXLL peptide to that of DHT (18, 34, 42) provide only subtle clues how these 
chemically similar ligands transmit different signals to the AF2 surface. Our structural data 
suggest that differences in A-ring H-bonding alter the conformational freedom of 
neighboring AF2 floor residue Leu-712. Structures of T-bound AR-H874Y indicate a gain-
of-function arising not from chemical differences between T and DHT or altered motif 
binding affinity, but from replacement of a water mediated H-bond network with direct H-
bonds between external helix-10 Tyr-874 side chain and internal helix-4 Tyr-739 and helix-5 
Met-742 backbone atoms. For both WT AR and AR-H874Y, small changes in H-bonding 
have measurable effects on motif binding at AF2 and ultimately AR transcriptional activity.  
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Chemical Properties of T and DHT–T is the major circulating male hormone and like 
DHT has 19 carbons and differs only by a ∆4,5 double bond in ring A. With two fewer 
protons than the saturated ring A of DHT, the ∆4,5 double bond of T polarizes the region and 
increases the negative charge at the 3-keto O and positive charge at carbon 5. Based on 
Coulomb’s law for simple electrostatic interactions (50), these properties of T impart greater 
H-bonding potential that accounts for its 10 fold greater water solubility than DHT. 
However, water solubility and inherent hydrophilicity and hydrophobicity do not explain 
androgen retention times in the binding pocket because T, DHT, and R1881 dissociate with 
similar rates from an AR fragment containing the LBD, and R1881 dissociates from AR at a 
rate intermediate between T and DHT (7). Water solubility and dissociation rate of R1881 
are further influenced by a 17-methyl group on ring D that introduces more hydrophobic 
character to a hydrophobic pocket near Met-780, Leu-704 and Leu-701. 
In the same sense, the saturated non-polar ring A of DHT is more chemically 
compatible with the hydrophobic environment of proximal ligand binding pocket residues 
than the unsaturated polar A-ring of T. Phe-764 is a conserved hydrophobic residue among 
steroid receptors (41) along with Val-746, Met-749, Leu-704, and Leu-707 that contact the 
bound ligand. Compared to T, the greater hydrophobic character and complementary shape 
of the DHT A-ring cannot explain the slower dissociation rate of DHT from full-length AR 
since T and DHT dissociate with similar rates from AR-(507-919). On the other hand, the 
saturated A-ring of DHT may more effectively increase AR AF2 activity by stabilizing the 
LBD core for higher affinity motif interactions.  
Counterintuitive Hypothesis for T and DHT Activity–Modulation of FXXLF or 
LXXLL motif binding at AF2 by T and DHT relies on a conserved H-bond between Arg-752 
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N-ε2 and the steroid 3-keto O which is influenced by the ∆4,5 double bond in T that imposes 
a more planar nature to the double bond side of ring A. Our T structures display a 3.0Å H-
bond heavy atom distance from the ring-A 3-keto O to Arg-752 the same as DHT, but an 
angle from the more planar A-ring of T (126
o
) that is slightly more favorable for H-bonding 
than the chair configuration in DHT (110
o
) (Figs. 2-8A, 2-8B and 2-8C). This contrasts a 
recent report indicating a better Arg-752 to 3-keto O H-bond for DHT than T (51).  
Ring A chemistry also influences a network of H-bonds through structural water 
HOH1 that is centrally positioned between ring A of T and key residues in AF2 backbone 
helices 3 and 5. HOH1 can accept a proton from side chains of helix-5 Arg-752 (3.0Å) and 
helix-3 Gln-711 (2.6Å) and donate a proton to the backbone carbonyl of helix-5 Met-745 
(2.7Å). Based on the distance and angular relationships, these H-bond interactions for bound 
T and DHT satisfy 3 of 4 possible tetrahedral coordinates to water (52). T appears more 
likely than DHT to also accept an H-bond from HOH1 because of the more planar ∆4,5 
double bond in ring A positions the 3-keto O of T 0.3Å closer to HOH1 and the greater 
negative charge centered on the 3-keto O of the dipolar A-ring. The 117
o
 angle for the 
assumed HOH1 O-H bond vector of T aligns well with the 120
o
 sp
2
 3-keto O electrons 
compared to 100
o
 for DHT (53). The polar nature and superior hydrophilic properties of the 
T A-ring over DHT may favor the coexistence of donated H-bonds from HOH1 to the 3-keto 
O and Met-745 despite formation of a non-ideal, constrained 80
o
 angle (T 3-keto O, HOH1, 
Met-745 O) within the tetrahedral geometry of HOH1.  
Our results suggest the counterintuitive hypothesis that greater H-bonding by T is 
detrimental to agonist activity. With shorter distances between HOH1 and the 3-keto O and 
Met-745 carbonyl and the negative charge character of its 3-keto O, the polarized A-ring of T 
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may over-constrain the geometry and introduce unfavorable hydrophilic character into the 
hydrophobic environment of the binding pocket. The T ∆4,5 polarized double bond is located 
in a hydrophobic region bounded by Met-745, Phe-764, Met-749, and Val-746, within 5Å of 
the Met-745 to Val-746 amide bond. This introduces a polar atom mismatch with the 3-keto 
O being 3.8Å to the Met-745 O and the presumably positive T C-5 atom within 5Å of the 
Val-746 NH. In contrast, through changes also not evident in the crystal structures, it was 
recently suggested that a novel high affinity nonsteroidal AR modulator may influence AF2 
activity by engaging more favorable hydrophobic π-bonding to Phe-764 and alternative H-
bonding to backbone residues in helices 3 and 5 (45). 
For DHT, the nonpolar saturated boat-configured A-ring provides a neutral 3-keto O 
and increases the distance between HOH1 and the 3-keto O to 3.5Å, which weakens or 
eliminates a second HOH1 mediated H-bond. More relaxed A-ring geometry of DHT is 
further evident in the 0.2Å longer distance between HOH1 and the Met-745 O. The saturated 
A-ring of DHT eliminates the polarized atom mismatch and provides better hydrophobic 
interactions with neighboring residues listed above. Just exactly how T and DHT transmit 
these different signals to the AF2 surface is not clear, but in both cases the side chain of Met-
745 lies above the steroid A-ring and projects towards Leu-712, a proximal residue that lies 
in the floor of AF2. 
AF2 Residue Leu-712–Leu-712 establishes key hydrophobic contacts with i+1 Phe-23 
of the AR Fi+1XXLF motif and i+1 Leu-745 of the TIF2 LXXLL motif. Physiological 
relevance for Leu-712 in AR activity is established by the L712F mutation that causes grade 
3 partial androgen insensitivity without altering equilibrium androgen binding affinity (7, 
54). Increased bulk by Phe-712 in AR-L712F may interfere at the i+1 motif binding site. 
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Low intensity difference map electron density indicates the Leu-712 side chain is equally 
positioned in two conformations in all of our T-bound crystal structures. Two conformers are 
also seen with Met-895, an AF2 helix-12 residue within ~4Å of Leu-712, but more distant to 
the i+1 and steroid A-ring binding sites. Notably, there were single conformers of Leu-712 
and Met-895 for WT AR LBD bound to DHT with FXXLF or LXXLL peptide (18, 34, 42).  
We cannot rule out the possibility that the two conformations of Leu-712 and Met-
895 are crystallographic artifacts. On the other hand, the better interactions between the 3-
keto O of T to HOH1 and HOH1 to Met-745 and the polarity mismatch in the hydrophobic 
region near steroid carbons C-4 and C-5 suggest a mechanism not directly discerned from the 
structure. The effects of T appear to transmit through Met-745 to nearest AF2 floor residue 
Leu-712, which contacts the i+1 residue of the bound peptide. Based on proximity to the A 
ring and HOH1, the signaling conduit transmits through Gln-711 and/or Met-745 to Leu-712. 
Of these, Met-745 is most likely since it lies above the T A-ring ∆4,5 double bond to directly 
transmit A-ring chemistry to the side chain position of Leu-712 (Fig. 2-8). Gln-711 (adjacent 
to Leu-712) is less likely because two conformers of Gln-711 were in only 2 of 4 T-bound 
structures and was possibly influenced by a spuriously bound buffer derived glycerol. More 
importantly, two conformers of Gln-711 were reported for WT AR bound to DHT and 
FXXLF peptide (18). Two conformations of Met-895 may be a more indirect contributor to 
AF2 or have a cross-helix influence from Leu-712. In contrast, DHT appears to impart 
greater structural integrity to Leu-712 and AF2 helix-12 Met-895 in and near AF2 allowing 
near maximum motif binding and AR transcriptional activity. Elimination of conformational 
heterogeneity in Leu-712 and Met-895 by DHT may be required for optimal AF2 activity.  
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There are examples where side chain conformations of ligand binding pocket residues 
are strongly influenced by chemical architecture of the bound ligand. The C19 methyl group 
of T (shown here) and DHT (34) direct the side chains of Met-745 and Trp-741 into identical 
positions relative to the binding pocket. The Trp-741 nitrogen in the T and DHT-bound 
structures may establish interactions with structural HOH3. In contrast, R1881 lacks a C19 
methyl group, which allows Trp-741 the conformational freedom to adopt a position where 
the indole nitrogen is rotated away from HOH3 (4, 7) as shown in Fig. 2-11. Nonsteroid 
ligands such as bicalutamide (44) or its S-1 agonist analog (43) extend ether linked para-
substituted phenyl groups into an open channel between the AF2 helix-12 Met-895 and helix-
5 Met-742 and cause Trp-741 to adopt yet a third unique conformation (Fig. 2-11).  
Prostate Cancer Mutant AR-H874Y–H874Y is an AR somatic mutation identified in 
the human CWR22 prostate cancer xenograft that was isolated from a hormone refractory 
bone marrow metastasis of a patient treated with flutamide and luteinizing hormone releasing 
hormone agonist (24) and in a bone marrow metastasis from another patient receiving similar 
treatment (55). AR-H874Y retains high affinity T and DHT binding (7, 56) but more 
effectively interacts with the FXXLF motif despite similar motif binding affinity to WT AR. 
Improved FXXLF motif binding contributes to the slower dissociation rate of T and nearly 
equivalent T-induced transcriptional response as DHT-bound WT AR. Optimal AR FXXLF 
motif binding and slow ligand dissociation are thus hallmarks of the fully stabilized AR 
consistent with properties of the AR N/C interaction (8, 57) and AR stabilization (7, 58). 
Greater AF2 activity of T-bound AR-H874Y is supported by the effects of MAGE-11, an AR 
coregulator that binds the AR FXXLF motif and targets AF2 for activation by SRC/p160 
coactivators (23).  
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The nearly identical crystal structures of bound T and DHT and surrounding pocket 
residues indicate that the DHT-like activity of T-bound AR-H874Y is not strictly ligand-
mediated. H874Y provides two direct H-bonds in the receptor core in place of 3 water-
mediated H-bonds in WT AR LBD that can stabilize the interior core near helix-5 Met-742, 
helix-4 Tyr-739, and exterior helix-10 that underlies AF2 helix-12. This tethers Met-742, a 
key residue proximal to the ligand binding pocket, and Tyr-739 near key AF2 domain 
residues, with exterior helix-10 via the mutant Tyr-874. Direct H-bonding likely improves 
AF2 motif binding and increases the lifetime of bound T. Agonist-induced stabilization of 
helix-10 is supported by the activity of S-1 bicalutamide which may form an H-bond from its 
fluorine atom to HOH3, a structural water that interacts with His-874 and is functionally 
replaced by the Tyr-874 phenolic oxygen (see Fig. 2-11) (43). The proposed destabilizing 
effects of T are more than compensated by the structural stabilizing effects of the H874Y 
mutation. Increased activity by AR-H874Y was also recognized for hydroxyflutamide and 
other ligands (24, 43). AR mutations that cause the androgen insensitivity syndrome support 
the importance of stabilizing helix-10 for AR function as well (59). 
Prostate cancer cell survival and tumor expansion is favored by mutations that 
increase AR response to T, particularly in recurrent prostate cancer where SRC/p160 
coactivators can be overexpressed (22). Our studies provide support for recent findings that 
local androgen production increases AR transcriptional activity in prostate cancer. Greater 
circulating T levels correlate with prostate cancer development (60, 61) and unlike normal 
prostate following androgen deprivation (62), T levels persist in recurrent prostate cancer 
tissue (63).  
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H-bond Chemistry and Protein Structure–Subtle changes in water mediated H-bond 
chemistry that influence AR transcriptional activity may result from thermodynamic effects 
on protein structure and protein-ligand interactions (64). H-bonds between protein groups 
and buried water molecules can stabilize structure through compensatory changes in enthalpy 
and entropy (65) as might occur for the H-bonding projections of Gln-711, Arg-752, Met-
745, His-874, and Tyr-874. Such water mediated H-bonds can provide favorable enthalpy but 
less favorable entropy than direct H-bonds in protein-ligand interactions (64, 66). Deeply 
buried structured water molecules engaged in multiple H-bonds increase protein flexibility 
and vibrational entropy, whereas direct protein-mediated H-bonds provide a more rigid 
structure with fewer degrees of freedom compared to water-mediated H-bonds (67). 
Replacement of structured water by direct H-bonds in AR-H874Y may reduce vibrational 
entropy and stabilize AF2 helix-12 for improved FXXLF and LXXLL motif binding (5, 7). 
Increased stabilization of AF2 helix-12 by direct H-bonding in AR-H874Y could increase the 
activity of T and weaker adrenal androgens. Nonsteroidal ligands such as bicalutamide or the 
S-1 analog have an extended para-phenyl substituent that binds in a channel between AF2 
and His-874 that can directly H-bond to the same HOH3 through a fluorine atom (43, 44).  
We conclude that T and DHT differentially modulate AR activity by altering the AR 
AF2 surface response towards AR FXXLF and coactivator LXXLL motif binding mediated 
through a network of water mediated H-bonds and hydrophobic interactions. T-bound WT 
AR acquires subtle conformational instability arising from the increased polarity of T, which 
decreases the effectiveness of AF2 to serve as an FXXLF and LXXLL motif-binding site. 
DHT-bound WT AR and prostate cancer mutant AR-H874Y bound to T or DHT fully engage 
the FXXLF and LXXLL motifs for maximal AR transcriptional activity. The biologically 
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active androgens T and DHT are examples of agonist-dependent modulation of AF2 
transcriptional activity that has profound physiological consequences in vivo.  
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Figure 2-1. AF2 Activity in the AR LBD. (A) Schematic diagram of AR LBD deletion 
mutants. Full-length human AR (amino acid residues 1-919) contains activation function 1 
(AF1, amino acid residues 142-337), DNA binding domain (DBD residues 559-623), hinge 
region residues 624-670, and LBD residues 671-919 that includes AF2. AR hinge region 
residues 624-639 contain the carboxyl-terminal portion of the bipartite AR nuclear targeting 
signal residues Arg-629, Lys-630, Lys-632, and Lys-633 (underlined) (38). AR-(624-919), -
(640-919) and –(658-919) with WT and mutant sequence were expressed as GAL4 DNA 
binding domain fusion proteins. AR residues 663-919 and H874Y mutant were expressed for 
crystallography as His6-tagged fusion proteins with intervening thrombin cleavage site. (B) 
Similar expression of GAL-AR-LBD fusion proteins. COS cells were transfected with 10 µg 
GAL-0 (lane 1), GAL-AR-(658-919) (lanes 2-5) and GAL-AR-(624-919) (lanes 6-9) with 
WT or mutant sequence. Protein extracts (60 µg of protein/lane) were separated on a 10% 
acrylamide gel containing SDS and the blot probed using an anti-GAL antibody. (C) 
Androgen-dependent activity of GAL-AR-(624-919), GAL-AR-(658-919) WT and H874Y 
mutants in CV1 cells requires coexpression of TIF2. CV1 cells plated in 6-cm dishes were 
transfected by calcium phosphate DNA precipitation with 5 µg 5XGAL4Luc3 reporter vector 
and 0.1 µg GAL-AR-(624-919) or GAL-AR-(658-919) with WT or H874Y sequence in the 
absence and presence of 2 µg pSG5-TIF2. Cells were treated with and without increasing 
concentrations of DHT (D) and T as indicated and luciferase activity was determined. Data 
are representative of three independent experiments. (D) Inhibition of the AR N/C and 
coactivator interactions by AR hinge residues 624-639. HeLa cells were transfected using 
FuGENE 6 by adding per well 0.1 µg 5XGAL4Luc, 50 ng VP16, VP-AR-(1-660), or VP-
TIF2-(624-1287) with 0.1 µg GAL-AR-(624-919), -(640-919) or -(658-919). Cells were 
incubated with and without 0.1-10 nM DHT for 24 h as indicated and assayed for luciferase 
activity. Data are representative of three independent experiments.  (E) Androgen-dependent 
transcriptional activity of GAL-AR-(624-919), GAL-AR-(658-919), and H874Y mutants in 
CWR-R1 cells. CWR-R1 cells (2 x 10
5
/well) were transfected using Effectene by adding per 
well 0.1 µg GAL-AR-(624-919), GAL-AR-(658-919) or H874Y mutants and 0.25 µg 
5XGAL4Luc3. Cells were treated with and without increasing concentrations of T and DHT 
for 24 h as indicated, and luciferase activity was determined. Data are representative of three 
independent experiments. (F) Androgen dependent AF2 activity of GAL-AR-(658-919) in 
CWR-R1 cells. CWR-R1 cells (2 x 10
5
/well) were transfected using Effectene by adding per 
well 0.1 µg GAL-AR-(658-919) or H874Y, K720A or E897K mutants and 0.25 µg 
5XGAL4Luc3. Lys-720 and Glu-897 are charge clamp residues in AF2. Cells were incubated 
with and without 0.1, 1, and 10 nM T for 24 h and luciferase activity was determined. Data 
are representative of at least three independent experiments. 
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Figure 2-2. Increased AR-H874Y LBD AF2 Activity Response to T. (A) CWR-R1 
prostate cancer cells (2 x 10
5
/well) were transfected using Effectene by adding per well 0.1 
µg GAL-0, GAL-AR-(658-919), or H874Y mutant and 0.25 µg 5XGAL4Luc3. Cells were 
incubated in the absence and presence of 0.1, 1 and 10 nM 5α-androstane-3α,17β-diol (Dl, 
Diol), androstenedione (Dn, Dione), T and DHT for 24 h as indicated, and luciferase activity 
was determined. (B) HeLa cells were transfected using FuGENE 6 by adding per well 0.1 µg 
GAL-0, GAL-AR-(658-919) or H874Y mutant and 0.25 µg 5XGAL4Luc3. Transfected cells 
were incubated with and without androgen as indicated for 24 h and assayed for luciferase 
activity. Data in A and B are representative of at least three independent experiments. 
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Figure 2-3. Increased Transcriptional Activity of AR-H874Y by T and Adrenal 
Androgens. (A) CWR-R1 cells (1.6 x 10
5
 cells/well) were transfected with 0.1 µg MMTV-
Luc/well of 12-well plates using Effectene. Cells were incubated in the absence and presence 
of increasing concentrations of DHT, T, androstenedione (Dione), and androstanediol (Diol) 
as indicated for 24 h and assayed for luciferase activity. (B) HeLa cells were transfected 
using FuGENE 6 by adding per well 10 ng pCMV5 empty vector (p5), pCMVhAR or the 
H874Y mutant and 0.25 µg PSA-Enh-Luc. Cells were incubated with and without 0.001 to 
10 nM DHT (D) or T, and 0.1 to 10 nM androstenedione (Dn, Dione) or 5α-androstane-
3α,17β-diol (Dl, Diol) for 24 h before luciferase activity was determined. Data in A and B are 
representative of three independent experiments.  
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Figure 2-4. MAGE-11 Increases AR-H874Y Activity Response to T and DHT. CV1 cells 
plated in 6-cm dishes were transfected using calcium phosphate DNA precipitation by adding 
per dish 0.1 µg of WT pCMVhAR (AR-WT) or H874Y mutant and 5 µg PSA-Enh-Luc 
reporter in the absence and presence of 2 µg pSG5-TIF2 and/or 2 µg pSG5-MAGE-11-(1-
429) (MAGE) as indicated. Cells were incubated with and without 0.1 nM T for 48 h before 
luciferase activity was determined. Data are representative of three independent experiments. 
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Figure 2-5. Fluorescence Binding Isotherms. (A) Increasing concentrations of AR LBD 
and AR-H874Y LBD purified in the presence of 10 µM T or DHT, and ERβ LBD in the 
presence of 40 µM estradiol were incubated for 1 h at room temperature without further 
ligand addition with fluorescein-labeled AR FXXLF peptide as described under 
“Experimental Procedures”. (B) Increasing concentrations of purified WT AR LBD, AR-
H874Y LBD, and ERβ LBD purified in the presence of 10 µM ligand were incubated for 1 h 
at room temperature in the presence of 40 µM T, DHT or estradiol and fluorescein-labeled 
TIF2 LXXLL peptide as described under “Experimental Procedures”. Affinity binding 
constants for AR FXXLF and TIF2 LXXLL peptides are summarized in Table 2-1. The data 
are the mean ± S.E. expressed as millipolarization units (mP) versus purified receptor LBD 
concentration.  
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Figure 2-6. Kinetics of T and DHT Dissociation from AR and AR-H874Y. (A) 
Dissociation rates of [
3
H]T and [
3
H]DHT were determined as described under “Experimental 
Procedures” by transient transfection of COS cells with 2 µg pCMVhAR (AR) and 2 µg 
pCMVhAR-H874Y (AR-H874Y). Transfected cells in culture were incubated for 2 h at 37˚C 
in the presence of 5 nM [
3
H]T and 3 nM [
3
H]DHT followed by a chase period with unlabeled 
50 µM T or 50 µM R1881 and assayed at 30-min intervals up to 2.5 h. Pseudo-first order 
ligand dissociation allowed use of unlabeled R1881 to prevent rebinding of [
3
H]DHT and 
avoid the complications of low water solubility of DHT. Dissociation half-times were 
calculated as the time required at 37˚C to reduce specific binding by 50%. Data are 
representative of three independent experiments. (B) Immunoblot of WT and H874Y AR and 
AR-(507-919) expression levels in COS cells. Cells transfected with 10 µg pCMVhAR, 
pCMVhAR-(507-919), and the corresponding H874Y mutants were incubated in serum free 
medium in the absence of hormone. Protein extracts (20 µg protein/lane) were separated on a 
10% acrylamide gel containing SDS and the transferred protein blot probed using anti-AR 
antibody AR-52. 
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Figure 2-7. Crystal Structures of WT and H874Y AR LBD Bound with T and AR 
FXXLF or TIF2 LXXLL Peptide. (A) Global front view of superimposed structures of WT 
and H874Y AR LBD bound to T and AR-(20-30) FXXLF or TIF2-(740-752) LXXLL peptide. 
Shown are WT AR LBD–T–AR FXXLF peptide (tan, LBD ribbon; magenta, peptide), WT 
AR LBD–T–TIF2 LXXLL peptide (lime green, LBD ribbon; cyan, peptide), H874Y AR 
LBD–T–AR FXXLF peptide (yellow, LBD ribbon; green, peptide) and H874Y AR LBD–T–
TIF2 LXXLL peptide (lavender, LBD ribbon; blue, peptide) and T (LBD ribbon color carbon, 
red oxygen). Human AR helix (H) and β-strand (BS) amino acid residues are H1 673-680; 
H2 not assigned; H3 697-721; H3' 725-727; H4 730-739; H5 741-756; BS3 761-765; BS4 
768-771; H6 772-776; H7 780-797; H8 801-812; BS5 815-817; H9 824-842; H10 851-882; 
H11 884-887; H12 893-908; BS6 911-913. (B) Rotated view of (A) looking towards the 
carboxyl-terminal end of helix-5 and NH2-terminal ends of helices 6 and 8. Residues 843-850 
between H9 and H10 were devoid of electron density. (C) Detailed view of the T-bound 
ligand binding pocket and surrounding residues of WT and H874Y AR LBD bound with AR-
(20-30) FXXLF or TIF2-(740-752) LXXLL peptide. In all four T-bound structures the ligand 
binding pockets are essentially identical to each other. A single conformation was observed 
for all the displayed side chains except for Leu-712 (50% A and B) and Gln-711 (80% A and 
20% B in the WT AR LBD–T–LXXLL and AR-H874Y LBD–T–FXXLF structures). A 
buffer-derived glycerol molecule (not shown) near Gln-711 was present in all 4 WT and 
H874Y AR LBD–T structures. Color scheme as in (A) with nitrogen atoms in blue and 
oxygen atoms in red; orange dashed lines designate potential interactions with neighboring 
polar atoms. (D) Detailed view to display the molecular architecture from the ligand binding 
pocket to the AF2 peptide-binding site and i+1 side chain of Phe-23 of bound AR-(20-30) 
FXXLF peptide and Leu-745 of bound TIF2 LXXLL peptide. Different conformers of Met-
734 and Tyr-739 correlate with the induced fit binding of the FXXLF or LXXLL motif. The 
WT and H874Y AR LBD bound to T and AR FXXLF or TIF2 LXXLL peptide are 
superimposed and use the color scheme of (A). Side chains for Leu-712 and Met-895 are 
distributed equally into two rotamers. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
65 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
66 
 
Figure 2-8. Potential A-ring and Water mediated H-bonding Schemes for T and DHT. 
Predicted A-ring H-bond distances and angles are shown based on the tetrahedral geometry 
of conserved structural water HOH1
 
(see Table 2-4). Arrowhead black dashed lines indicate 
the direction of donated H-bonds and orange dashed lines designate potential interactions 
with neighboring polar atoms of WT AR LBD bound to T and AR-(20-30) FXXLF peptide 
(tan) (A); WT AR LBD bound to DHT and GRIP-1-(740-752) LXXLL peptide (green) (42) 
(B); and the superimposition of A and B (C). Superior hydrophilic properties and a shorter 
distance are thought to enhance the HOH1 to T 3-keto O H-bond over that in DHT.  
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Figure 2-9. Comparison of WT AR LBD–T–AR FXXLF and WT AR LBD–DHT–
LXXLL. Detailed view shows nearly identical molecular architecture of T and DHT-bound 
AR LBD from the ligand binding pocket to AF2 peptide-binding site. Shown here for WT 
AR LBD–T–AR-(20-30) FXXLF peptide (tan) but seen in all of our T-bound AR LBD 
structures are the two side chain conformations for Leu-712 and Met-895. By comparison 
with previously reported WT AR LBD–DHT (green) with GRIP1-(740-752) LXXLL peptide 
(IT63, 42) or FXXLF (not shown, ITR7, 18), those side chains were conformed into a single 
rotamer. The i+1 motif residues, Phe-23 (magenta) of the AR FXXLF peptide and Leu-745 
(cyan) of the GRIP-1 LXXLL peptide, are shown. Orange dashed lines designate potential 
interactions with neighboring polar atoms. Portions of the LBD backbone are transparently 
displayed. 
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Figure 2-10. Detailed Crystal Structure Comparison of WT and H874Y AR LBD Bound 
to T and AR FXXLF Peptide. (A) Detailed view of WT AR LBD bound to T and AR-(20-
30) FXXLF peptide showing a water mediated H-bond network from His-874 (tan) nitrogen 
(blue) through HOH3 (red sphere) to the helix-5 Met-742 amide and HOH4 to the helix-4 
Tyr-739 backbone carbonyl. These conserved receptor core structural waters link His-874, 
which lies beneath helix-12, to Tyr-739. Black dashed arrowhead lines indicate the direction 
of donated H-bonds; orange dashed lines designate potential interactions with neighboring 
polar atoms; interatomic distances are reported in Angstroms; T rings labeled A-D.  (B) 
Detailed view of AR-H874Y LBD–T–AR-20-30 FXXLF peptide. Note the extended phenolic 
hydroxyl of AR H874Y prostate cancer mutation Tyr-874 displaces structural water HOH3 
and provides direct H-bonds to the backbone amide of helix-5 Met-742 and the carbonyl of 
helix-4 Tyr-739 (yellow). H-bonds labeled as in (A) with HOH4 shown as blue sphere.  
 (C) Superposition of (A) and (B) showing how the phenolic hydroxyl group of helix-10 
mutant Tyr-874 of AR-H874Y nearly extends to the same position as HOH3 in the WT AR 
LBD structure with conservation of backbone positions for Try-739, Trp-741, and Arg-752. 
(D) Superposition of WT AR LBD (tan) bound to T and AR-(20-30) FXXLF (i+1 Phe-23, 
green) and AR-H874Y LBD (yellow) bound to T and AR-(20-30) FXXLF (i+1 Phe-23, 
magenta). TIF2-(740-752) LXXLL i+1 residue Leu-745 (cyan) is shown for comparison. 
Direct H-bonding by Tyr-874 to the backbone of Tyr-739 displaces HOH3 and could further 
stabilize another H-bonding network represented with orange dashed lines that links Met-
734 CO to Gln-738, Gln-902, and Lys-905.  
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Figure 2-11. Structural Differences Between the Steroid and Nonsteroidal Ligand 
Binding Pockets. Superimposition of WT AR LBD crystal structures bound with an FXXLF 
peptide and T (brown), DHT (green) (18), R1881 (magenta) (4), and S-1 bicalutamide 
agonist analog (cyan) (43) and AR-H874Y LBD bound to the AR FXXLF peptide and T 
(yellow). The C-19 bridgehead methyl group on T and DHT forces the Met-745 and Trp-741 
side chains away from the steroid A-ring. For R1881 and S-1, the absence of an equivalent 
methyl group allows these side chains to adopt different rotamers that fill the vacated space 
above ring-A. The para-fluoro phenyl group on S1 extends into the space between helix-12 
Met-895 and helix-5 Met-742 and directs Trp-741 to a third unique conformation. 
Appropriate para-phenyl substituents are thought to stabilize the AR LBD core by interacting 
with HOH3 (43). 
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Table 2-1. Androgen Dependent AR LBD and AR-H874Y LBD Binding Affinities for 
AR FXXLF and TIF2 LXXLL Peptides. Fluorescence polarization measurements were 
determined using fluorescein-labeled peptides as described under “Experimental Procedures” 
for 1 h at room temperature for purified AR LBD, AR-H874Y LBD, and ERβ LBD 
containing 10 µM T, 10 µM DHT, or 40 µM estradiol as indicated without further ligand 
addition.  
 
 
 
AR and ERβ LBD Binding Affinities (Kd, µM) for FXXLF 
and LXXLL Peptides 
 T DHT E2 
FXXLF    
AR-LBD 5.5 ± 0.3 3.0 ± 0.4 – 
AR-LBD-H874Y 4.9 ± 0.6 3.5 ± 0.6 – 
ERβ-LBD – – >30 
LXXLL    
AR-LBD 27 ± 4 13.1 ± 1.5 – 
AR-LBD-H874Y 25 ± 5 17.2 ± 2.1 – 
ERβ-LBD – – 1.2 ± 0.1 
 
 
 
Table 2. Dissociation Half-times of [
3
H]T and [
3
H]DHT. Dissociation rates of [
3
H]T and 
[
3
H]DHT from AR, AR-(507-919), and the corresponding H874Y mutants expressed from 
pCMV5 were determined in transfected COS cells at 37˚C as described under “Experimental 
Procedures”. Dissociation half-times were calculated as the mean ± S.E. from at least three 
independent assays.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Dissociation half-times of [
3
H]T and [
3
H]DHT  
(min at 37˚C) 
 T DHT 
AR 55 ± 6 188 ± 36 
AR-H874Y 197 ± 27 268 ± 51 
AR507-919 25 ± 3 32 ± 4 
AR507-919-H874Y 49 ± 4 87 ± 6 
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Table 2-3. Crystallographic Data and Refinement Statistics. 
a
Rsym =∑ | Iavg  - Ii | / ∑ Ii is 
the data consistency where Iavg is the mean observed intensity and Ii is the observed intensity. 
b
Rfactor = ∑ | Fobs - Fcalc | / ∑ Fobs , where Fobs and Fcalc are the observed and calculated 
structure factors. Rfree is calculated from 3.2% of randomly selected reflections excluded in 
refinement and Rfactor calculations. 
c
Reported as the r.m.s.d. from ideal geometry. 
d
Structure 
coordinates and structure factor files are available at the Protein Data Bank website. 
 
 
 
Crystal 
AR H874Y T 
AR20-30 
AR H874Y T 
TIF2-III 
AR WT T 
AR20-30 
AR WT T 
TIF2-III 
X-ray source /λ(Å) APS-22BM /  
0.98 
APS-17BM / 
0.98 
APS-17BM / 
0.98 
APS-17BM / 
0.98 
Resolution (Å) 50.0 - 1.80 25.0 - 1.92 24.0 - 1.87 27.0 - 1.90 
Space group P212121 P212121 P212121 P212121 
Unit cell (Å) a=55.9 
b=66.1 
c=70.7 
a=54.4 
b=66.8 
c=69.9 
a=56.0 
b=66.4 
c=70.8 
a=54.8 
b=66.9 
        c=70.2 
Unique reflections  24,591 20,085 22,190 20,937 
Complete (%)  
(last shell) 
98.5 (87.4) 99.5 (98.1) 98.6 (87.8) 99.9 (100.0) 
I/ζ (last shell) 41.1 (3.8) 41.6 (3.0) 41.9 (2.4) 47.4 (3.8) 
Rsym
a 
(%)  
(last shell) 
4.2 (29.9) 4.7 (54.6) 4.4 (60.0) 4.4 (52.6) 
Refinement  Refmac Refmac Refmac Refmac 
Resolution range 42.7 - 1.8 20.5 - 1.92 20.5 - 1.87 20.6 - 1.90 
R factor
b
 / R free
b
 
(%) 
18.0 / 20.9 18.2 / 22.1 17.3 /  21.7 18.0 / 22.0 
Bond lengths
c
 (Å) 0.008 0.009 0.008 0.009 
Bond angles
c
 
(degrees) 
1.07 1.15 1.17 1.13 
Mean B value 23.7 30.4 28.0 28.7 
Non-hydrogen 
atoms: 
protein / peptide 
ligand 
solvent / other 
2265 
 
2058 
21 
170 / 16 
2303 
 
2125 
21 
151 / 6 
2275 
 
2055 
21 
183 / 16 
2330 
 
2140 
21 
158 / 11 
RCSB access code
d
 2Q7K 2Q7L 2Q7I 2Q7J 
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Table 2-4. Hydrogen Bond Distances and Angles for WT AR LBD Bound with T and 
AR FXXLF Peptide or DHT and LXXLL Peptide. Gln-711 N is oriented up for WT AR 
LBD–T with AR-(20-30) FXXLF peptide (Protein Data Bank 2Q7I) and WT AR LBD–DHT 
with ARA70 FXXLF peptide (Protein Data Bank 1T63) (42) consistent with the original AR 
LBD–DHT structure (34). Distances and angles were measured by PyMol from heavy atom 
(H), proton (P), carbonyl oxygen (CO), carbonyl oxygen, or carbon (C), heavy atom to heavy 
atom (H2H), heavy atom to proton (H2P). Ideal water geometry is tetrahedral with ~109º 
angles.  
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WT AR LBD-T-FXXLF 
BOND DISTANCE (Å) BOND ANGLE (°) 
 ATOM ATOM H2H H2P ATOM ATOM ATOM H2H2H H2P2H 
H -
bonds HOH1 M745O 2.7 – HOH1 M745O M745C – 117 
 
R752Nε2 T-O3 3.0 2.3 R752Nε2 H T-O3 126 – 
HOH1 T-O3 3.2 – HOH1 T-O3 T-C3 – 117 
R752Nε1 HOH1 3.0 2.0 HOH1 H R752Nε1 151 – 
Q711Nε2 HOH1 2.6 1.8 Q711Nε2 H HOH1 142 – 
HOH2 Q711O 3.0 – HOH2 Q711O Q711C – 146 
Alter-
nate R752Nε2 HOH1 3.1 2.2 R752Nε2 H HOH1 145 – 
Poten-
tial HOH1 Q711O 3.4 – HOH1 Q711O Q711C – 77 
Intera-
ctions HOH2 F764O 2.7 – HOH2 F764O F764C – 143 
 Q711Nε2 T-O3 3.7 3.0 Q711Nε2 H T-O3 127 – 
 H2H 
H2P 
(P2P*) 
HOH1 Geometry 3-keto O HOH1 R752Nε1 102 112 
 
R752Nε1 HOH1 Q711Nε2 117 128* 
Q711Nε2 HOH1 T-O3 78 67 
Q711Nε2 HOH1 M745O 124 112 
M745O HOH1 R752Nε1 117 119 
M745O HOH1 T-O3 80 – 
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WT AR LBD-DHT-LXXLL 
BOND DISTANCE (Å) BOND ANGLE (°) 
 
ATOM ATOM H2H H2P ATOM ATOM ATOM H2H2H H2P2H 
HOH1 M745O 2.9 – HOH1 M745O M745O – 117 
H -
bonds R752Nε2 T-O3 3.0 2.5 R752Nε2 H T-O3 110 – 
 
R752Nε1 HOH1 3.1 2.2 R752Nε2 H HOH1 151 – 
Q711Nε2 HOH1 2.7 1.9 Q711Nε2 H HOH1 135 – 
HOH2 Q711O 3.1 – HOH2 Q711O Q711C – 137 
Alter-
nate R752Nε2 HOH1 3.0 2.1 R752Nε1 H HOH1 145 – 
Poten-
tial HOH1 Q711O 3.4 – HOH1 Q711O Q711C – 79 
Interac-
tions HOH1 T-O3 3.5 – HOH1 T-O3 T-C3 – 100 
 
HOH2 F764O 2.9 – HOH2 F764O F764C – 143 
Q711Nε2 T-O3 4.0 3.3 Q711Nε2 H T-O3 128 – 
   H2H 
H2P 
(P2P*) 
HOH1 Geometry  M745O HOH1 R752Nε1 116 116 
 
R752Nε1 HOH1 Q711Nε2 121 134* 
Q711Nε2 HOH1 M745O 122 108 
Q711Nε2 HOH1 T-O3 79 68 
M745O HOH1 T-O3 79 – 
R752Nε1 HOH1 T-O3 98 109 
 
 
CHAPTER 3  
 
MELANOMA ANTIGEN GENE PROTEIN-A11 (MAGE-11) F-BOX LINKS THE 
ANDROGEN RECEPTOR NH2-TERMINAL TRANSACTIVATION DOMAIN TO 
p160 COACTIVATORS 
 
Abstract 
 
Androgen-dependent transcriptional activity by the androgen receptor (AR) and its 
coregulators is required for male reproductive development and function. In humans and 
other primates, melanoma antigen gene protein-A11 (MAGE-11) is an AR selective 
coregulator that increases AR transcriptional activity. Here we show that the interaction 
between AR and MAGE-11 is mediated by AR NH2-terminal FXXLF motif binding to a 
highly conserved MAGE-11 F-box in the MAGE homology domain, and is modulated by 
serum-stimulation of mitogen-activated protein kinase phosphorylation of MAGE-11 Ser-
174. The MAGE-11-dependent increase in AR transcriptional activity is mediated by a direct 
interaction between MAGE-11 and transcriptional intermediary factor 2 (TIF2) through the 
NH2-terminal region of TIF2, and by a MAGE-11 FXXIF motif interaction with an F-box-
like region in activation domain 1 of TIF2. The results suggest that MAGE-11 functions as a 
bridging factor to recruit AR co-activators through a novel FXX(L/I)F motif-F-box 
interaction paradigm. 
Introduction 
The androgen receptor (AR)
 
is a ligand-activated transcription factor that mediates the 
biological effects of testosterone (T) and dihydrotestosterone (DHT). High affinity binding of 
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androgen targets AR to the nucleus where it interacts with coregulators and androgen 
response element DNA associated with androgen-regulated genes. Naturally occurring 
functional knockouts of AR in the human population caused by AR gene mutations result in 
the androgen insensitivity syndrome, and demonstrate the functional importance of AR in 
male sex development and maturation (1). Gain-of-function AR somatic mutations identified 
in clinical specimens of prostate cancer support a critical role for AR during tumor 
progression to castration-recurrent growth (1–4). The multidomain structure of AR includes 
the carboxyl-terminal ligand binding domain with activation function 2 (AF2), a hydrophobic 
interaction surface structurally dependent on bound androgen (5). AR AF2 binds LXXLL 
motifs of steroid receptor p160 coactivators (SRC), but interacts preferentially with the 
FXXLF motif in the AR NH2 terminus (6, 7). AR activation function 1 (AF1) in the 
unstructured NH2-terminal region interacts with multiple coregulatory proteins (8, 9).  
 AR undergoes an androgen-dependent NH2- and COOH-terminal (N/C) interaction 
mediated by the AR NH2-terminal FXXLF motif (
23
FQNLF
27
) binding to AF2 in the ligand 
binding domain (5, 10–14). The ligand-dependent AR N/C interaction stabilizes AR and 
underlies the potency differences between testosterone and DHT (2, 11, 13–15). The AR N/C 
interaction coordinates transcriptional activity between AF1 and AF2, in part by 
competitively inhibiting the SRC/p160 coactivator LXXLL motif binding to AF2 (15). The 
regulatory effect of the AR N/C interaction is modulated by melanoma antigen gene protein-
A11 (MAGE-11), a MAGE gene family member and AR coregulator that binds the AR NH2-
terminal FXXLF motif, competes with the AR N/C interaction, and enhances AR 
transcriptional activity by increasing accessibility of AF2 for SRC/p160 coactivator 
recruitment (16).  
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 MAGE-11 expression is limited to human and nonhuman primates (17, 18), 
suggesting it arose during mammalian evolution as an additional control mechanism in the 
AR signaling network. Post-translational modification of MAGE-11 by phosphorylation of 
Thr-360, and subsequent monoubiquitinylation of Lys-240 and Lys-245 within the MAGE 
homology domain, a highly conserved region of the MAGE gene family, is induced by 
epidermal growth factor (EGF) and stabilizes the interaction with AR (19). The increase in 
MAGE-11 levels in castration-recurrent prostate cancer during androgen deprivation therapy 
by DNA hypomethylation at the transcriptional start site supports the concept that MAGE-11 
increases AR signaling in prostate cancer (20).  
 To understand the molecular mechanisms whereby MAGE-11 enhances AR 
transactivation, we pursued observations that MAGE-11 acts coordinately with 
transcriptional intermediary factor 2 (TIF2), one of the SRC/p160 coactivators implicated in 
AR signaling (16, 19). Previous studies have shown that TIF2 can associate with the NH2-
terminal region of AR, although the sites of interaction were not well defined (8, 10, 21). We 
considered the possibility that MAGE-11 enhances AR activity from AF1 through a direct 
interaction between MAGE-11 and TIF2.  
 The present study provides evidence that the AR NH2-terminal FXXLF motif interacts 
with a highly conserved MAGE-11 F-box (residues 329–369) in the MAGE homology 
domain, and that the interaction is modulated by mitogen-activated protein (MAP) kinase 
phosphorylation of MAGE-11 Ser-174 in response to serum stimulation. MAGE-11 also 
interacts directly with the NH2-terminal region of TIF2, and with the TIF2 AD1 region 
through a MAGE-11 FXXIF motif (
260
FPEIF
264
). The results suggest AR-mediated gene 
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transcription involves a novel protein interaction paradigm of the FXX(L/I)F motif binding to 
the F-box.  
Materials and Methods 
Plasmids–Expression plasmids include pCMV-AR (22), FLAG-AR (16), pCMV-AR-
(1–660) (23), pCMV-ARΔ120–472 (19), VP-AR-(1–660) (6), GAL-AR-(16–36) and -(4–52) 
(24), pSG5-MAGE-(1–429) (pSG5-MAGE), GAL-MAGE-(2–429) (GAL-MAGE), VP-
MAGE-(2–429) (VP-MAGE), FLAG-MAGE-(2–429) (FLAG-MAGE) (16), pSG5-HA-
MAGE-(2–429) and -(112–429), GAL-MAGE-K236A, -K240A,K245A, and -T360A, VP-
MAGE-K236A,K240A,K245A and T360A (19), GAL-TIF2.0-(1–627), 2.1-(624–1287), 2.2-
(1288–1464), 2.3-(624–1287), 2.3m123-(624–1179-L644E,L645A,L693A, 
L694A,L748A,L749A), 2.8-(1011–1179) and 2.12-(940–1131), VP-TIF2.0-(1–627), and 
pSG5-TIF2 (25).  
 Reporter vectors include prostate-specific antigen (PSA) enhancer luciferase (PSA-
Enh-Luc) (26), mouse mammary tumor virus-luciferase (MMTV-Luc), MMTVΔ-(−421–
−364)-Luc, which contains a deletion of a negative response element (27–29), and 
5×GAL4Luc3 (30). MMTVΔ-(−421–−364)-Luc was created by PCR mutagenesis of 
MMTV-Luc (31), with the XhoI/BamHI fragment inserted at the same sites of MMTV-Luc.  
GST-TIF2-(1–627), -(624–1141), -(1180–1464), and –(1288–1464) were created by PCR 
amplifying corresponding regions of pSG5-TIF2 and inserting the EcoRI/XhoI-digested 
fragments into similarly digested pGEX-4T-1. FLAG-TIF2 vectors were constructed by a 
triple ligation: TIF2-(1–569) was PCR amplified from pSG5-TIF2 and digested with 
EcoRI/NdeI to obtain TIF2-(1–370); TIF2-(370–1464) was obtained by digesting the parent 
template with NdeI/XbaI; both fragments were ligated into EcoRI/XbaI sites of pCMV5-
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FLAG-b. VP-TIF2.0-I336A, Y337A, pCMV-ARΔ120–472-V33E, -K720A, -E897K, and -
L26A,F27A, MAGE-11 alanine mutants, and phosphomimetics were created using 
QuikChange site-directed mutagenesis (Stratagene).  
 pSG5-HA-MAGE-(112–307), -(112–298), -(112–276), -(165–307) and -(Δ329–369) 
were created by PCR amplification using primers containing EcoRI/SalI ends and ligation 
into pSG5-HA. Additional MAGE-11 F-box deletion mutants were created by double PCR 
mutagenesis to create an EcoRI/XhoI MAGEΔ329–369 fragment that was inserted into the 
same sites of pSG5-HA to make pSG5-HA-MAGEΔ329–369, and into EcoRI/SalI sites of 
FLAG-b to make FLAG-MAGEΔ329–369.  
 GAL-MAGE-(85–205) and –(112–205) were created by PCR amplifying pSG5-
MAGE and inserting EcoRI/XhoI-digested fragments into GAL0 digested with EcoRI and 
SalI. GAL-MAGE-(112–170) was created by PCR amplifying the parent template and 
ligating the EcoRI/SalI-digested fragment into the same sites of GAL0. GAL-MAGE-(251–
272) wild-type and F260A,F264A mutant were created by cloning a small DNA insert into 
EcoRI and SalI sites of GAL0. All PCR-amplified regions were verified by DNA 
sequencing.  
DNA Transfection-CWR-R1 prostate cancer cells were maintained and transfected 
using Effectene (Qiagen) as described (2, 32). CWR-R1 cells (1.6 × 10
5
 cells/well) were 
transfected in 12-well plates with 0.1 μg/well of MMTV-Luc or MMTVΔ-(−421–−364)-Luc 
in the absence and presence of 0.1 μg of pSG5-MAGE-11 and/or 0.1 μg of pSG5-TIF2. 
Medium was replaced 24 h later with serum-free, phenol red-free medium in the absence and 
presence of DHT and/or EGF and incubated at 37 °C overnight.  
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 For small interfering RNA (siRNA) studies, CWR-R1 cells (4 × 10
5
/well) in 6-well 
plates were plated in 1 ml of antibiotic-free medium without EGF and transfected using 
Lipofectamine 2000 reagent (Invitrogen) in antibiotic-free medium with 0.1 μg of MMTVΔ-
(−421–−364)-Luc and 0.2 μg of pSG5 or pSG5-MAGE with and without 4 nM TIF2 siRNA-
3 (GAUCAGAAGUGACUAUUAA) or siCONTROL nontargeting siRNA pool (Dharmacon 
RNA Technologies). After 48 h at 37 °C, cells were transferred to serum-free, phenol red-
free medium containing antibiotics in the absence and presence of 0.1 DHT and 0.01 μg/ml 
of EGF. After 24 h cells were lysed in 0.25 ml of buffer containing 1% Triton X-100, 2 mM  
EDTA, and 25 mM Tris phosphate, pH 7.8 (19). Luciferase activity was measured using an 
automated Lumistar Galaxy multiwell plate luminometer (BMG Labtech). Luciferase data 
are representative of at least three independent experiments, with the graphs showing the 
mean ± S.E.  
 COS cells (4 × 10
5
/6-cm dish) were transfected in antibiotic-free medium using 
Lipofectamine 2000 with pSG5-MAGE, pSG5-TIF2, pCMV-AR, or empty parent vector in 
the absence and presence of 1 nM siRNA targeting MAGE-11, TIF2, AR, or nonspecific 
siCONTROL. The next day cells were placed to serum-free medium, and 24 h later extracts 
were analyzed by immunoblot as described below.  
 For inhibition of endogenous PSA mRNA expression, CWR-R1 cells (10
6
/6-cm dish) 
were transfected using Lipofectamine 2000 in 2% charcoal-stripped serum medium without 
antibiotics with 4 nM MAGE-11 siRNA-2 (GCACUGAUCCUGCAUGCUAUU), MAGE-11 
siRNA-3 (CAACUGCUCUUUGGCAUUGUU), AR siRNA-3 
(UCAAAGAACUCGAUCGUAUUU), TIF2 siRNA-3, and siCONTROL nonspecific siRNA 
(Dharmacon RNA Technologies). After 48 h cells were treated for 6 h in fresh medium with 
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and without 10 nM DHT and 10 ng/ml of EGF. RNA was extracted in 1 ml of TRIzol 
(Invitrogen) and analyzed by quantitative reverse transcription-PCR using SuperScript II 
reverse transcriptase (Invitrogen), 4 μg of RNA reverse transcription-PCR, 
CTCATCCTGTCTCGGATTGT and AGAAACAGGCTGTGCCGAC PSA primers (amplify 
a 189-bp fragment spanning amino acids residues 20–82), and control peptidylprolyl 
isomerase A primers ATCTTGTCCATGGCAAATGC and GCCTCCACAATATTCATGCC 
(amplify a 134-bp fragment spanning amino acids residues 97–141). Reactions were 
performed using a Roche LightCycler in 20 μl containing 0.4 μg of cDNA, 10 μl of 2× 
QuantiTect SYBR PCR Master Mix (Qiagen), and 2 μl of 2 μM primers at 95 °C for 15 min 
followed by 55 cycles of 94 °C for 15 s, 58 °C (PSA) or 55 °C (peptidylprolyl isomerase A) 
for 30 s, 72 °C for 30 s, and 79 °C for 8 s. A no template control was included in each run 
using standard curves for PSA and peptidylprolyl isomerase A (33).  
 LAPC-4 human prostate cancer cells were cultured in RPMI 1640 medium 
(Invitrogen) supplemented with 2 mM l-glutamine, penicillin, streptomycin, 10% fetal 
bovine serum, and 1 nM methyltrienolone (R1881) (34). LAPC-4 cells (5 × 10
5
 cells/well) in 
6-well plates containing 1 ml of antibiotic-free medium without R1881 were transfected the 
following day using Lipofectamine 2000 with 0.1 μg/well of MMTVΔ-(−421–−364)-Luc in 
the absence and presence of 3 nM siRNA. After 48 h at 37 °C, cells were transferred to 
serum-free, phenol red-free medium containing antibiotics in the absence and presence of 0.1 
nM DHT and 0.1 μg/ml of EGF, and luciferase activity was measured 24 h later.  
 Human endometrial Ishikawa cells (10
5
 cells/well) were transfected in 12-well plates 
using FuGENE 6 (Roche Applied Science) (19, 33) with 0.1 μg/well of PSA-Enh-Luc and 
0.1 μg of pSG5 empty vector, wild-type, and mutant pSG5-MAGE. The next day medium 
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was replaced with serum-free, phenol red-free medium in the absence and presence of 1 nM 
DHT with and without 0.1 μg/ml EGF. Twenty-four h later, luciferase activity was measured.  
 Monkey kidney CV1 cells (4.2 × 10
5
/6-cm dish) were transfected using calcium 
phosphate (15) with 0.05 or 0.1 μg of wild-type or mutant pCMV-AR and the indicated 
amounts of pSG5-TIF2, pSG5-MAGE, MMTV-Luc, or PSA-Enh-Luc. Immediately after 
transfection and 24 h later, cells were placed in serum-free, phenol red-free medium in the 
absence and presence of 1 nM DHT, incubated for 24 h at 37 °C, and luciferase activity was 
measured.  
 Mammalian two-hybrid assays were performed in human HeLa epithelial cervical 
carcinoma cells (5 × 10
4
 cells/well) transfected using FuGENE 6 (2) in 12-well plates with 
0.1 μg/well of 5×GAL4Luc3, 0.05 μg of wild-type or mutant GAL-MAGE, GAL-TIF2, 
GAL-AR-(4–52), or GAL-AR-(16–36) with 0.1 μg of wild-type or mutant VP-AR-(1–660), 
VP-MAGE, or VP-TIF2.0. The day after transfection, cells were transferred to serum-free 
medium and incubated overnight at 37 °C before luciferase activity was measured.  
Immunochemistry-Immunoblotting and immunoprecipitation were performed by 
transfecting each 10-cm dish with 2–4 dishes/group, 1.8–2.5 × 106 monkey kidney COS-1 
cells and 6 × 10
6
 human embryonic kidney 293 cells using DEAE dextran (2, 7), 2.0 × 10
6
 
CV1 cells using 450 μl of H2O, 75 μl of CaCl2, and 675 μl of 2× HBS added to 8 ml of 
medium/10-cm dish (2× HBS = 0.28 M NaCl, 0.05 M Hepes, and 1.5 mM Na2HP04, pH 7.1). 
HeLa cells (7.5 × 10
5
) and 4.4 × 10
5
 Ishikawa cells were transfected using 8 μl of FuGENE 6 
and 160 μl of medium in 6 ml of medium. Twenty-four h after transfection, cells were 
transferred to serum-free, phenol red-free medium in the absence and presence of 0.1 μg/ml 
of EGF, 10 nM DHT, and/or 1 μm MG132, a proteosome inhibitor. After 24 h, cells were 
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harvested in phosphate-buffered saline. For siRNA experiments, COS-1 cells (4 × 10
5
 
cells/well) plated in antibiotic-free medium in 6-well plates were transfected using 
Lipofectamine 2000 reagent with pSG5, pSG5-MAGE, pSG5-TIF2, or pCMV-AR in the 
absence and presence of siRNA.  
 For phosphorylation studies, COS cells (2 × 10
6
/10-cm dish) were transfected using 
DEAE dextran and extracted in immunoprecipitation (IP) lysis buffer containing 0.15 M 
NaCl, 0.5% Nonidet P-40, 10% glycerol, 50 mM Tris-HCl, pH 7.5, Complete protease 
inhibitor mixture (Roche), 1 mM dithiothreitol, and 1 mM phenylmethylsulfonyl fluoride. 
Protein concentration was measured using the Bio-Rad assay and bovine serum albumin as 
standard. Cell extracts were incubated in the absence and presence of 800 IU of λ-
phosphatase (New England Biolabs) for 1 h at 4 °C. For immunoblots, cells were solubilized 
in immunoblot (IB) lysis buffer containing 0.15 M NaCl, 1% Triton X-100, 0.1% SDS, 1% 
sodium deoxycholate, 0.5 mM EDTA, 50 mM Tris-HCl, pH 7.5, 1 mM 
phenylmethylsulfonyl fluoride, 1 mM dithiothreitol, and Complete protease inhibitor mixture 
(Roche). For inhibition of MAP kinase, U0126 (Promega) was added immediately after 
transfection to serum-containing medium. Cells were transferred 24 h later to serum-free 
medium with and without the same concentration of U0126 and 1 μm MG132. The next day 
cells were solubilized in IB lysis buffer containing Phosphatase Mixture Inhibitors 1/2 
(Sigma). Protein extracts were combined with 0.2 volumes of 6× sample buffer containing 
10% SDS, 30% glycerol, 30% 2-mercaptoethanol, and 0.35 M Tris-HCl, pH 6.8.  
 Immunoprecipitation was performed using 2–4 10-cm dishes/group of transfected 
COS-1 or HEK293 cells harvested in phosphate-buffered saline and pooled (15). Cells were 
solubilized in IP lysis buffer containing 0.05 M sodium fluoride. Lysates were precleared 
85 
 
using 0.1 ml of agarose (Sigma) by rotating for 1 h at 4 °C. Samples were transferred to 15 μl 
of anti-FLAG M2 affinity-agarose (Sigma) and incubated at 4 °C for 1 h or overnight. 
Samples were washed 3 times with IP lysis buffer, and protein was resuspended in 0.05 ml of 
2× SDS sample buffer containing 3.3% SDS, 10% 2-mercaptoethanol, 10% glycerol, and 
0.12 M Tris-HCl, pH 6.8. Immunoprecipitates, protein extracts, and EZ-Run Prestained Rec 
protein ladder (Fisher Bioreagents) were separated on 8, 10, or 12% acrylamide gels 
containing SDS and transferred overnight to nitrocellulose membranes at 4 °C.  
 Immunoblots were probed using the following antibodies: rabbit anti-HA tag (1:2500, 
Abcam, ab9110), mouse anti-β-actin (1:5000, Abcam), rabbit anti-GAL (1:500, Santa Cruz 
Biotechnology, sc-577), rabbit anti-VP16 activation domain (1:2000, Abcam, ab4809), 
mouse anti-FLAG M2 monoclonal antibody (1:2000, Sigma, F3165), mouse anti-TIF2 
(1:275, BD Transduction Laboratories, 610985), rabbit anti-Skp1 (1:400, Abcam, ab10546), 
rabbit AR32 immunoglobulin G (22) (0.4 μg/ml), rabbit AR52 immunoglobulin G (5 μg/ml) 
(35, 36), rabbit anti-MAGE-11 peptide antibodies MagAb-(13–26), -(59–79), and -(94–108) 
immunoglobulin G (6–10 μg/ml) (33), and rabbit polyclonal FLAG-MAGE antibody (10 
μg/ml) raised against purified baculovirus-expressed FLAG-tagged human MAGE-11. 
Incubations with primary antibody were performed for 1 h at room temperature or overnight 
at 4 °C, and with anti-mouse and anti-rabbit horseradish peroxidase-conjugated secondary 
IgG antibodies (1:10,000, Amersham Biosciences) at room temperature for 1 h. Signals were 
detected using chemiluminescence (SuperSignal West Dura Extended Duration Substrate, 
Pierce).  
In Vitro Binding and Kinase Assays-Glutathione S-transferase (GST) affinity matrix 
binding assays were performed with GST-TIF2 fusion proteins and 
35
S-labeled MAGE-11 
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expressed from pSG5-MAGE-11 using the TnT T7 Quick Coupled transcription-translation 
system (Promega) (6, 10). GST empty vector pGEX-4T-1 and GST-TIF2 fusion proteins 
were expressed in XL1-Blue Escherichia coli by incubating in the presence of 1 mM 
isopropyl 1-thio-β-D-galactopyranoside for 3 h at 37 °C. Cell pellets were resuspended in 
GST binding buffer containing 0.5% Nonidet P-40, 1 mM EDTA, 0.1 M NaCl, 20 mM Tris-
HCl, pH 8.0, with 1 mM dithiothreitol, 1 mM phenylmethylsulfonyl fluoride, and protease 
inhibitor mixture (Sigma). Protein expression was normalized by Coomassie Blue staining of 
a mini-gel. Fusion proteins were incubated with glutathione-Sepharose 4B beads (Amersham 
Biosciences) for 1.5 h at 4 °C, washed in GST binding buffer, and combined with 
35
S-labeled 
MAGE-11 prepared using 25 μCi/sample of [35S]methionine (PerkinElmer Life Sciences) 
and incubated for 2 h at 4 °C. Beads were washed, eluted using 2× SDS sample buffer, and 
analyzed on a 10% gel containing SDS.  
 In vitro kinase assays were performed as described (19) except using full-length 
recombinant active extracellular signal-regulated kinase 1 (ERK1) expressed from 
baculovirus in Sf9 cells (BioVision, 0.1 μg/μl, specific activity 383 nmol/min/mg) and GST-
MAGE-
171
PPQSPQEES
179
, GST-MAGE-
171
PPQAPQEES
179
, and GST-APRTPGGRR ERK1 
peptide substrates modeled after myelin basic protein (37). GST fusion proteins were 
expressed from pGEX-4T-1 by cloning short inserts into EcoRI/XhoI (MAGE-11) and 
EcoRI/SalI sites (ERK1 control peptide) designed to disrupt the cloning site for rapid clone 
identification. GST-peptide-Sepharose bead suspensions (50 μl) were washed in kinase 
buffer (1 mM EGTA, 0.4 mM EDTA, 5 mM MgCl2, 0.05 mM dithiothreitol, and 5 mM 
MOPS, pH 7.2) and incubated in kinase buffer containing 5 μl of 0.25 mM ATP and 0.16 
μCi/μl of [γ-32P]ATP (10 mCi/ml, 3000 Ci/mmol, PerkinElmer Life Sciences) for 30 min at 
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30 °C. Samples were separated on an 8–16% gradient minigel containing SDS (Invitrogen). 
Dried gels were exposed to x-ray film for 16 h and rehydrated for protein staining using 
Coomassie Blue.  
Results 
Dependence of AR Transactivation on MAGE-11 and TIF2-The ability of MAGE-11 
to function as an AR coregulator in association with TIF2 was evaluated in CWR-R1 prostate 
cancer cells where the response to DHT was maximal at 0.1 nM DHT. Expression of MAGE-
11 enhanced the dose-dependent increase in AR transactivation in CWR-R1 cells in response 
to DHT, and DHT and EGF, to a greater extent than TIF2 (Fig. 3-1A). Coexpression of 
MAGE-11 and TIF2 increased both ligand-dependent and ligand-independent AR activity to 
a greater extent than MAGE-11 or TIF2 alone.  
 TIF2 siRNA-3 inhibited TIF2 expression (Fig. 3-1B), and the MAGE-11-dependent 
increase in AR transcriptional activity in CWR-R1 cells (Fig. 3-1C), supporting the 
synergistic effects of MAGE-11 and TIF2. In LAPC-4 prostate cancer cells, the DHT and 
EGF-dependent increase in AR transactivation was inhibited by MAGE-11 siRNA-2, but not 
siRNA-3 (Fig. 3-1D), consistent with their relative inhibitory effects on MAGE-11 
expression (Fig. 3-1B).  
 In CWR-R1 cells, endogenous AR was readily detected on immunoblots (Fig. 3-1E), 
whereas endogenous MAGE-11 was evident ∼14 h after inducing quiescent cells to enter the 
cell cycle by treating with DHT and EGF (Fig. 3-1E, upper panel). The results suggest that 
endogenous MAGE-11 levels are low and cell cycle regulated, which may have hindered our 
attempts to coimmunoprecipitate endogenous MAGE-11 with AR or TIF2. However, we 
were able to demonstrate that siRNA knockdown of AR, MAGE-11, or TIF2 in CWR-R1 
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cells decreased the DHT and EGF-stimulated increase in PSA, an endogenous AR-regulated 
gene (Fig. 3-1E, lower panel). The results suggest that MAGE-11 functions coordinately 
with TIF2 to increase AR transactivation.  
Identification and Function of a MAGE-11 F-box-The carboxyl-terminal region of 
MAGE-11 contains sites of EGF-dependent phosphorylation and ubiquitinylation required 
for MAGE-11 to interact with AR (Fig. 3-2A) (16, 19). Examination of the MAGE-11 
sequence revealed a predicted α-helical F-box-like sequence 
IPEEΨ3XΨ2X2ΨXΨX7Ψ2X6ΨX8Ψ2 similar to cyclin F, where Ψ is a hydrophobic residue and 
X is any amino acid. Sequence similarity with the F-box of cyclin F was noted throughout the 
MAGE gene family (Fig. 3-2B). The functional significance of MAGE-11 F-box residues 
329–369 was supported by the presence of the EGF-dependent Thr-360 Chk1 
phosphorylation site within the F-box (underlined in Fig. 3-2B), because phosphorylation at 
Thr-360 is required for MAGE-11 to interact with AR (16, 19).  
 The functional properties of the MAGE-11 F-box were investigated by creating 
alanine point mutations at conserved hydrophobic residues (Fig. 3-2C) and testing their effect 
on AR transactivation in Ishikawa cells, a human endometrial cell line that responds to EGF 
(Fig. 3-2D). The MAGE-11 F-box mutations reduced or eliminated the MAGE-11-dependent 
increase in AR transcriptional activity in response to DHT, and DHT and EGF. 
Coimmunoprecipitation of AR with FLAG-MAGE in the absence and presence of DHT and 
EGF was not eliminated by the single or double mutations within the MAGE-11 F-box (data 
not shown), although deletion of the F-box inhibited the coimmunoprecipitation of MAGE-
11 with FLAG-AR (Fig. 3-2E). The results suggest that a MAGE-11 F-box dependent 
interaction increases AR transcriptional activity.  
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Synergistic Effects of TIF2 on AR AF2 Activity Depend on the MAGE-11 F-box-The 
MAGE-11 and TIF2-dependent increase AR transcriptional activity that derives from AF2 in 
the ligand binding domain was investigated using full-length AR and ARΔ120–472, a 
deletion mutant in which the AR NH2-terminal AF1 region was deleted (Fig. 3-3B, lower 
panel). ARΔ120–472 retains the AR NH2-terminal FXXLF motif (
23
FQNLF
27
) that interacts 
with MAGE-11 and AR AF2. Androgen-dependent transcriptional activity of ARΔ120–472 
depends entirely on AF2.  
 In agreement with results in Fig. 3-2D, MAGE-11 F-box mutants, as shown for 
MAGE-L358A, L359A, eliminated the MAGE-11 and TIF2-dependent increase in AR 
transactivation (Fig. 3-3A). The ability of MAGE-11 and TIF2 to increase androgen-
dependent ARΔ120–472 activity (Fig. 3-3, B and C) demonstrates the synergistic effects of 
MAGE-11 and TIF2 on AF2 activity.  
 The dependence of ARΔ120–472 transactivation on TIF2 binding to AF2 was 
demonstrated by the loss of activity caused by introducing the AR AF2 K720A or E897K 
charge clamp mutation that prevents TIF2 binding to AF2 (Fig. 3-3B), and by a TIF2 LXXLL 
motif mutant unable to bind AF2 (data not shown) (10). Transcriptional activity of ARΔ120–
472 was also eliminated by V33E, an AR mutation that inhibits AR FXXLF motif binding to 
MAGE-11 but not to AF2 (16) (Fig. 3-3B). This demonstrates that MAGE-11 binding to 
ARΔ120–472 is required to relieve repression of AF2 activity caused by the AR N/C 
interaction.  
 The inhibitory effect of the AR N/C interaction on AF2 transcriptional activity was 
also indicated by the TIF2- dependent increase in ARΔ120–472-FXXAA activity (Fig. 3-3B, 
L26A,F27A). In this case, mutations in the AR FXXLF motif inhibit binding to both AF2 and 
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MAGE-11 (6, 16), allowing TIF2 activation of AF2. ARΔ120–472 activity in the presence of 
TIF2 was also inhibited by the double and most of the single mutations in the MAGE-11 F-
box (Fig. 3-3, C and D). The results indicate that the MAGE-11 F-box is required for the 
synergistic effects of MAGE-11 and TIF2 on AR AF2 transcriptional activity.  
MAGE-11 F-box Binds the AR FXXLF Motif and Skp1-Mammalian two-hybrid assays 
provide evidence that the MAGE-11 F-box interacts with the AR FXXLF motif (Fig. 3-4). A 
series of single F-box mutations in GAL-MAGE eliminated the interaction with VP-AR-(1–
660), an AR NH2-terminal fragment that contains the AR FXXLF motif and DNA binding 
domain (Fig. 3-4A). The AR FXXLF motif-dependent interaction with MAGE-11 was shown 
by loss of the interaction with VP-AR-(1–660)-FXXAA (LFAA) as reported previously (16). 
Interaction of the AR FXXLF motif with MAGE-11 was also eliminated by the MAGE-
T360A mutation that disrupts a Chk1 phosphorylation site within the MAGE-11 F-box, and 
by mutations at monoubiquitinylation sites outside the F-box region (19).  
 To further characterize MAGE-11 F-box binding to the AR FXXLF motif, VP-MAGE 
single residue F-box mutants were coexpressed with GAL-AR-(4–52) or GAL-AR-(16–36), 
two short AR NH2-terminal FXXLF motif peptides. VP-MAGE F-box mutations inhibited the 
interaction with the AR NH2-terminal peptides (Fig. 3-4, B and C). The interaction was also 
influenced by a mutation at a potential MAP kinase phosphorylation site at MAGE-11 Ser-
174, which lies outside the F-box. VP-MAGE binding to GAL-AR-(4–52) or GAL-AR-(16–
36) decreased with the MAGE-11 S174A mutation, but was unchanged by the S174D 
phosphomimetic.  
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 MAGE-11 also interacted with Skp1 based on coimmunoprecipitation of endogenous 
Skp1 with FLAG-MAGE in HEK293 cells (Fig. 3-4D). This suggests an additional and more 
classical function of the MAGE-11 F-box.  
 The results indicate a MAGE-11 F-box interaction with the AR FXXLF motif that is 
influenced by phosphorylation at Thr-360 within the F-box, and potential phosphorylation at 
Ser-174 NH2-terminal to the F-box. MAGE-11 also interacts with Skp1, which suggests the 
MAGE-11 F-box serves as a binding site for Skp1, and MAGE-11 may associate with a 
Skp1-cullin-based E3 ubiquitin ligase complex.  
Serum Stimulation of MAP Kinase Phosphorylation of MAGE-Ser-174-The MAGE-
11 sequence flanking Ser-174 contains several potential Ser-Pro phosphorylation sites that 
include the MAP kinase consensus sequence 
172
PQSP
175
 (Fig. 3-5A). This, together with 
evidence that the S174A mutation inhibited MAGE-11 interaction with the AR FXXLF motif 
peptides, led us to investigate whether MAGE-11 is phosphorylated at Ser-174 by MAP 
kinase.  
 GAL-MAGE-(112–205) is a fusion protein that contains the MAGE-(168–182) Ser-
Pro region and migrates as a double band before, and single band after treatment with λ-
phosphatase (Fig. 3-5B, lanes 1 and 2), which suggests GAL-MAGE-(112–205) is 
phosphorylated. Evidence that Ser-174 is a phosphorylation site was obtained from GAL-
MAGE-(112–205)-S174A, which migrated as a single band of similar mobility before and 
after treatment with λ-phosphatase (Fig. 3-5B, lanes 3 and 4). GAL-MAGE-(112–205)-
S181A or -S117A mutants maintained the double band migration, which was eliminated by 
treatment with λ-phosphatase (Fig. 3-5B, lanes 5 and 9). The GAL-MAGE-(112–205)-
S174A,S181A double mutant (Fig. 3-5B, lanes 7 and 8), and GAL-MAGE-(112–170), which 
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lacks Ser-174 (Fig. 3-5B, lanes 11 and 12), migrated as single bands before and after 
treatment with λ-phosphatase. The results point to Ser-174 as a phosphorylation site in 
MAGE-11. Based on the MAP kinase consensus sequence at Ser-174, and decreased binding 
of AR FXXLF motif peptides to MAGE-S174A but not the MAGE-S174D phosphomimetic, 
we investigated whether a MAP kinase inhibitor or hormone stimulation would influence 
phosphorylation of MAGE-Ser-174.  
 Increasing concentrations of U0126, a MEK1 inhibitor that prevents activation of 
ERK1/2 (38), eliminated the double band migration of GAL-MAGE-(112–205), but had no 
effect on GAL-MAGE-(112–205)-S174A (Fig. 3-5C). Neither treatment with EGF (0.1 
μg/ml) nor dibutyryl cyclic AMP (10 mM) altered the double band migration of GAL-
MAGE-(112–205) (data not shown). However, addition of 10% serum to quiescent cells 
caused a time-dependent increase in intensity of the slower migrating band (Fig. 3-5D). In 
addition, introducing the MAGE-S174A mutation eliminated in vitro ERK1 phosphorylation 
of a GST-MAGE-(171–179) fusion peptide (Fig. 3-5E). The results suggest that serum 
stimulation of ERK1 phosphorylation at MAGE-Ser-174 modulates the MAGE-11 F-box 
interaction with the AR FXXLF motif.  
Interaction Between MAGE-11 and TIF2-The studies suggested that MAGE-11 and 
TIF2 act synergistically to increase AR transactivation through AF2 (Figs. 3-1 and 3-3), but 
it remained unclear whether MAGE-11 could increase TIF2-dependent AR transcriptional 
activity independent of AF2. To address this, we made use of AR-(1–660), a constitutively 
active AR NH2-terminal fragment that contains AF1, but lacks the AR ligand binding domain 
and AF2.  
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 The relatively low activity of AR-(1–660) increased ∼2-fold with the coexpression of 
TIF2 (Fig. 3-6A). This agrees with previous evidence that AR activation by TIF2 in the 
absence of MAGE-11 depends largely on TIF2 LXXLL motif binding to AR AF2 (6). AR-
(1–660) activity increased to a greater extent with the expression of MAGE-11, and increased 
further with the coexpression of MAGE-11 and TIF2. The MAGE-11 and TIF2-dependent 
increase in AR-(1–660) activity was inhibited by MAGE-11 F-box mutations that interfere 
with MAGE-11 binding to the AR-(1–660) FXXLF motif (Fig. 3-6B).  
 The results raised the possibility of a direct interaction between MAGE-11 and TIF2 
that could increase AR transcriptional activity in the absence and presence of androgen. An 
interaction between endogenous MAGE-11 and TIF2 in CWR-R1 or LAPC-4 cells could not 
be observed, possibly due to the low level cell cycle-dependent expression of MAGE-11 
(Fig. 3-1E). Furthermore, the association between MAGE-11 and TIF2 may be transient like 
AR and MAGE-11 in the presence of DHT (16). However, an interaction between TIF2 and 
MAGE-11 was demonstrated by coimmunoprecipitation of HA-MAGE with FLAG-TIF2 
(Fig. 3-7A), and by the coimmunoprecipitation of TIF2 with FLAG-MAGE (Fig. 3-7B). A 
direct interaction between MAGE-11 and TIF2 was supported by in vitro affinity matrix 
binding studies. MAGE-11 interacted to the greatest extent with the TIF2 NH2-terminal 
region present in GST-TIF2.0-(1–627), and to a lesser extent with TIF2 carboxyl-terminal 
fragments, some of which contain AD1-(1011–1179) (Fig. 3-7C). The results suggest that 
MAGE-11 interacts directly with TIF2 to increase AR transcriptional activity.  
MAGE-11 and TIF2 Interacting Domains-Mapping the interaction regions between 
MAGE-11 and TIF2 was performed initially using MAGE-11 deletion mutants (Fig. 3-8A). 
The requirement for MAGE-11 residues 112–298 was shown by coimmunoprecipitation of 
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MAGE-(112–429), -(112–307), and -(112–298) with FLAG-TIF2, compared with weaker 
interactions with MAGE-(112–276) and -(165–307) (Fig. 3-8B). Further resolution of the 
MAGE-11 interaction domains for TIF2 was limited by poor expression of the smaller 
MAGE-11 fragments.  
 In agreement with the in vitro binding results (Fig. 3-7C), regions in TIF2 (see 
diagram, Fig. 3-9A) that interacted with MAGE-11 included TIF2 NH2-terminal 1–627 and 
AD1 1011–1179 residues. This was evident by the coimmunoprecipitation of HA-MAGE 
and HA-MAGE-(112–429) with FLAG-TIF2 (Fig. 3-8C, top panel, lanes 3 and 4), FLAG-
TIF2.0-(1–627) (lanes 5 and 6), and FLAG-TIF2.8-(1011–1179), which contains AD1 (lanes 
7 and 8). The MAGE-(112–307) region NH2-terminal to F-box residues 329–369 was 
sufficient to interact with the NH2-terminal region of TIF2 (Fig. 3-8D). Interaction between 
MAGE-11 and the NH2-terminal region of TIF2 was also demonstrated in mammalian two-
hybrid assays using VP-TIF2.0-(1–627) and GAL-MAGE-(85–205) (Fig. 3-8E). The GAL-
MAGE-(85–205)-S174D phosphomimetic of MAP kinase site Ser-174 had greater inherent 
transcriptional activity than wild-type GAL-MAGE-(85–205) or the S174A mutant. 
However, the fold-increase in the presence of VP-TIF2.0-(1–627) and GAL-MAGE-(85–
205) or the S174A and S174D mutants was similar relative to the VP16 empty vector 
controls. This suggests that phosphorylation at Ser-174 does not influence the interaction 
between MAGE-11 and TIF2.  
 Interaction between MAGE-11 and the AD1 region of TIF2 was also demonstrated by 
the ability of MAGE-11 to increase the transcriptional activity of GAL-TIF2 fusion proteins 
(Fig. 3-9A). Both full-length MAGE-11 and MAGE-(112–429) increased the transcriptional 
activity of GAL-TIF2.1-(624–1287) and GAL-TIF2.3-(624–1179)-m123, where the latter 
95 
 
contains mutations at each of the three TIF2 LXXLL motifs (Fig. 3-9B). These results support 
the in vitro binding and coimmunoprecipitation evidence that MAGE-11 interacts directly 
with TIF2 independent of the TIF2 LXXLL motifs.  
 Evidence that transcriptional activity arising from the MAGE-11 interaction with 
TIF2 requires the TIF2 AD1 region was supported by the absence of a MAGE-dependent 
increase in GAL-TIF2.0-(1–627) activity (Fig. 3-9B), even though the TIF2 NH2-terminal 
region, which lacks AD1, interacts with MAGE-11 (see Figs. 3-7C and 3-8E). Full-length 
MAGE-11 and the MAGE-(112–429) fragment also increased the activity of GAL-TIF2.8-
(1011–1179) and GAL-TIF2.12-(940–1131), TIF2 fragments with only AD1 in common 
(Fig. 3-9A and 3-9C).  
 Mutations in the MAGE-11 F-box inhibited the ability of MAGE-11 to increase the 
AD1 activity of GAL-TIF2.8 (Fig. 3-9D). This appears to reflect a decreased transcriptional 
response of GAL-TIF2.8 AD1 to p300, which is known to interact with TIF2. Alone, p300 
resulted in a small increase in GAL-TIF2.8 activity. In the presence of MAGE-11, p300 
increased TIF2 AD1 activity in a MAGE-11 F-box-dependent manner (Fig. 3-9E). The 
results indicate that the MAGE-(165–298) region interacts with the NH2-terminal and AD1 
regions of TIF2, and that the MAGE-11 F-box influences TIF2 AD1 activation by p300.  
MAGE-11 FXXIF Motif-Within the MAGE-(165–298) region that interacts with TIF2 
is a predicted α-helical FXXIF motif with the sequence 260FPEIF264 flanked by charged 
residues similar to the AR FXXLF motif sequence 
23
FQNLF
27
 (Fig. 3-10A). The AD1 region 
of TIF2 also contains a predicted α-helical sequence with spacing of hydrophobic residues 
similar to the F-box in cyclin F, Skp2, and MAGE-11 (Fig. 3-10B). We therefore 
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investigated whether the MAGE-11 FXXIF motif contributes to the interaction with TIF2 
AD1.  
 Interaction between MAGE-11 and the AD1 region of TIF2 was indicated by the 
coimmunoprecipitation of HA-MAGE-(112–429) with FLAG-TIF2.8-(1011–1179) (Fig. 3-
11A, top panel, lane 2). Coimmunoprecipitation of TIF2-AD1 and MAGE-11 was not 
eliminated by single F260A and F264A mutations in the 
260
FPEIF
264
 region of HA-MAGE-
(112–429) (Fig. 3-11A, lanes 3 and 4) or HA-MAGE-(112–276) (data not shown). However, 
the MAGE-11-dependent increase in GAL-TIF2.1-(624–1287), and the increase in GAL-
TIF2-(624–1179)-m123 activity, was inhibited by the F260A or F264A mutations in MAGE-
11 (Fig. 3-11B). These same mutations also inhibited the TIF2-dependent increase in AR 
(Fig. 3-11C) and ARΔ120–472 transcriptional activity (Fig. 3-11D). In mammalian two-
hybrid assays, interaction between GAL-MAGE-(251–272), a short fusion peptide that 
contains the MAGE-11 FXXIF motif, and VP-TIF2.1-(624–1287), but not VP-TIF2.2-(1288–
1464) (Fig. 3-11E), provided evidence that the MAGE-11 FXXIF motif mediates an 
interaction with TIF2. 
Discussion 
Interaction Between MAGE-11 and TIF2-MAGE-11 increases AR transcriptional 
activity in part by increasing the recruitment of SRC/p160 coactivators (10, 21, 39). In the 
absence of MAGE-11, the AR N/C interaction competitively inhibits SRC/p160 coactivator 
binding to AF2, which shifts the dominant activation function from AF2 to AF1 (5) (Fig. 3-
12A). MAGE-11 relieves the AR N/C interaction-induced repression of AR AF2 activity by 
binding the AR FXXLF motif and increasing AF2 accessibility for SRC/p160 coactivator 
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binding. Here we show that MAGE-11 also interacts directly with TIF2 to increase both 
ligand-dependent and ligand-independent AR activity.  
 The results suggest that MAGE-11 functions as a bridging factor to stabilize and 
recruit SRC/p160 coactivators in a manner less dependent on AR binding of androgen. 
MAGE-11 interacts with the NH2-terminal region of TIF2, and with TIF2 AD1 through a 
MAGE-11 FXXIF motif (Fig. 3-12B). TIF2, SRC1, and TRAM1 each increases the activity 
of the AR-(1–660) NH2-terminal and the DNA binding domain fragment to a greater extent 
in the presence of MAGE-11. SRC/p160 coactivator interaction with the AR NH2-terminal 
region (10, 21) may be facilitated by their interaction with MAGE-11.  
MAGE-11 is an F-box Protein-MAGE-11 is a member of a multigene MAGE family 
whose functions are largely uncharacterized. MAGE- 11 is expressed in the human male and 
female reproductive tracts, and undergoes phosphorylation and monoubiquitinylation to 
interact with the AR FXXLF motif (16, 19, 33). Well characterized steroid receptor 
coactivator interaction motifs include the LXXLL motifs of SRC/p160 coactivators (40), 
FXXLF motifs of putative AR coactivators (7), bromodomains, and others (41). MAGE-11 
residues 329–369 function as an F-box interaction site for the AR FXXLF motif (Fig. 3-12), 
and a MAGE-11 FXXIF motif interacts with an F-box-like sequence in the AD1 region of 
TIF2.  
 The ∼40 amino acid F-box, named for a weakly conserved hydrophobic repeat first 
identified in cyclin F (42), is present in the S-phase kinase-associated protein Skp2, which 
interacts with Skp1 in the Skp1-cullin-Skp2-F-box (SCF) E3 ubiquitin ligase complex (42–
44). About 70 F-box proteins identified in humans are involved in phosphorylation-
dependent ubiquitination (42, 45). F-box proteins generally lack intrinsic activity (43, 46) 
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and are classified by their carboxyl-terminal substrate recognition motifs that recruit target 
proteins involved in gene regulation (44, 47–49). FBWs (FBXW) have WD40 repeats, FBLs 
(FBXL) have leucine-rich repeats, and FBXs (FBXO) lack these motifs or have other protein 
interaction motifs (45). F-box proteins include Skp2 of the SCF complex (48, 50, 51), and 
FBW7 (FBXW7 in humans, hCdc4 in Saccharomyces cerevisiae), a tumor suppressor that 
mediates the ubiquitinylation and degradation of cell cycle regulatory proteins such as c-Myc 
(52–54).  
 Based on our studies, MAGE-11 and its family members are F-box proteins that may 
function as components of the SCF complex. MAGE-11 would be in the FBX class of F-box 
proteins because it lacks a WD40 LxGH…D/N(X)5(W/F/Y)(D/N) repeat sequence (55). 
MAGE-11 shares size and sequence similarity with Skp2, but lacks the repeating leucine-rich 
β-strand and α-helix arrangement of Skp2 (56). The carboxyl-terminal position of the 
MAGE-11 40-amino acid F-box (amino acids 329–369) in the conserved MAGE homology 
domain differs from the NH2-terminal position of the F-box in components of the SCF 
complex. On the other hand, poxvirus ankyrin repeat proteins interact with Skp1 and have a 
30-residue F-box-like sequence in the carboxyl-terminal region (57). The conserved nature of 
the MAGE-11 F-box across the MAGE family, the MAGE-11 F-box interaction with the AR 
FXXLF motif, the F-box requirement for the MAGE-11-dependent increase in GAL-TIF2 
transcriptional activity, and evidence that MAGE-11 interacts with Skp1, suggest that the 
MAGE-11 F-box has multiple binding partners involved in domain sharing.  
 F-box proteins have functions other than as bait for the SCF complex (47). For 
example, the F-box protein MoKA is a KLF7 coregulator independent of the SCF complex 
and ubiquitination (58). MAGE-11 binding to the AR FXXLF motif is associated with 
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increased AR transcriptional activity and increased degradation of AR and MAGE-11 (15, 
16, 19, 59). Agonist-induced down-regulation of other steroid receptors (49, 60–63) occurs 
for AR through its association with MAGE-11. Like Skp2, MAGE-11 is expressed at low 
levels in a cell cycle-dependent manner, although MAGE-11 levels increase in human 
endometrium during the window of receptivity to implantation, and in castration-recurrent 
prostate cancer (20, 33).  
 Whether the phosphorylation and monoubiquitinylation-dependent MAGE-11 F-box 
interaction with the AR FXXLF motif involves the action of an SCF ubiquitin E3 ligase 
complex remains to be established. Substrates such as c-Myc and cyclin E, which bind the 
FBXW7 F-box protein that binds Skp1 in the SCF complex, are targeted for ubiquitinylation 
by phosphorylation within a phosphodegron (64). MAGE-11 is phosphorylated within the F-
box by checkpoint kinase Chk1, which triggers monoubiquitinylation at lysines 240 and 245 
(19), and by MAP kinase in response to serum. Monoubiquitinylation, which has been shown 
to mediate interactions between regulatory components of the proteosome required for 
transcription (65), may be required for an SCF function of MAGE-11.  
 MAGE-11 F-box binding to the AR FXXLF motif, and MAGE-FXXIF motif binding 
to an F-box-like sequence in AD1 of TIF2, suggests a novel F-box-FXX(L/I)F protein 
interaction paradigm. Selectivity for the MAGE-11 F-box-AR FXXLF motif interaction is 
supported by the lack of MAGE-11 binding to FXXLF motifs present in other AR 
coactivators, even though these same FXXLF motifs interact with AR AF2 (7, 16). Single 
amino acid mutations disrupt the MAGE-11 F-box-AR FXXLF motif and MAGE-11 FXXIF-
TIF2 AD1 interactions, although these same mutations did not eliminate 
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coimmunoprecipitation of the complex. This suggests that the protein structure outside the 
region to some extent compensates for single residue F-box mutations.  
 The FXX(L/I)F motifs in AR and MAGE-11, and the uncharacterized FXXIY motif in 
TIF2, are each flanked by charged residues that may facilitate protein-protein interactions by 
increasing the solubility of the hydrophobic region. AR FXXLF motif binding to AF2 is 
influenced by complementary charged clusters that surround the AF2 region of AR (24). The 
TIF2 FXXIY motif 
333
FSQIY
337
 and Skp1 FXXIL motif 
101
FELIL
105
 within the interaction 
region for Skp2 (Fig. 3-10A) are also flanked by charged residues (43). Although functions 
for the TIF2 and Skp1 FXXLF-like motifs have not yet been demonstrated, the presence of 
flanking charged residues support a role in mediating protein-protein interactions. The 
ubiquitinylation-dependent interaction between the AR FXXLF motif and the MAGE-11 F-
box may be relevant to other MAGE gene family members with sequence homology within 
the MAGE-11 F-box.  
Post-translational Regulation by Phosphorylation-Phosphorylation of steroid 
receptors and their coactivators has been linked to ubiquitinylation and subsequent 
degradation (41, 63, 66–68). AR signaling is regulated by its own phosphorylation (29, 69, 
70), which includes EGF-dependent MAP kinase phosphorylation at AR Ser-515 (29), and 
MAP kinase phosphorylation of SRC/p160 coregulators (41, 67, 68, 71). MAP kinase 
signaling was also implicated in AR activity based on the inhibitory effects of U0126, a MAP 
kinase MEK1 inhibitor (29, 72, 73).  
 MAGE-11 Thr-360 phosphorylation by checkpoint kinase Chk1 within the MAGE-11 
F-box is required for its interaction with the AR FXXLF motif. AR FXXLF motif binding to 
MAGE-11 is modulated by serum stimulation of MAP kinase phosphorylation at MAGE-
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Ser-174, although mutation of Ser-174 did not eliminate the ability of MAGE-11 to increase 
AR transcriptional activity (19). MAGE-11 Ser-174 appears to be a post-translational 
regulatory site phosphorylated by ERK1, based on the inhibitory effect of the S174A 
mutation in the context of shorter AR NH2-terminal fragments (19), and the greater 
transcriptional activity of GAL-MAGE-11 fusion proteins containing the S174D 
phosphomimetic. Conformational changes in nuclear receptor coregulators are regulated by 
peptidyl-prolyl isomerase 1 (Pin1), which targets phosphorylated Ser/Thr-Pro residues (74, 
75). Pin1, which is highly expressed in metastatic prostate cancer, may exert regulatory 
effects on MAGE-11 mediated by MAP kinase phosphorylation at Ser-174.  
AR Reactivation in Prostate Cancer-AR becomes reactivated during androgen 
deprivation therapy and prostate cancer progression to castration-recurrent growth (76, 77). 
This involves mechanisms that include increases in mitogen signaling, SRC/p160 coactivator 
levels (32), sensitivity to low levels of androgen (19, 32, 73, 78), and local tissue androgen 
synthesis (79). Of the coregulators that interact with AR (80), both the SRC/p160 
coactivators and MAGE-11 levels increase in castration-recurrent prostate cancer (20, 81, 
82). MAGE-11 mRNA levels can increase by ∼1000-fold in clinical specimens of castration-
recurrent prostate cancer compared with benign prostate, and by ∼50-fold in the castration-
recurrent CWR22 human prostate cancer xenograft (20). Increased expression of MAGE-11 
in prostate cancer during androgen deprivation therapy is associated with DNA 
hypomethylation at CpG sites in the MAGE-11 promoter and may also result from increased 
cyclic AMP signaling. The ability of MAGE-11 to increase AR transcriptional activity by 
interacting with TIF2 suggests that increased levels of both coactivators contribute to AR 
reactivation in castration-recurrent prostate cancer.  
102 
 
REFERENCES 
1.  Quigley, C. A., De Bellis, A., Marschke, K. B., El-Awady, M. K., Wilson, E. M., and 
French, F. S. (1995) Endocrine Reviews 16, 271–321 
 
2.  Askew, E. B., Gampe, R. T., Stanley, T. B., Faggart, J. L., and Wilson, E. M. (2007) 
J. Biol. Chem. 282, 25801–25816 
 
3.  He, B., Gampe, R. T., Hnat, A. T., Faggart, J. L., Minges, J. T., French, F. S., and 
Wilson, E. M. (2006) J. Biol. Chem. 281, 6648–6663  
 
4.  Newmark, J. R., Hardy, D. O., Tonb, D. C., Carter, B. S., Epstein, J. I., Isaacs, W. B., 
Brown, T. R., and Barrack, E. R. (1992) Proc. Natl. Acad. Sci. USA 89, 6319–6323 
 
5.  He, B., Gampe, R. T., Kole, A. J., Hnat, A. T., Stanley, T. B., An, G., Stewart, E. L., 
Kalman, R. I., Minges, J. T., and Wilson, E. M. (2004) Mol. Cell 16, 425–438 
 
6.  He, B., Kemppainen, J. A., and Wilson, E. M. (2000) J. Biol. Chem. 275, 22986–
22994 
 
7.  He, B., Minges, J. T., Lee, L. W., and Wilson, E. M. (2002) J. Biol. Chem. 277, 
10226–10235 
 
8.  Lavery, D. N., and McEwan, I. J. (2008) Biochemistry 47, 3352–3359 
 
9.  Lavery, D. N., and McEwan, I. J. (2008) Biochemistry 47, 3360–3369 
 
10.  He, B., Kemppainen, J. A., Voegel, J. J., Gronemeyer, H., and Wilson, E. M. (1999) 
J. Biol. Chem. 274, 37219–37225  
 
11.  Langley, E., Kemppainen, J. A., and Wilson, E. M. (1998) J. Biol. Chem. 273, 92–
101 
 
12.  Langley, E., Zhou, Z. X., and Wilson, E. M. (1995) J. Biol. Chem. 270, 29983–29990 
 
13.  Wong, C. I., Zhou, Z. X., Sar, M., and Wilson, E. M. (1993) J. Biol. Chem. 268, 
19004–19012 
 
14.  Zhou, Z. X., Lane, M. V., Kemppainen, J. A., French, F. S., and Wilson, E. M. 
(1995) Mol. Endocrinol. 9, 208–218  
 
15.  He, B., Bowen, N. T., Minges, J. T., and Wilson, E. M. (2001) J. Biol. Chem. 276, 
42293–42301 
 
16.  Bai, S., He, B., and Wilson, E. M. (2005) Mol. Cell. Biol. 25, 1238–1257 
 
103 
 
17.  Chomez, P., De Backer, O., Bertrand, M., De Plaen, E., Boon, T., and Lucas, S. 
(2001) Cancer Res. 61, 5544–5551 
 
18.  Rogner, U. C., Wilke, K., Steck, E., Korn, B., and Poustka, A. (1995) Genomics 29,  
        725-731 
 
19.  Bai, S., and Wilson, E. M. (2008) Mol. Cell. Biol. 28, 1947–1963 
 
20.  Karpf, A. R., Bai, S., James, S. R., Mohler, J. L., and Wilson, E. M. (2009) Mol. 
 Cancer Res. 7, 523–535 
 
21.  Bevan, C. L., Hoare, S., Claessens, F., Heery, D. M., and Parker, M. G. (1999) Mol. 
 Cell. Biol. 19, 8383–8392 
 
22.  Lubahn, D. B., Joseph, D. R., Sar, M., Tan, J., Higgs, H. N., Larson, R. E., French, F. 
 S., and Wilson, E. M. (1988) Mol. Endocrinol. 2, 1265–1275 
 
23.  Simental, J. A., Sar, M., Lane, M. V., French, F. S., and Wilson, E. M. (1991) J. Biol. 
 Chem. 266, 510–518 
 
24.  He, B., and Wilson, E. M. (2003) Mol. Cell. Biol. 23, 2135–2150 
 
25.  Voegel, J. J., Heine, M. J., Tini, M., Vivat, V., Chambon, P., and Gronemeyer, H. 
 (1998) EMBO J. 17, 507–519 
 
26.  Huang, W., Shostak, Y., Tarr, P., Sawyers, C., and Carey, M. (1999) J. Biol. Chem. 
 274, 25756–25768 
 
27.  Giffin, W., Torrance, H., Rodda, D. J., Préfontaine, G. G., Pope, L., and Hache, R. J. 
 (1996) Nature 380, 265–268 
 
28.  Gottlieb, T. M., and Jackson, S. P. (1993) Cell 72, 131–142 
 
29.  Ponguta, L. A., Gregory, C. W., French, F. S., and Wilson, E. M. (2008) J. Biol. 
 Chem. 283, 20989–21001 
 
30.  He, B., Lee, L. W., Minges, J. T., and Wilson, E. M. (2002) J. Biol. Chem. 277, 
 25631–25639 
 
31.  Zhou, Z. X., Sar, M., Simental, J. A., Lane, M. V., and Wilson, E. M. (1994) J. Biol. 
 Chem. 269, 13115–13123 
 
32.  Gregory, C. W., Johnson, R. T., Mohler, J. L., French, F. S., and Wilson, E. M. 
 (2001) Cancer Res. 61, 2892–2898 
 
104 
 
33.  Bai,
 
S., Grossman, G., Yuan, L., Lessey, B. A., French, F. S., Young, S. L., and 
 Wilson, E. M. (2008) Mol. Hum. Reprod. 14, 107–116 
 
34.  Craft, N., Shostak, Y., Carey, M., and Sawyers, C. L. (1999) Nature Med. 5, 280–285 
 
35.  Quarmby, V. E., Yarbrough, W. G., Lubahn, D. B., French, F. S., and Wilson, E. M. 
 (1990) Mol. Endocrinol. 4, 22–28 
 
36.  Tan, J. A., Joseph, D. R., Quarmby, V. E., Lubahn, D. B., Sar, M., French, F. S., and 
 Wilson, E. M. (1988) Mol. Endocrinol. 2, 1276–1285 
 
37.  Erickson, A. K., Payne, D. M., Martino, P. A., Rossomando, A. J., Shabanowitz, J., 
 Weber, M. J., Hunt, D. F., and Sturgill, T. W. (1990) J. Biol. Chem. 265, 19728–
 19735 
 
38.  Favata, M. F., Horiuchi, K. Y., Manos, E. J., Daulerio, A. J., Stradley, D. A., Feeser, 
 W. S., Van Dyk, D. E., Pitts, W. J., Earl, R. A., Hobbs, F., Copeland, R. A., Magolda, 
 R. L., Scherle, P. A., and Trzaskos, J. M. (1998) J. Biol. Chem. 273, 18623–18632 
 
39.  Onate, S. A., Boonyaratanakornkit, V., Spencer, T. E., Tsai, S. Y., Tsai, M. J., 
 Edwards, D. P., and O'Malley, B. W. (1998) J. Biol. Chem. 273, 12101–12108 
 
40.  Heery, D. M., Kalkhoven, E., Hoare, S., and Parker, M. G. (1997) Nature 387, 733–
 736  
 
41.  Han, S. J., Lonard, D. M., and O'Malley, B. W. (2009) Trends Endocrinol. Metab. 20, 
 8–15 
 
42.  Bai, C., Sen, P., Hofmann, K., Ma, L., Goebl, M., Harper, J. W., and Elledge, S. J. 
 (1996) Cell 86, 263–274 
 
43.  Schulman, B. A., Carrano, A. C., Jeffrey, P. D., Bowen, Z., Kinnucan, E. R., Finnin, 
 M. S., Elledge, S. J., Harper, J. W., Pagano, M., and Pavletich, N. P. (2000) Nature 
 408, 381–386 
 
44.  Zheng, N., Schulman, B. A., Song, L., Miller, J. J., Jeffrey, P. D., Wang, P., Chu, C., 
 Koepp, D. M., Elledge, S. J., Pagano, M., Conaway, R. C., Conaway, J. W., Harper, J. 
 W., and Pavletich, N. P. (2002) Nature 416, 703–709 
 
45.  Jin, J., Cardozo, T., Lovering, R. C., Elledge, S. J., Pagano, M., and Harper, J. W. 
 (2009) Genes Dev. 18, 2573–2580 
 
46.  Westbrook, T. F., Hu, G., Ang, X. L., Mulligan, P., Pavlova, N. N., Liang, A., Leng, 
 Y., Maehr, R., Shi, Y., Harper, J. W., and Elledge, S. J. (2008) Nature 452, 370–374 
 
47.  Hermand, D. (2006) Cell Div. 1, 30 
105 
 
48.  Jackson, P. K., and Eldridge, A. G. (2002) Mol. Cell 9, 923–925 
 
49.  von der Lehr, N., Johansson, S., Wu, S., Bahram, F., Castell, A., Cetinkaya, C., 
 Hydbring, P., Weidung, I., Nakayama, K., Nakayama, K. I., Söderberg, O., Kerppola, 
 T. K., and Larsson, L. G. (2003) Mol. Cell 11, 1189–1200 
 
50.  Craig, K. L., and Tyers, M. (1999) Prog. Biophys. Mol. Biol. 72, 299–328  
 
51.  Nie, L., Wu, H., and Sun, X. H. (2008) J. Biol. Chem. 283, 684–692 
 
52.  Onoyama, I., and Nakayama, K. I. (2008) Cell Cycle 7, 3307–3313  
 
53.  Welcker, M, and Clurman, B. E. (2008) Nat. Rev. Cancer 8, 83–93 
 
54.  Yada, M., Hatakeyama, S., Kamura, T., Nishiyama, M., Tsunematsu, R., Imaki, H., 
 Ishida, N., Okumura, F., Nakayama, K., and Nakayama, K. I. (2004) EMBO J. 23, 
 2116–2125 
 
55.  van der Voorn, L., and Ploegh, H. L. (1992) FEBS Lett. 307, 131–134 
 
56.  Hao, B., Zheng, N., Schulman, B. A., Wu, G., Miller, J. J., Pagano, M., and Pavletich, 
 N. P. (2005) Mol. Cell 20, 9–19  
 
57.  Sonnberg, S., Seet, B. T., Pawson, T., Fleming, S. B., and Mercer, A. A. (2008) Proc. 
 Natl. Acad. Sci. USA 105, 10955–10960 
 
58.  Smaldone, S., Laub, F., Else, C., Dragomir, C., and Ramirez, F. (2004) Mol. Cell. 
 Biol. 24, 1058–1069 
 
59.  Chandra, S., Shao, J., Li, J. X., Li, M., Longo, F. M., and Diamond, M. I. (2008) J. 
 Biol. Chem. 283, 23950–23955  
 
60.  Dennis, A. P., Haq, R. U., and Nawaz, Z. (2001) Front. Biosci. 6, D954–959 
 
61.  Muratani, M., and Tansey, W. P. (2003) Nat. Rev. Mol. Cell. Biol. 4, 192–201 
 
62.  Verma, S., Ismail, A., Gao, X., Fu, G., Li, X., O'Malley, B. W., and Nawaz, Z. (2004) 
 Mol. Cell. Biol. 24, 8716–8726  
 
63.  Wu, R. C., Feng, Q., Lonard, D. M., and O'Malley, B. W. (2007) Cell 129, 1125–
 1140 
 
64.  Nash, P., Tang, X., Orlicky, S., Chen, Q., Gertler, F. B., Mendenhall, M. D., Sicheri, 
 F., Pawson, T., and Tyers, M. (2001) Nature 414, 514–521  
 
106 
 
65.  Archer, C. T., Burdine, L., Liu, B., Ferdous, A., Johnston, S. A., and Kodadek, T. 
 (2008) J. Biol. Chem. 283, 21789–21798 
 
66.  Hoang, T., Fenne, I. S., Cook, C., Børud, B., Bakke, M., Lien, E. A., and Mellgren, 
 G. (2004) J. Biol. Chem. 279, 49120–49130 
 
67.  Rowan, B. G., Garrison, N., Weigel, N. L., and O'Malley, B. W. (2000) Mol. Cell. 
 Biol. 20, 8720–8730 
 
68.  Rowan, B. G., Weigel, N. L., and O'Malley, B. W. (2000) J. Biol. Chem. 275, 4475–
 4483 
 
69.  Gioeli, D., Ficarro, S. B., Kwiek, J. J., Aaronson, D., Hancock, M., Catling, A. D., 
 White, F. M., Christian, R. E., Settlage, R. E., Shabanowitz, J., Hunt, D. F., and 
 Weber, M. J. (2002) J. Biol. Chem. 277, 29304–29314 
 
70.  Lopez, G. N., Turck, C. W., Schaufele, F., Stallcup, M. R., and Kushner, P. J. (2001) 
 J. Biol. Chem. 276, 22177–22182 
 
71.  Zhou, Z. X., Kemppainen, J. A., and Wilson, E. M. (1995) Mol. Endocrinol. 9, 605–
 615 
 
72.  Agoulnik, I. U., Bingman, W. E., Nakka, M., Li, W., Wang, Q., Liu, X. S., Brown, 
 M., and Weigel, N. L. (2008) Mol. Endocrinol. 22, 2420–2432 
 
73.  Gregory, C. W., Fei, X., Ponguta, L. A., He, B., Bill, H. M., French, F. S., and 
 Wilson, E. M. (2004) J. Biol. Chem. 279, 7119–7130 
 
74.  Chen, S. Y., Wulf, G., Zhou, X. Z., Rubin, M. A., Lu, K. P., and Balk, S. P. (2006) 
 Mol. Cell. Biol. 26, 929–939  
 
75.  Yi, P., Wu, R. C., Sandquist, J., Wong, J., Tsai, S. Y., Tsai, M. J., Means, A. R., and 
 O'Malley, B. W. (2005) Mol. Cell. Biol. 25, 9687–9699  
 
76.  Gregory, C. W., Hamil, K. G., Kim, D., Hall, S. H., Pretlow, T. G., Mohler, J. L., and 
 French, F. S. (1998) Cancer Res. 58, 5718–5724 
 
77.  Yuan, X, and Balk, S. P. (2009) Urol. Oncol. 27, 36–41  
 
78.  Culig, Z., Hobisch, A., Cronauer, M. V., Radmayr, C., Trapman, J., Hittmair, A., 
 Bartsch, G., and Klocker, H. (1994) Cancer Res. 54, 5474–5478 
 
79.  Mohler, J. L., Gregory, C. W., Ford, O. H., Kim, D., Weaver, C. M., Petrusz, P., 
 Wilson, E. M., and French, F. S. (2004) Clin. Cancer Res. 10, 440–448 
 
80.  Heemers, H. V., and Tindall, D. J. (2007) Endocr. Rev. 28, 778–808 
107 
 
81.  Agoulnik, I. U., Vaid, A., Nakka, M., Alvarado, M., Bingman, W. E., Erdem, H., 
 Frolov, A., Smith, C. L., Ayala, G. E., Ittmann, M. M., and Weigel, N. L. (2006) 
 Cancer Res. 66, 10594–10602 
 
82.  Gregory, C. W., He, B., Johnson, R. T., Ford, O. H., Mohler, J. L., French, F. S., and 
 Wilson, E. M. (2001) Cancer Res. 61, 4315–4319 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
108 
 
Figure 3-1. Dependence of AR Transactivation on MAGE-11 and TIF2. (A) CWR-R1 
cells were transfected with 0.1 μg of MMTV-Luc with or without 0.1 μg of pSG5-MAGE-11 
or pSG5-TIF2. Cells were incubated in the absence and presence of DHT (shown as -log 
DHT concentration) and 0.1 μg/ml of EGF. (B) COS cells were transfected using 
Lipofectamine 2000 with 1 μg of pSG5 or pSG5-MAGE (top panel), 1 μg of pSG5 or pSG5-
TIF2 (middle panel), and 0.5 μg of pCMV5 or pCMV-AR (bottom panel) in the absence and 
presence of 1 nm nonspecific (NS) siRNA, MAGE-11 siRNA-2 and -3, TIF2 siRNA-3, and 
AR siRNA-3. Cell extracts were analyzed by immunoblot for MAGE-11 (10 μg of 
protein/lane), TIF2 (40 μg/lane), AR (30 μg/lane), and β-actin. (C) CWR-R1 cells were 
transfected with 0.1 μg of MMTVΔ-(−421–−364)-Luc, 0.2 μg of pSG5 or pSG5-MAGE in 
the absence and presence of 4 nm nonspecific or TIF2 siRNA-3, and incubated in the absence 
and presence of 0.1 nm DHT and 0.01 μg/ml of EGF. (D) LAPC-4 cells were transfected 
with 0.1 μg of MMTVΔ-(−421–−364)-Luc and 3 nm siRNA and incubated in the absence 
and presence of 0.1 nm DHT and 0.1 μg/ml EGF. (E) top panel, CWR-R1 cells incubated for 
48 h in serum-free medium were treated for the indicated times with 0.1 nm DHT and 10 
ng/ml of EGF. Cell extracts in IB lysis buffer (200 μg of protein/lane) (lanes 2–8) were 
analyzed by immunoblot using 10 μg/ml of MAGE-Ab-(13–26), -(59–79), and -(94–108) 
antibodies overnight at 4 °C, and AR32 and β-actin antibodies (33). Extracts of COS cells 
expressing pCMV-AR (30 μg of protein) and pSG5-MAGE (0.25 μg of protein) served as 
controls (lane 1). Bottom panel, CWR-R1 cells were transfected with 4 nm siRNA and 
incubated for 6 h with or without 10 nm DHT and 10 ng/ml of EGF. RNA was extracted and 
analyzed by quantitative reverse transcription-PCR as described under ―Experimental 
Procedures‖ for endogenous PSA mRNA relative to peptidylprolyl isomerase A. 
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Figure 3-2. Requirement for a MAGE-11 F-box in AR Transactivation. (A) Schematic 
diagram of full-length MAGE-11 showing the MAGE homology domain (MHD) with F-box 
residues 329–369, phosphorylation site Thr-360 within the F-box, Lys-240 and Lys-245 
monoubiquitinylation (Ub) sites outside the F-box, and the NH2-terminal nuclear localization 
signal (NLS). (B) Sequence homology between MAGE-11 F-box residues 329–369, cyclin F 
F-box residues 35–73, and MAGE family members, with conserved acidic residues in blue 
and hydrophobic residues in red. (C) Alanine mutagenesis of the MAGE F-box at conserved 
hydrophobic residues. (D) Ishikawa cells were transfected with pCMV-AR (10 ng/well), 0.1 
μg/well of PSA-Enh-Luc, and 0.1 μg of pSG5 empty vector (—), pSG5-MAGE wild-type 
(WT), or the indicated F-box mutant. Cells were incubated in the absence and presence of 1 
nm DHT with or without 0.1 μg/ml of EGF. Bottom panel, Ishikawa cells were transfected 
with 2 μg of pSG5 (—), pSG5-MAGE WT, and the indicated F-box mutant. Cells were 
extracted in IB lysis buffer and 30 μg of protein/lane analyzed on immunoblots probed with 
antibody raised against FLAG-tagged human MAGE-11 (2 μg/ml). (E) FLAG-b empty 
vector (—) or FLAG-AR (4 μg) were expressed in COS cells with pSG5-HA-MAGE-(112–
429) WT or Δ329–369 F-box deletion (0.5 μg of DNA/10-cm dish). Cells were treated in the 
absence and presence of 10 nm DHT and 0.1 μg/ml EGF, lysed in IP lysis buffer, and 
incubated with FLAG resin overnight at 4 °C. Immunoprecipitates and cell extracts (25 μg of 
protein/lane) were analyzed by immunoblot using FLAG and HA antibodies. 
 
 
 
 
 
 
 
111 
 
Figure 3-3. Requirement for MAGE-11 F-box in AR Transactivation by TIF2. (A) CV1 
cells were transfected with 0.1 μg of pCMV-AR and 5 μg of MMTV-Luc, 2 μg of pSG5-
TIF2, 2 μg of pSG5-MAGE wild-type (WT) or L358A/L359A F-box mutant, and incubated 
in the absence and presence of 1 nm DHT. (B) CV1 cells were transfected with 5 μg of 
MMTV-Luc and 0.1 μg of pCMV-ARΔ120–472 WT or the indicated mutant, 2 μg of pSG5-
TIF2 (pSG5-T) and/or 2 μg of pSG5-MAGE (pSG5-M). Cells were incubated in the absence 
and presence of 1 nm DHT. Inset, pCMV-ARΔ120–472 WT and mutants (5 μg) were 
expressed in COS cells because expression was too low in CV1 cells. Cell extracts (30 μg of 
protein/lane) were analyzed on immunoblots probed with AR52 antibody. Bottom panel, 
schematic diagram of full-length human AR amino acid residues 1–919 with the NH2-
terminal FXXLF motif 
23
FQNLF
27
, activation function 1 (AF1), DNA binding domain 
(DBD), activation function 2 (AF2) in the ligand binding domain (LBD), and the ARΔ120–
472 deletion mutant that lacks AF1. (C) pCMV-ARΔ120–472 (0.1 μg) was expressed in CV1 
cells with 5 μg of MMTV-Luc, 2 μg of pSG5-TIF2 and/or 2 μg of pSG5-MAGE WT or the 
indicated F-box mutant. Cells were incubated in the absence and presence of 1 nm DHT. (D) 
pCMV-ARΔ120–472 (0.1 μg) was expressed in CV1 cells with 5 μg of MMTV-Luc in the 
absence and presence of 2 μg of pSG5-TIF2 and/or 2 μg of pSG5-MAGE WT or single 
residue F-box mutant. Cells were incubated in the absence and presence of 1 nm DHT. 
Bottom panel, CV1 cells were transfected with pSG5 (8 μg/10-cm dish) (—), pSG5-MAGE 
WT or the indicated single residue F-box mutant. Cell extracts in IB lysis buffer (95 μg of 
protein/lane) were analyzed on immunoblots probed with antibody raised against FLAG-
tagged MAGE-11. 
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Figure 3-4. Interaction Between MAGE-11 F-box and AR FXXLF Motif. (A) GAL-
MAGE wild-type (WT), F-box mutant, or GAL-MAGE-K236A/K240A/K245A (KA) (0.05 
μg) were transfected in HeLa cells with 0.1 μg of 5×GAL4Luc3 and 0.1 μg of VP16 empty 
vector (—), VP-AR-(1–660) or VP-AR-(1–660)-L26A,F27A (LFAA) with a mutation in the 
AR FXXLF motif. Bottom panel, GAL-MAGE F-box or KA mutants, WT and GAL0 (—) (2 
μg/10-cm dish) were expressed in HeLa cells. Cell extracts prepared in IB lysis buffer (150 
μg of protein/lane) were analyzed on immunoblots probed using GAL antibody (1:100 
dilution). (B) HeLa cells were transfected with 0.1 μg of 5×GAL4Luc3, 0.05 μg of GAL-AR-
(4–52), and 0.1 μg of VP16 (—), VP-MAGE WT, or the indicated mutant. Bottom panel, 
HeLa cells were transfected with VP-MAGE mutants (lanes 1–8), VP-MAGE WT (lane 9), 
and VP16 empty vector (—) (lane 10) (2 μg/10-cm dish). Cell extracts in IB lysis buffer (100 
μg of protein/lane) were analyzed by immunoblot using VP16 antibody. (C) HeLa cells were 
transfected with 0.05 μg of GAL-AR-(4–52) or GAL-AR-(16–36), 0.1 μg of 5×GAL4Luc3 
and 0.1 μg of VP16 empty vector (—) or VP-MAGE WT or the indicated mutant. D, 
coimmunoprecipitation of endogenous Skp1 with FLAG-MAGE. FLAG empty vector (—) 
(3 μg), FLAG-MAGE (3 μg), and FLAG-MAGE-(112–429) (6 μg) were expressed in 
HEK293 cells. The next day cells were treated for 24 h with 100 ng/ml of EGF and 1 μm 
MG132. IP of an overnight incubation and cell extracts (35 μg of protein/lane) were analyzed 
using FLAG and Skp1 antibodies. 
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Figure  3-5. Serum Stimulation of MAP Kinase Phosphorylation of MAGE-11 Ser-174. 
(A) MAGE-11 Ser-Pro sites Ser-168, Ser-170, Ser-174, and Ser-181 (underlined) include 
consensus MAP kinase site 
172
PQSP
175
. (B) GAL-MAGE-(112–205) wild-type (WT) and 
mutants and GAL-MAGE-(112–170) (5 μg) were expressed in COS cells. Cell extracts in IP 
lysis buffer without sodium fluoride (35 μg) were incubated in the absence and presence of 
800 IU of λ-phosphatase for 1 h at 4 °C, and the immunoblot probed with GAL antibody. (C) 
GAL0 (—), GAL-MAGE-(112–205) WT, or S174A mutant (5 μg) were expressed in COS 
cells. Immediately after transfection and the next day, serum-free medium containing 1 μm 
MG132 and U0126 was added. Cells were extracted in IB lysis buffer containing 
phosphatase mixture inhibitors 1/2. Protein extracts (35 μg of protein/lane) were analyzed on 
immunoblots probed using GAL and β-actin antibodies. (D) GAL-MAGE-(112–205) (5 μg) 
was expressed in COS cells incubated in the absence (lanes 1, 3, 5, and 7) or presence of 
10% fetal bovine serum (lanes 2, 4, 6, and 8). Cells were harvested at 0, 30, 60, and 120 min 
in IB lysis buffer. Cell extracts (35 μg of protein/lane) were analyzed by immunoblots probed 
with GAL and β-actin antibodies. (E) ERK1 in vitro phosphorylation of MAGE-11 Ser-174. 
In vitro kinase assay (top panel) was performed as described (19) at 30 °C for 30 min with 
0.16 μCi/μl of [γ-32P]ATP, 0.1 μg of active ERK1 kinase and purified GST0 (lane 1), GST-
MAGE-(171–179) WT (lane 2), and S174A mutant (lane 3), and ERK1 substrate modeled 
after myelin basic protein (37) (lane 4). The dried gel was exposed to x-ray film for 16 h, and 
rehydrated for Coomassie Blue staining to demonstrate equivalent protein loading (bottom 
panel). 
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Figure 3-6. MAGE-11 and TIF2-Dependent Increase in AR AF1 Activity. (A) CV1 cells 
were transfected with 5 μg of PSA-Enh-Luc and 0.05 μg of pCMV5 empty vector (p5) or 
pCMV-AR-(1–660) in the absence and presence of 0.1 μg of pSG5-MAGE and/or 2 μg of 
pSG5-TIF2. (B) CV1 cells were transfected with 5 μg of PSA-Enh-Luc and 0.05 μg of p5 or 
0.05 μg of pCMV-AR-(1–660) in the absence and presence of 2 μg of pSG5-TIF2 and/or 1 
μg of pSG5-MAGE WT or the indicated F-box mutant. 
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Figure 3-7. Interaction Between MAGE-11 and TIF2. (A) FLAG-b empty vector (—) (8 
μg) and 5 μg of pSG5-HA-MAGE (lane 1), or 8 μg of FLAG-TIF2 and 5 μg of pSG5-HA-
MAGE (lane 2) were expressed in COS cells. Cells were incubated overnight in the presence 
of 0.1 μg/ml EGF and 1 μm MG132, harvested in IP lysis buffer, and incubated with FLAG 
resin overnight at 4 °C. Immunoprecipitates and cell extracts (40 μg of protein/lane) were 
analyzed on immunoblots probed with HA and TIF2 antibodies. (B) pSG5-TIF2 (8 μg) was 
expressed with 4 μg of FLAG-b empty vector (—) or 4 μg of FLAG-MAGE in COS cells. 
Cells were incubated overnight in the presence of 0.1 μg/ml EGF and 1 μm MG132, 
harvested in IP lysis buffer, and incubated with FLAG resin overnight at 4 °C. 
Immunoprecipitates and cell extracts (50 μg of protein/lane) were analyzed on immunoblots 
probed using FLAG and TIF2 antibodies. (C) in vitro GST affinity matrix assays using the 
indicated GST-TIF2 fusion fragments expressed in E. coli and 
35
S-labeled MAGE-11 
expressed from pSG5-MAGE-11 using the TnT T7 Quick Coupled transcription-translation 
system. Input lane contains 2% of the total 
35
S-labeled MAGE-11 used in the reactions. 
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Figure 3-8. MAGE-11 and TIF2 Interaction Domains. (A) schematic diagram of full-
length MAGE-11 and deletion fragments, with nuclear localization signal (NLS, residues 18–
22), monoubiquitinylation sites Lys-240 and -245, Ser-174 and Thr-360 phosphorylation 
sites (19), MAGE homology domain (MHD), and the F-box region. (B) FLAG-b empty 
vector (—) (8 μg) (lanes 1–5) or 8 μg of FLAG-TIF2 (lanes 6–10) were expressed in COS 
cells with 0.5 μg of pSG5-HA-MAGE-(112–429), 1 μg of pSG5-HA-MAGE-(112–307), or 2 
μg of pSG5-HA-MAGE-(165–307), -(112–298), and –(112–276). Cells were incubated with 
0.1 μg/ml of EGF and 1 μm MG132, solubilized in IP lysis buffer and immunoprecipitated 
using FLAG affinity resin overnight at 4 °C. IP (upper panel) and cell extracts (lower panels) 
(15 μg of protein/lane for HA-MAGE, 55 μg of protein/lane for FLAG-TIF2) were analyzed 
on immunoblots probed using HA and FLAG antibodies. (C) FLAG-b empty vector (lanes 1 
and 2) (—), FLAG-TIF2 (lanes 3 and 4), FLAG-TIF2.0-(1–627), or FLAG-TIF2.8-(1011–
1179) (8 μg) were expressed in COS cells with 5 μg of pSG5-HA-MAGE or 0.5 μg of pSG5-
HA-MAGE-(112–429). Cells were incubated with 0.1 μg/ml of EGF and 1 μm MG132, 
extracted in IP lysis buffer, and incubated with FLAG affinity resin overnight at 4 °C. 
Immunoprecipitates (upper panel) and cell extracts (lower panels) (25 μg of protein/lane) 
were analyzed on immunoblots probed using FLAG and HA antibodies. (D) FLAG-b empty 
vector (—) (8 μg) (lanes 1–3) and FLAG-TIF2.0-(1–627) (lanes 4–6) were expressed in COS 
cells with 1 μg of pSG5-HA-MAGE-(112–429), 2 μg of pSG5-HA-MAGE-(165–429), or 2 
μg of pSG5-HA-MAGE-(112–307). Cells were incubated with 0.1 μg/ml of EGF and 1 μm 
MG132, extracted in IP lysis buffer, and incubated with FLAG resin for 1 h at 4 °C. 
Immunoprecipitated proteins (upper panel) and cell extracts (lower panels) (25 μg of 
protein/lane) were analyzed on immunoblots probed using HA and FLAG antibodies. (E) 
HeLa cells were transfected with 0.05 μg of GAL-MAGE-(85–205) wild-type (WT), S174A 
or S174D mutant, 0.1 μg of 5×GAL4Luc3, and 0.05 μg of VP16 empty vector (—) or VP-
TIF2.0-(1–627). Bottom panel, GAL0 empty vector (—) (2 μg) and 2 μg of GAL-MAGE-
(85–205) WT, S174A, or S174D mutant were expressed in HeLa cells. Cell extracts (200 μg 
of protein/lane) were analyzed on immunoblots probed using a GAL antibody. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
119 
 
 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
120 
 
Figure 3-9. MAGE-11 Increases TIF2 AD1 Activity. (A) schematic diagram of GAL-TIF2 
fusion proteins showing three LXXLL motifs (LX) beginning at residues 641, 690, and 745, 
activation domain 1 (AD1) residues 1011–1131, glutamine (Q)-rich region 1131–1179, and 
activation domain 2 (AD2) residues 1288–1464. (B) HeLa cells were transfected with 0.1 μg 
of 5×GAL4Luc3 and 0.05 μg of GAL-TIF2.0-(1–627), GAL-TIF2.1-(624–1287), and GAL-
TIF2.3-(624–1179)-m123, which contains L644E,L645A,L693A,L694A,L748A,L749A 
mutations in the LXXLL motifs, or GAL-TIF2.2-(1288–1464), and 0.1 μg of pSG5 empty 
vector (—), pSG5-HA-MAGE or pSG5-HA-MAGE-(112–429). (C) HeLa cells were 
transfected with 0.1 μg/well of 5×GAL4Luc3 and 2 ng of GAL-TIF2.8-(1011–1179) or 
GAL-TIF2.12-(940–1131), which contain AD1 and 0.1 μg of pSG5 (—), pSG5-HA-MAGE, 
or pSG5-HA-MAGE-(112–429). (D) GAL-TIF2.8-(1011–1179) (2 ng), which contains AD1 
was expressed in HeLa cells with 0.1 μg/well of 5×GAL4Luc3, 0.1 μg of pSG5 (—), or 0.1 
μg of pSG5-HA-MAGE-(112–429) wild-type (WT) or the indicated F-box mutant. Bottom 
panel, HeLa cells were transfected with 2 μg of pSG5, pSG5-HA-MAGE-(112–429) WT, 
and the indicated F-box mutant. Cell extracts (150 μg of protein/lane) were analyzed on 
immunoblots probed with HA antibody. (E) HeLa cells were transfected with 0.1 μg/well of 
5×GAL4Luc3, 2 ng of GAL-TIF2.8-(1011–1179), and 0.05 μg of pSG5 (—), pSG5-HA-
p300, or pSG5-HA-MAGE-(112–429) WT or V337A/L338A F-box mutant. 
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Figure 3-10. FXXLF and F-box Related Sequences in AR, MAGE-11, TIF2, Skp1, and 
Skp2. (A) FXXLF-like motifs include AR-(15–36) FXXLF motif 23FQNLF27 that mediates 
the androgen-dependent AR N/C interaction with AF2 (6) and interaction with MAGE-11 
(7). MAGE-11-(252–273) FXXIF motif 260FPEIF264 interacts with the AD1 region of TIF2. 
TIF2-(325–346) FXXIY motif 333FSQIY337 function is unknown. Skp1-(93–114) FXXIL 
motif 
101
FELIL
105
 is in a region that interacts with the Skp2 F-box (43). Acidic and basic 
residues (blue) flank the FXXLF-like motifs (red). (B) F-box related sequences have 
predicted α-helical structure and relatively conserved spacing of two acidic residues (blue) 
and multiple hydrophobic residues (red). F-box-like sequences similar to the cyclin F F-box-
(35–73) include MAGE-11 F-box-(329–369) that interacts with the AR FXXLF motif, Skp2 
F-box-(99–139) that interacts with a region that contains the Skp1 FXXIL motif (43), and 
TIF2 AD1 F-box-(1073–1112) that interacts with the MAGE-11 FXXIF motif. 
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Figure 3-11. MAGE-11 FXXIF Motif-Dependent Interaction with TIF2. (A) top panels, 
FLAG-b empty vector (lane 1) (—) or FLAG-TIF2.8-(1011–1179) (lanes 2–4) (8 μg) were 
expressed in COS cells with 0.5 μg of pSG5-HA-MAGE-(112–429) wild-type (WT) (lanes 1 
and 2) or the indicated mutant (lanes 3 and 4). Cells were incubated with 0.1 μg/ml of EGF 
and 1 μm MG132 and immunoprecipitated overnight at 4 °C using FLAG resin. IP (upper 
panel) and cell extracts (25 μg of protein for HA-MAGE, 50 μg of protein for FLAG-TIF2.8, 
lower panels) were analyzed on immunoblots using HA and FLAG antibodies. Bottom 
panels, HeLa cells were transfected with 2 μg of pSG5 (—), pSG5-HA-MAGE-(2–429) WT, 
F260A, or F264A mutant (left panel), and pSG5-HA-MAGE-(112–429) WT, F260A, or 
F264A mutant, and pSG5 (—) (right panel). Cells extracts in IB lysis buffer (150 μg of 
protein/lane) were analyzed on immunoblots using HA antibody. (B) GAL-TIF2.1-(624–
1287) or GAL-TIF2.3m123 (TIF2-(624–1179)-L644E,L645A,L693A,L694A,L748A,L749A) 
(0.05 μg) were transfected in HeLa cells with 0.1 μg of pSG5 (—), pSG5-HA-MAGE-(112–
429) WT or mutant, and 0.1 μg of 5×GAL4Luc3. (C) CV1 cells were transfected with 0.1 μg 
of pCMV-AR and 5 μg of PSA-Enh-Luc with and without 2 μg of pSG5-TIF2 and 1 μg of 
WT or mutant pSG5-HA-MAGE. Cells were incubated in the absence and presence of 1 nm 
DHT. Bottom panel, CV1 cells were transfected with 8 μg of pSG5 (–), pSG5-HA-MAGE-
(112–429) WT, F260A, or F264A mutant. Cells extracts in IB lysis buffer (200 μg of 
protein/lane) were analyzed on immunoblots probed with HA antibody. (D) CV1 cells were 
transfected with 0.1 μg of pCMV-ARΔ120–472 with and without 2 μg of pSG5-TIF2, 2 μg 
of WT or mutant pSG5-HA-MAGE, and 5 μg of MMTV-Luc. Cells were incubated in the 
absence and presence of 1 nm DHT. Bottom panel, CV1 cells were transfected with 8 μg of 
pSG5 (—), pSG5-HA-MAGE WT, F151A, F260A, or F264A mutant. Cell extracts in IB 
lysis buffer (150 μg/lane) were analyzed on immunoblots using HA antibody. (E) HeLa cells 
were transfected with 0.1 μg of 5×GAL4Luc3, 50 ng of GAL0 empty vector (—), WT or 
mutant GAL-MAGE-(251–272), and 0.1 μg of VP16 empty vector (—), VP-TIF2.0-(1–627), 
VP-TIF2.1-(624–1287), or VP-TIF2.2-(1288–1464). Bottom panel, HeLa cells were 
transfected with 2 μg of GAL0 (lane 1), GAL-MAGE-(251–272) WT (lane 2), or 
F260A,F264A mutant (lane 3). Cell extracts (100 μg of protein/lane) were analyzed on 
immunoblots using GAL antibody. 
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Figure 3-12. Interactions Between AR, MAGE-11, and TIF2. (A) Schematic diagram of 
dynamic interactions between AR (blue), MAGE-11 (orange), and TIF2 (light blue) in the 
context of the AR antiparallel dimer bound to DNA. Indicated is the AR NH2-terminal (N) 
activation function 1 (AF1), AR carboxyl-terminal (C) activation function 2 (AF2), and the 
AR FXXLF motif interaction site for MAGE-11 and AF2 in the N/C interaction. (B) Detailed 
schematic diagram of interactions between MAGE-11 (orange) F-box residues 329–369 in 
the carboxyl-terminal MAGE homology domain (MHD) with the AR (blue) NH2-terminal 
FXXLF motif 
23
FQNLF
27
, which is modulated by phosphorylation in the MAGE-11 F-box at 
Thr-360, monoubiquitinylation (Ub) at Lys-240 and -245 (19), and serum stimulation of 
MAP kinase phosphorylation of MAGE-11 Ser-174 outside the F-box. AR transcriptional 
activity is increased by MAGE-11 F-box binding of the AR FXXLF motif, which 
competitively inhibits AR FXXLF motif binding to AF2 in the AR N/C interaction. This 
exposes AF2 in the AR ligand binding domain (LBD) for TIF2 (light blue) LXXLL (LX) 
motif binding. MAGE-11 also increases AR transcriptional activity through direct 
interactions with the TIF2 NH2-terminal region and with AD1 mediated in part by MAGE-11 
FXXIF motif 
260
FPEIF
264
. 
 
 
 
CHAPTER 4 
 
TRANSCRIPTIONAL SYNERGY BETWEEN MAGE-11 AND p300 IN 
ANDROGEN RECEPTOR SIGNALING 
 
Abstract 
Androgen receptor (AR) mediated gene regulation involves interactions with 
coregulatory proteins that include the melanoma antigen gene protein-A11 (MAGE-11). To 
understand the functional significance of sequence similarity between MAGE-11 and the 
adenovirus early protein E1A, we determined whether MAGE-11 contributes to AR 
transcriptional activity through an interaction with p300, a potent and ubiquitous 
transcriptional regulator. Here we report that MAGE-11 interacts with the NH2-terminal 
region of p300 through MAGE-11 MXXIF motif sequence 
185
MXXIF
189
, with transcriptional 
activity depending on the MAGE-11 F-box and MAP kinase phosphorylation. The MAGE-
11 and p300-dependent increase in AR transactivation required the NH2-terminal regions of 
AR and p300, p300 acetyltransferase activity, and AR FXXLF motif sequence 
23
FQNLF
27
 
interactions with MAGE-11 and p300. The p300 NH2-terminal FXXLF motif sequence 
33
FGSLF
37
 was required for transcriptional activation by the p160 coactivator, transcriptional 
intermediary protein 2 (TIF2). Increased expression of p300 decreased the ubiquitinylation of 
MAGE-11 and transiently increased endogenous MAGE-11 levels. Autoacetylation of p300 
and decreased acetylation of TIF2 was evident in the MAGE-11, p300 and TIF2 complex. 
The studies suggest that MAGE-11 links the AR and p300 NH2-terminal domains to promote 
transcriptional synergy through a cadre of FXXLF-related interacting motifs. 
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Introduction 
The androgen receptor (AR) regulates gene transcription required for male sex 
development by binding androgens with high affinity and interacting with coregulatory 
proteins. AR transcriptional activity derives from activation function 1 (AF1) in the NH2-
terminal region and the activation function 2 (AF2) hydrophobic surface in the ligand 
binding domain. AR AF2 interacts with p160 coactivator LXXLL motifs and the AR NH2-
terminal FXXLF motif 
23
FQNLF
27
 that mediates the androgen-dependent NH2- and carboxyl-
terminal (N/C) interaction (1). The competitive relationship between AR FXXLF and p160 
coactivator LXXLL motif binding to AF2 exerts an inhibitory effect on p160 coactivator-
induced AF2 transcriptional activity (2, 3). These findings, together with the greater AR AF2 
binding affinity for the AR FXXLF than coactivator LXXLL motifs (4), suggest that AF1 in 
the AR NH2-terminal region is the principal AR activation domain.  
  While regulation of steroid receptors through the AF2 site is relatively well described, 
the molecular mechanisms by which coregulatory proteins mediate AR AF1 activity are not 
understood. One recently described AR coregulator that interacts with the AR NH2-terminal 
region, modulates the AR N/C interaction and increases AR transcriptional activity is the 
melanoma antigen gene protein-A11 (MAGE-11). MAGE-11 binds the AR NH2-terminal 
FXXLF motif and interacts directly with p160 coactivators to increase AR transcriptional 
activity (5, 6). The interaction between AR and MAGE-11 is mediated by a MAGE-11 F-box 
and modulated by epidermal growth factor (EGF)-induced phosphorylation of Thr-360 
within the F-box and monoubiquitinylation at lysine residues outside the F-box (6, 7).  
 The functional importance of MAGE-11 as an AR coregulator is supported by its 
regulated expression in both normal physiology and cancer. MAGE-11 levels increase by 
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~50 fold in the epithelium of the normal cycling human endometrium during the window of 
implantation (8), and to a similar extent in the CWR22 human prostate cancer xenograft 
during castration-recurrent growth. MAGE-11 levels were increased up to ~1000 fold in a 
subset of patients with castration-recurrent prostate cancer (9). The functional importance of 
AR signaling in prostate cancer initiation and progression suggests that increased expression 
of MAGE-11 provides a mechanism to enhance AR signaling when circulating androgen 
levels are low.  
The ability of MAGE-11 to increase the constitutive activity of AR-(1–660), an NH2-
terminal and DNA binding fragment, when MAGE-11 itself lacks inherent transcriptional 
activity, provided support for the idea that MAGE-11 functions as an AR coregulator through 
direct interactions with coactivators. Based on sequence similarity between MAGE-11 and 
the adenovirus early protein E1A, an oncogenic protein that interacts strongly with p300, we 
investigated the possible interaction between MAGE-11 and p300, a ubiquitous 
transcriptional regulator and potent acetyltransferase. p300 activates gene transcription by 
acetylating histones and transcription factors, and as a coactivator of promoter-specific 
nuclear receptors (10). Studies described here address the mechanisms underlying the 
MAGE-11-dependent increase in AR transcriptional activity arising from AR NH2-terminal 
AF1.  
Materials and Methods 
Expression Plasmids and Reporter Vectors–pCMV-hAR (11), pCMV-AR-(1–660) 
(12), VP-AR and VP-AR-(1–660) with wild-type sequence, L26A,F27A (LFAA) and ∆9–28 
mutants (1, 13), pSG5-MAGE-11 (pSG5-MAGE), VP-MAGE-11-(2–429) (VP-MAGE) and 
pCMV-FLAG-MAGE-11-(2–429) (FLAG-MAGE) (5), pSG5-HA-MAGE-(112–429) and 
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FLAG-ubiquitin (FLAG-Ub) (7), wild-type and F-box mutants of pSG5-HA-MAGE 
fragments and pSG5-HA-MAGE-(112–429) (6), and pSG5-transcriptional intermediary 
factor 2 (TIF2) (14) and pCMV-FLAG-TIF2 (6) expression plasmids were described. 
Reporter vectors included prostate-specific-enhancer-luciferase (PSA-Enh-Luc) which 
contains the -3935 to -4326 upstream enhancer region of the PSA gene cloned upstream of a 
E4 TATA box in pGL3 basic (15), and 5XGAL4Luc3 which contains 5 copies of the GAL4 
upstream enhancer element (16, 17).  
pSG5-HA-p300 was prepared by blunt-end cloning a Not1/HindIII fragment of 
CMVb-NHAp300 (provided by Dr. David Livingston, Dana-Farber Cancer Institute) into the 
BamHI site of pSG5. pSG5-HA-p300-D1399Y, I97A,F98A and I188A,F189A were created 
by QuikChange site-directed mutagenesis (Stratagene) using pSG5-HA-p300 as template. 
GAL-MAGE and VP-MAGE fragments were created by PCR mutagenesis. pCMV-FLAG-
p300 fragments were created by PCR amplifying pSG5-HA-p300, digesting with EcoR1/ClaI 
(FLAG-p300-(2–300) and 2–357) or HindIII/ClaI (FLAG-p300-(270–357), 300–670, 357–
670 and 450–670) and ligating into the same sites of pCMV-FLAG. Additional FLAG-p300 
fragments were created by ligating EcoRI/XbaI fragments of GAL-p300-(2–270) and 2–300 
and a SalI/XbaI fragment of GAL-p300-(230–670) into the same sites of pCMV-FLAG. 
GST-p300-(2–357) was created by inserting the EcoRI/SalI fragment from FLAG-p300-(2–
357) into the same sites of pGEX-4T-1. 
GAL-p300-(2–300), 230–670, 501–999, 1000–1600, 1601–1900 and 1901–2414 
were created by PCR amplifying the indicated regions of pSG5-HA-p300 and cloning 
SalI/ClaI digested fragments into the same sites of GAL0. GAL-p300-(2–357) was created 
by digesting FLAG-p300-(2–357) with EcoRI/XbaI and ligating the fragment into the same 
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sites of GAL0. GAL-p300-(2–300)-L36A,F37A was created using QuikChange site-directed 
mutagenesis and GAL-p300-(2–300) as template. GAL-p300-(230–670) was created by PCR 
amplifying pSG5-HA-p300, digesting with SalI/ClaI and inserting the fragment into GAL0.  
Other GAL-p300 fragments were created by PCR amplifying GAL-p300-(2–300), 
digesting the fragments with SalI/ClaI (GAL-p300-(2–270), 2–230, 2–180, 90–300 and 90–
270) or EcoRI/ClaI (GAL-p300-(48–300)) and ligating into the same sites of GAL0. All PCR 
amplified regions were verified by DNA sequencing. 
Expression Studies–Monkey kidney CV1 cells (4 x 105/6 cm dish) were transfected 
using calcium phosphate DNA precipitation (3) with 0.1 µg pCMV-AR and the indicated 
amounts of wild-type and mutant pSG5-MAGE, pSG5-TIF2 and pSG5-HA-p300 and 3 or 5 
µg PSA-Enh-Luc. After transfection and 24 h later, cells were placed in serum-free, phenol-
red free media in the absence and presence of 1 nM dihydrotestosterone (DHT). The next day 
the medium was replaced and 24 h later cells were extracted in 0.25 ml luciferase lysis buffer 
containing 1% Triton X-100, 2 mM EDTA and 25 mM Tris phosphate, pH 7.8. Luciferase 
activity was measured using an automated Lumistar Galaxy multiwell plate luminometer 
(BMG Labtech). Luciferase activity shown is representative of at least three independent 
experiments and the graphs show the mean ± S.E.  
Two hybrid transfection assays were performed in HeLa human epithelial cervical 
carcinoma cells using FuGENE-6 (Roche) by plating 5 x 10
4
 cells/well in 12 well plates (4). 
Cells were transfected with 0.1 µg/well 5XGAL4Luc3 and 0.05 µg GAL-p300 fragments 
with 0.05 µg pVP16 empty vector or VP-MAGE. The day after transfection, cells were 
transferred to serum-free medium and incubated overnight at 37°C before luciferase activity 
was measured.  
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Small interfering RNA (siRNA) was transfected into COS cells (4 x 10
5
/well in 6 
well plates) using Lipofectamine 2000 (Invitrogen) in the absence of antibiotics with 1 µg 
pSG5-MAGE, 1 µg pSG5-TIF2 or 2 µg pSG5-HA-p300 in the absence and presence of 5 nM 
MAGE-11 siRNA-2 GCACUGAUCCUGCAUGCUAUU, MAGE-11 siRNA-3 
CAACUGCUCUUUGGCAUUGUU, 5 nM TIF2 siRNA-3 
GAUCAGAAGUGACUAUUAA, 10 nM p300 siRNA-1 GAAAUUAGGUUACACAACA, 
p300 siRNA-2 GGACUACCCUAUCAAGUAA, p300 siRNA-3 
GAACAUGGCUCCACAACCA, p300 siRNA-4 GGCAGUAUGUCGAUGAUAU and 
nonspecific siRNA-5 UGGUUUACAUGUCGACUAA (Dharmacon RNA Technologies). 
The day after transfection, cells were harvested or transferred to serum-free medium and 
harvested 24 h later for immunoblot analysis. For siRNA experiments in HeLa cells, cells 
were plated in antibiotic free medium and transfected using Lipofectamine 2000.  
Immunoblotting–Relative expression levels of wild-type and mutant vectors were 
determined by transfecting COS cells (2 x 10
6
/10 cm dish) with 5–8 µg DNA using DEAE 
dextran (4, 18). The next day cells were transferred to serum-free media with or without 1 
µM MG132 proteosome inhibitor (Sigma), and 24 h later harvested in phosphate buffered 
saline. Cell pellets were extracted in 0.1 to 0.2 ml of immunoblot (IB) lysis buffer containing 
1% Triton X-100, 1% sodium deoxycholate, 0.1% sodium dodecyl sulfate (SDS), 0.15 M 
NaCl, 2 mM EDTA, 0.05 mM NaF, 2 mM sodium vanadate, 50 mM Tris-HCl, pH 7.5 with 1 
mM phenylmethylsulfonyl fluoride, 1 mM dithiothreitol and complete protease inhibitor 
cocktail (Roche). Cell extracts were analyzed on 8, 10 or 12% acrylamide gels containing 
SDS. Proteins were transferred overnight to nitrocellulose membranes at 4°C and transblots 
were probed with the following antibodies: rabbit anti-GAL4 DNA binding domain (Santa 
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Cruz Biotechnology sc-577, 1:500 dilution); rabbit polyclonal FLAG-MAGE antibody-1 (0.5 
μg/ml) raised against purified baculovirus-expressed FLAG-tagged human MAGE-11; 
affinity purified rabbit polyclonal human p300 (C-20) antibody (Santa Cruz Biotechnology 
sc-585, 1:75–200 dilution); mouse anti-β-actin (Abcam, 1:5000 dilution); mouse anti-TIF2 
(BD Transduction Laboratories, 1:100–250 dilution); rabbit anti-MAGE-11 peptide 
antibodies MAGE-Ab-13–26, 59–79 and 94–108 immunoglobulin G (4–10 μg/ml) (8); 
mouse anti-FLAG M2 monoclonal antibody (Sigma F3165,1:500–2000 dilution); rabbit 
polyclonal acetylated-lysine antibody (Cell Signaling 9441, 1:1000 dilution); and rabbit anti-
HA-tag (Abcam ab9110, 1:2000 dilution). Gels were calibrated using EZ-Run prestained Rec 
protein ladder (Fisher Bioreagents) and immunoreactivity detected by chemiluminescence 
(SuperSignal West Dura Extended Duration Substrate, Pierce). 
Immunoprecipitation was performed by transfecting COS cells as above with two 10 
cm plates/group. For protein acetylation assays, cells were treated for 1 h prior to harvest 
with histone deacetylatase inhibitor 5 mM nicotinamide with and without 5 mM sodium 
butyrate. Cell lysates were prepared in ¼ volume immunoprecipitation (IP) lysis buffer 
containing 1% Triton X-100, 0.5% deoxycholate, 0.15 M NaCl, 0.05 M NaF, 1 mM EDTA 
and 50 mM Tris, pH 7.6 with 1 mM phenylmethylsulfonyl fluoride, 1 mM dithiothreitol, 
complete protease inhibitor cocktail (Roche) with or without deacetylatase inhibitors 5 mM 
nicotinamide and 5 mM sodium butyrate. Lysates were diluted 4 fold with IP buffer lacking 
deoxycholate and precleared for 1 h at 4C with 0.1 ml Sepharose CL-4B (Sigma). Samples 
were transferred to 15 µl anti-FLAG M2 agarose (Sigma) for overnight incubation at 4C. 
The next day samples were pelleted and washed with IP lysis buffer without deoxycholate, 
resuspended in 0.05 ml 2X SDS sample buffer containing 3.3% SDS, 10% 2-
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mercaptoethanol, 10% glycerol and 0.12 M Tris-HCl, pH 6.8, incubated for 5 min at 90C 
and analyzed on immunoblots as described above.  
In vitro Binding Assays–Glutathione S-transferase (GST) interaction assays were 
performed using pGEX-4T-1 empty vector and pGEX-4T-1-p300-(2–357) (GST-p300-(2–
357)). [
35
S]-MAGE-11 was prepared using pSG5-MAGE and the TNT T7 Quick Coupled 
transcription-translation system (Promega) (1, 6, 19). GST fusion proteins were expressed in 
BL-21 DE3 Echerichia coli with 1 mM isopropyl 1-thio-β-D-galactopyranoside for 3 h at 
37˚C. Cell pellets were resuspended in GST binding buffer containing 0.5% Nonidet P-40, 1 
mM EDTA, 0.1 M NaCl, 10% glycerol, 20 µg/ml bovine serum albumin and 20 mM Tris-
HCl, pH 8.0 with 1 mM dithiothreitol and complete protease inhibitor cocktail (Roche). 
Glutathione-Sepharose 4B (GE Healthcare) was incubated for 1.5 h at 4C with GST-0 and 
GST-p300-(2–357) cell lysates after sonication. Beads were washed with GST buffer, 
combined with 25 µCi [
35
S]-MAGE-11 and incubated overnight at 4C. The resin was 
washed, eluted with SDS and analyzed on an 8–16% gradient minigel containing SDS 
(Invitrogen). The dried gel was exposed to x-ray film for 48 h.  
Results 
MAGE-11 Increases p300-Dependent AR Transcriptional Activity–To determine 
whether MAGE-11 increases AR transcriptional activity through mechanisms that involve 
p300, AR was expressed in the absence and presence of MAGE-11 and p300. Androgen-
dependent AR transcriptional activity increased to a greater extent with the expression of 
MAGE-11 than with p300, and was highest when MAGE-11 and p300 were coexpressed 
(Fig. 4-1A). MAGE-11 and p300 further increased AR transcriptional activity when 
expressed with TIF2 (Fig. 4-1B), consistent with previous findings that MAGE-11 binds the 
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AR FXXLF motif, exposes AF2 for p160 coactivator recruitment and interacts directly with 
TIF2 (5, 6).  
Further investigation determined whether the effects of MAGE-11 and p300 on AR 
transcriptional activity are mediated through the AR NH2-terminal AF1 region. Expression of 
MAGE-11 or p300 increased activity of AR-(1–660), an AR NH2-terminal and DNA binding 
domain fragment, and were synergistic when expressed together (Fig. 4-1C). As seen with 
full-length AR, TIF2 alone did not increase AR-(1–660) activity unless expressed with p300 
or MAGE-11 (Fig. 4-1D).  
The MAGE-11 dependence of the TIF2-induced increase in AR transcriptional 
activity could be explained by previous findings that MAGE-11 interacts with TIF2 (6), and 
binding of MAGE-11 to the AR FXXLF motif overcomes an inhibitory effect of the AR N/C 
interaction on TIF2 binding to AF2 (3) (see diagram, Fig. 4-11). However, dependence on 
MAGE-11 for the p300-induced increase AR transcriptional activity through the AR NH2-
terminal region raised the possibility that MAGE-11 interacts with p300. 
MAGE-11 Interacts with the NH2-terminal Region of p300–An interaction between 
MAGE-11 and p300 was demonstrated in mammalian two hybrid assays by expressing VP-
MAGE and p300–GAL4 DNA binding domain fusion proteins (Fig. 4-2A). MAGE-11 
interacted with the p300-(2–300) NH2-terminal region to a greater extent than with p300-
(230–670) (Fig. 4-2B). MAGE-11 did not interact with the p300 501–999 Kix domain, 1000–
1600 Bromo domain, PHD (plant homeodomain) and histone acetyltransferase domains (20–
22) or the 1601–1900 ZZ and TAZ2 domains (23). Constitutive activity of carboxyl-terminal 
fragment p300-(1901–2414) that includes an IBID domain (24) was only slightly increased 
by MAGE-11.  
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To further localize and establish an influence of MAGE-11 on transcriptional activity 
from the p300 NH2-terminal region, additional GAL-p300 fragments were expressed with the 
MAGE-(112–429) carboxyl-terminal fragment (Fig. 4-2C). Similar to the two hybrid 
interaction results (Fig. 4-2B), MAGE-(112–429) increased the activity of GAL-p300-(2–
357), 2–300, 2–270 and 230–670 compared to other p300 NH2-terminal fragments (Fig. 4-
2C). Overall activity decreased with deletion of the p300 NH2-terminal region in GAL-p300-
(48–300) or with mutations in a p300 NH2-terminal FXXLF motif sequence 
33
FGSLF
37 
in 
GAL-p300-(2–300)-L36A,F37A. The results suggest that MAGE-11 interacts with and 
increases transcriptional activity of the p300 NH2-terminal region.  
p300 Interacts with the Carboxyl-terminal Region of MAGE-11–To identify the 
region in MAGE-11 that interacts with p300, VP-MAGE fragments were expressed in 
mammalian two hybrid assays with GAL-p300-(2–300) (Figs. 4-3A and 4-3B). Full-length 
VP-MAGE and VP-MAGE-(112–429) interacted with GAL-p300-(2–300), but not with 
MAGE-(112–362) or 112–252 (Fig. 4-3B). This suggested that the entire MAGE-11 
carboxyl-terminal region is required to interact with p300 as demonstrated previously for 
MAGE-11 binding to the AR FXXLF motif (5). In agreement with results of Fig. 4-2B, 
MAGE-(112–429) strongly increased GAL-p300-(2–300) activity. However, there was little 
to no increase with shorter fragments and less of an increase with full-length MAGE-11 (Fig. 
4-3C), even though GAL-p300-(2–300) interacted with full-length MAGE-11 (Fig. 4-3B).  
The carboxyl-terminal region of MAGE-11 contains a conserved F-box (Fig. 4-3A, 
amino acid residues 329–369) that interacts with the AR FXXLF motif (6). The requirement 
for the MAGE-11 F-box to increase GAL-p300-(2–300) transcriptional activity was indicated 
by the loss of activity with a series of single amino acid MAGE-11 F-box mutants (Fig. 4-
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3D) shown previously to decrease MAGE-11 binding to the AR FXXLF motif (6). Mutation 
of mitogen-activated protein (MAP) kinase site Ser-174 blocked the MAGE-(112–429)-
dependent increase GAL-p300-(2–300) activity, and was recovered with the MAGE-(112–
429)-S174D phosphomemetic (Fig. 4-3E). A predicted MAGE-11 phosphorylation site at 
Ser-298 when mutated to alanine decreased the MAGE-(112–429)-dependent increase in 
GAL-p300-(2–300) activity, but was only partially restored with the S298D 
phosphomemetic. A direct interaction between MAGE-11 and the p300 NH2-terminal region 
was supported by in vitro binding studies in which GST-p300-(2–357) interacted with [35S]-
labeled MAGE-11 (Fig. 4-3F).  
The results suggest that the carboxyl-terminal region of MAGE-11 interacts with the 
NH2-terminal region of p300 and increases p300 transcriptional activity through mechanisms 
that depend on the MAGE-11 F-box and MAP kinase phosphorylation. The inhibitory effect 
of the MAGE-11 NH2-terminal region on GAL-p300 transcriptional activity suggested an 
auto-regulatory mechanism.  
MAGE-11 MXXIF Motif Interacts with p300–To characterize further the MAGE-11 
interaction with p300, full-length p300 was expressed with a series of GAL-MAGE 
fragments (Fig. 4-4A). p300 activated full-length GAL-MAGE and GAL-MAGE-(112–429) 
to only a limited extent (Fig. 4-4B), even though these regions interacted with p300 (Fig. 4-
3B). However, p300 strongly activated GAL-MAGE-(112–205), 140–205, 161–205, 85–205 
and 85–152, but not 100–152 (Fig. 4-4B).  
Within the MAGE-(85–205) region activated by p300 are two M/IXXIF motifs, 
94
ITQIF
98 
and 
185
MDAIF
189 
(Fig. 4-4A). Functional importance of the 
185
MXXIF
189
 motif was 
suggested by decreased p300-dependent GAL-MAGE-(85–205)-I188A,F189A activity, and 
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loss of GAL-MAGE-(140–205)-I188A, F189A activity in a MAGE-11 fragment that lacked 
the 
94
IXXIF
98
 motif (Fig. 4-4C). Disruption of the 
94
IXXIF
98
 motif in GAL-MAGE-(85–205)-
I97A, F98A, a fragment that contained the 
185
MXXIF
189
 motif, had no effect on p300-
dependent activity. However, p300-dependent transcriptional activity decreased with GAL-
MAGE-(85–152)-I97A,F98A, a 94IXXIF98 motif mutant that lacked the 185MXXIF189 motif. 
The functional requirement for the MAGE-11 
185
MXXIF
189
 motif was also evident in 
AR transcription assays. Mutations in either the MXXIF or IXXIF motif in full-length 
MAGE-11 did not significantly decrease AR transcriptional activity when p300 or TIF2 were 
not expressed (Fig. 4-4D). However, mutations in the 
185
MXXIF
189
 motif minimized or 
eliminated the MAGE-11-dependent increase in AR transcriptional activity with the 
expression of p300 and/or TIF2, whereas AR activity remained similar to wild-type with 
mutations in the 
94
IXXIF
98
 motif.  
The results suggest that the MAGE-11 MXXIF motif 
185
MDAIF
189 
is a primary 
interaction site for p300, and IXXIF
 
motif sequence 
94
ITQIF
98
 is a secondary interaction site. 
The inability of p300 to increase GAL-MAGE or GAL-MAGE-(112–429) activity when 
smaller fragments were strongly activated suggested that the MAGE-11 carboxyl-terminal 
region has an inhibitory effect. 
Functional Requirement for AR and p300 NH2-terminal FXXLF Motifs–p300 contains 
an FXXLF motif sequence 
33
FGSLF
37
 in a similar relative position to the AR FXXLF motif 
(Fig. 4-5A). Evidence that the p300 FXXLF motif was required to enhance GAL-p300-(2–
300) activity (Fig. 4-2C) and the close proximity of flanking charged residues (Fig. 4-5A) 
suggested that the p300 NH2-terminal FXXLF motif is functionally important. Since previous 
studies demonstrated AR activation of androgen responsive enhancer/promoters depends on 
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the AR FXXLF motif (25), we investigated the requirement for these NH2-terminal FXXLF 
motifs in AR interaction with p300.  
Interaction between VP-AR-(1–660) and GAL-p300-(2–300) required the AR 
FXXLF-motif since the interaction was eliminated with VP-AR-(1–660)-L26A,F27A when 
the p300 FXXLF motif was present (Fig. 4-5B). Deletions of the p300 FXXLF motif in GAL-
p300-(48–300) or GAL-p300-(90–300) decreased overall activity and the requirement for the 
AR FXXLF motif, but did not eliminate the interaction with AR. A weak androgen-dependent 
interaction between full-length VP-AR and GAL-p300-(2–300) was inhibited with VP-AR-
L26A,F27A and VP-AR∆9–28 in which the AR FXXLF motif was mutated or deleted (Fig. 
4-5C). However, deletion of the p300 FXXLF motif increased the androgen-dependent 
interaction between GAL-p300-(48–300) and VP-AR that was eliminated with VP-AR-
L26A,F27A or VP-AR∆9–28.  
To better understand the functional requirement for the p300 NH2-terminal FXXLF 
motif, GAL-p300-(2–300) was expressed with TIF2. GAL-p300-(2–300) was strongly 
activated by TIF2 (Fig. 4-5D) in a p300 FXXLF motif-dependent manner. TIF2-dependent 
GAL-p300-(2–300) activity was inhibited with GAL-p300-(48–300) where the p300 FXXLF 
motif was deleted, and with GAL-p300-(2–300)-L36A,F37A in which the p300 FXXLF motif 
was mutated.  
The contribution of endogenous MAGE-11 to the TIF2-dependent increase in GAL-
p300-(2–300) activity was indicated through the use of siRNAs to lower protein levels. 
MAGE-11 siRNA-2 reduced MAGE-11 levels (Fig. 4-6A, top panel) and inhibited inherent 
GAL-p300-(2–300) transcriptional activity, but did not eliminate the increase in activity with 
TIF2 (Fig. 4-6B). MAGE-11 siRNA-3 was less effective in decreasing MAGE-11 levels 
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(Fig. 4-6A), and the TIF2-induced increase in GAL-p300-(2–300) activity was similar to that 
seen in the absence and presence of nonspecific siRNA. TIF2 siRNA-3 decreased both TIF2 
expression (Fig. 4-6A, bottom panel) and the TIF2-dependent increase in GAL-p300-(2–300) 
activity (Fig. 4-6B).  
The results suggest that the AR interaction with p300 is influenced by NH2-terminal 
FXXLF motifs present in both proteins, and that the p300 FXXLF motif facilitates 
transcriptional activation by TIF2.  
Multiple Functions of the AR FXXLF Motif–Previous studies have demonstrated the 
requirement for the androgen-dependent AR N/C interaction between the AR FXXLF motif 
and AF2 for AR to activate androgen responsive enhancer/promoters (1, 25). These findings 
and the requirement for the AR FXXLF motif in interactions with MAGE-11 and p300 
provided evidence that the AR N/C interaction influences AR transactivation by p300.  
To investigate this further, we determined the effect of MAGE-11 and p300 using an 
experimental paradigm that depended on the AR N/C interaction. AR-(507–919), a DNA and 
ligand binding domain fragment that retains high affinity androgen binding (26), was not 
activated by DHT with or without the expression of MAGE-11 or p300 alone or together 
(Fig. 4-7A). However, expression of AR-(507–919) with AR-(1–503), an AR NH2-terminal 
fragment that lacks the AR DNA and ligand binding domains, increased androgen-dependent 
transcriptional activity. Activity was further increased with the expression of MAGE-11 or 
p300, and was greatest when expressed together. Dependence on the AR N/C interaction was 
demonstrated by loss of activity when AR-(507–919) was expressed with MAGE-11 or p300 
alone or together with AR-(1–503)-L26A,F27A in which the AR FXXLF motif was mutated.  
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The requirement for endogenous p300 in AR N/C interaction-dependent AR 
transactivation was further demonstrated using p300 siRNA. p300 siRNA-1, 3 and 4 each 
decreased both p300 levels (Fig. 4-7B) and the androgen-dependent activity of AR-(507–
919) and AR-(1–503) expressed with MAGE-11 (Fig. 4-7C). Specificity of siRNA inhibition 
was suggested by wild-type activity using nonspecific siRNA, or with p300 siRNA-2 that did 
not reduce p300 levels.  
To demonstrate further that MAGE-11 functionally links AR and p300 through the 
AR FXXLF motif, GAL-AR-(16–36), which contains only the AR NH2-terminal FXXLF 
motif region, was expressed with wild-type or mutant MAGE-11 and p300 alone or together. 
Neither MAGE-11 nor p300 alone increased GAL-AR-(16–36) activity, but were strongly 
synergistic (Fig. 4-7D). Mutations in the MAGE-11 
185
MXXIF
189
 motif that was required for 
MAGE-11 to interact with p300 (Fig. 4-4) reduced p300 activation of GAL-AR-(16–36), 
with only a slight decrease with mutations in the MAGE-11 
94
IXXIF
98
 motif in agreement 
with the results in Fig. 4-4. Dependence of p300-induced GAL-AR-(16–36) activity on AR 
FXXLF motif binding to MAGE-11 was demonstrated by loss of the transcriptional response 
with MAGE-11 F-box mutants MAGE-L358A and T360A, and the ubiquitinylation site 
mutant K240A,K245A, where each mutation disrupts MAGE-11 binding to the AR FXXLF 
motif (6, 7). Dependence on the AR FXXLF motif was also shown by the lack of activity 
with the GAL-AR-(16–36)-L26A,F27A FXXLF motif mutant. GAL-AR-(16–36) activity was 
also reduced by p300-D1399Y, a p300 acetyltransferase mutant (27).  
The results suggest that AR transcriptional activity mediated by the AR N/C 
interaction depends on the ability of MAGE-11 to link AR and p300 by binding the AR 
FXXLF motif that also mediates the AR N/C interaction. The results support the notion that 
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AR transcriptional activation by p300 is mediated through sequential AR FXXLF motif 
interactions with the AR AF2 site, MAGE-11 and p300.  
Dependence on p300 Acetyltransferase Activity–The decrease in MAGE-11-
dependent GAL-AR-(16–36) activity with the p300 acetyltransferase mutant led us to 
investigate the requirement for p300 acetyltransferase activity in MAGE-11-induced AR 
activity. AR transcriptional activity in the presence of MAGE-11 or TIF2 alone or together 
increased with p300 but not with p300-D1399Y (Fig. 4-8A). Similarly, the p300-dependent 
increase in GAL-MAGE-(85–205) and 140–205 activity was eliminated with the p300-
D1399Y acetylation mutant (Fig. 4-8B).  
Since protein stability can be influenced by acetylation or ubiquitinylation of lysine 
residues (28), we determined whether p300 acetyltransferase activity influences MAGE-11 
ubiquitinylation. In the absence of p300, MAGE-(112–429) was strongly ubiquitinylated 
(Fig. 4-8C) as reported previously (7). Coexpression of p300 or the p300-D1399Y 
acetyltransferase mutant inhibited MAGE-(112–429) ubiquitinylation. However, there was 
no evidence that MAGE-11 was acetylated by p300 (data not shown), although acetylated 
forms of TIF2 and p300 were present in the complex with MAGE-11 that were not detected 
with p300-D1399Y (Fig. 4-9A). Acetylation of TIF2 declined with the coexpression of 
MAGE-11, and was not detected with p300-D1399Y (Fig. 4-9B).  
The results indicate that p300 acetyltransferase activity is required for MAGE-11 and 
p300 to increase AR transcriptional activity. However, MAGE-11 was not acetylated by 
p300 even though there was evidence for the acetylation of both p300 and TIF2. In 
agreement with these findings, p300 inhibited MAGE-11 ubiquitinylation independent of 
acetyltransferase activity, and MAGE-11 had an inhibitory effect on TIF2 acetylation.  
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p300 Increases Endogenous MAGE-11–Evidence that p300 inhibits the 
ubiquitinylation of MAGE-11 (Fig. 4-8C) raised the possibility that p300 might influence the 
endogenous levels of MAGE-11. To pursue this further, p300 was expressed in COS cells 
and assayed at the indicated times in serum-free medium. MAGE-11 was not detected when 
p300 was not expressed or through 5 h when p300 was expressed (Fig. 4-10). However, 
endogenous MAGE-11 was detected at 7 h but not at 9, 14 and 24 h when p300 levels 
declined. The transient increase in MAGE-11 suggests that p300 influences its cell cycle 
expression.  
Discussion 
AR Transcriptional Regulation by MAGE-11 and p300–We have demonstrated 
transcriptional synergy between AR, the AR coregulator MAGE-11 and p300, a ubiquitous 
and potent transcriptional regulator and acetyltransferase (22, 29, 30). MAGE-11 links the 
NH2-terminal regions of AR and p300 to increase AR transcriptional activity dependent on 
p300 acetyltransferase activity through FXXLF-related motif interactions in the AR, MAGE-
11, p300 and TIF2 transcription complex. The AR FXXLF motif functions not only in the 
androgen-dependent AR N/C interaction (1, 2) and binding of MAGE-11 (1, 5), but also is  
involved in AR interaction and activation by the p300 NH2-terminal region (Fig. 4-11). The 
multiple AR FXXLF motif interactions were each eliminated by AR-L26A,F27A mutations 
that disrupt the AR FXXLF motif α-helical structure (1, 5). The ability of MAGE-11 to link 
AR and p300 was demonstrated further by the transcriptional activity of two AR fragments 
that depends on the AR N/C interaction. MAGE-11 and p300 also increased the activity of 
GAL-AR-(16–36), an AR FXXLF motif fusion peptide.  
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The findings suggest that the AR FXXLF motif mediates an increase in AR 
transcriptional activity not only through the AR N/C interaction, but also by recruiting 
MAGE-11 and interacting with the NH2-terminal region of p300. The critical function of the 
AR N/C interaction is supported by AR AF2 site mutations that disrupt AR FXXLF motif 
binding and AR function (19). The studies support the supposition that a single interaction 
motif undergoes multiple transient interactions during the process of AR mediated 
transcription. Dependence of androgen responsive enhancer/promoters on the AR NH2-
terminal FXXLF motif (25) may be explained by the AR FXXLF motif-dependent AR N/C 
interaction, the functional requirement of the AR FXXLF motif to bind MAGE-11, and for 
MAGE-11 to link AR to p300. However, we found little evidence that p300 could increase 
AR transactivation in the absence of MAGE-11. In agreement with this, the previously 
reported ability of p300 to increase AR transcriptional activity made use of prostate cancer 
cell lines (31) that have relatively high levels of AR and MAGE-11.  
Sites that interact with FXXLF-related motifs also serve multiple functions that differ 
in specificity. For example, the AF2 site in the AR ligand binding domain binds the AR NH2-
terminal FXXLF motif, p160 coactivator LXXLL motifs and FXXLF-related motifs in putative 
AR coactivators (25, 32), but does not bind the p300 NH2-terminal FXXLF motif (18). In 
contrast, the MAGE-11 F-box binds the AR FXXLF motif but not FXXLF motifs present in 
AR coactivators or p300 (6). However, the MAGE-11 F-box was required for the functional 
interaction between MAGE-11 and p300, where MAGE-11 increased GAL-p300 activity. 
The MAGE-11 F-box at amino acid residues 329–369 begins with the sequence 329IPEE332 
followed by a conserved arrangement of hydrophobic amino acids similar to the F-box of 
cyclin F (6). p300 contains a similar 
43
LPDE
46
 sequence positioned close to the 
33
FGSLF
37
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FXXLF motif but with a different arrangement of hydrophobic residues than the MAGE-11 
F-box. Deletion of this putative p300 F-box region in GAL-p300-(48–200) increased the 
interaction with full-length AR that was influenced by the AR FXXLF motif. This suggests 
that an F-box-like sequence in the NH2-terminal region of p300 may interact with another 
protein that competes with AR binding to p300. The existence of multiple overlapping motifs 
and surfaces is consistent with MAGE-11 and p300 coordinating temporal interactions 
during AR transactivation. 
Both MAGE-11 and p300 are downstream targets of MAP kinase (6, 33), and p300 is 
phosphorylated in a time-dependent manner in response to EGF (34). In response to serum 
stimulation, MAGE-11 is phosphorylated by MAP kinase at Ser-174, a conserved residue in 
the MAGE-A subfamily (6). The MAGE-S174A mutant eliminated the functional interaction 
between MAGE-11 and p300 that was restored with the S174D phosphomemetic. The 
MAGE-11 S174A mutation also diminished MAGE-11 interaction with the AR FXXLF motif 
(6). Inhibition of GAL-p300 activity by MAGE-S174A suggests that phosphorylation-
dependent changes influence the ability of p300 to function with MAGE-11 to modulate AR 
transcriptional activity. The results suggest that MAP kinase phosphorylation at Ser-174 
regulates several important aspects of MAGE-11 function.  
Requirement for p300 Acetyltransferase Activity–p300 has a modular structure with 
multiple protein interaction sites. These include a cysteine and histidine rich Taz1 domain at 
residues 332–417, a Kix domain (566–646) that interacts with CBP binding protein CREB, a 
bromo domain that interacts with p53 (1053–1156), a PHD domain (1198–1278), a 
glutamine-rich C-terminal region that interacts with the p160 coactivator activation domain-1 
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(14, 35, 36), and a lysine acetyltransferase domain between amino acid residues 1284–1517 
(22).  
The NH2-terminal region of p300 was implicated previously in ligand-dependent 
nuclear receptor signaling, although the interaction sites were not defined (10, 37). The 
closely related cyclic AMP response element binding protein-binding protein (CBP) (10, 29) 
mediated ligand-independent effects of the AR NH2-terminal region through the CBP 271–
452 amino acid region (31), and the CBP steroid receptor coactivator 1 (SRC1) interaction 
domain (SID) carboxyl-terminal residues 2058–2130 interact with SRC1 activation domain 1 
(AD1) residues 926–960 conserved among p160 coactivators (36, 38). We found that the 
ability of MAGE-11 to partner with p300 and increase AR transcriptional activity depended 
on p300 NH2-terminal FXXLF motif 
33
FGSLF
37
 in a location similar to the AR FXXLF motif. 
The p300 FXXLF motif was required for a functional interaction of the NH2-terminal region 
with TIF2, and for the MAGE-11-dependent increase in GAL-p300 transcriptional activity.  
p300 acetyltransferase activity has multiple targets that include the acetylation of 
histone tail lysine residues that opens the chromatin structure for active transcription. p300 
also acetylates nonhistone proteins such as p160 coactivators, p53 and β-catenin (29, 39–42). 
TIF2 was reported to be acetylated by CBP, and the p160 activator for thyroid hormone and 
retinoid receptors (ACTR) was acetylated by p300 and modulated the interaction of ACTR 
with nuclear receptors (43). p300 acetyltransferase activity was also linked to AR signaling. 
AR was acetylated at Lys-632 and 633 by p300 and p/CAF, a p300 associated protein (44). 
However, these basic residues are part of the AR bipartite nuclear targeting signal (45) so 
that inhibitory effects on AR nuclear transport may complicate interpretation of the 
consequences of acetylation on AR transcriptional activity. The dependence of MAGE-11 on 
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p300 acetyltransferase activity to increase AR transcriptional activity was associated with the 
acetylation of p300 and TIF2.  
Protein stability and function are influenced by the competing and complementary 
effects of acetylation and ubiquitinylation at lysine residues (28). For example, p300 
regulates the levels of p53 by promoting p53 degradation through association with the 
MDM2 E3-like ubiquitin ligase (46). Although MAGE-11 was not acetylated by p300, p300 
inhibited MAGE-11 ubiquitinylation through an acetylation-independent mechanism. The 
transient increase in endogenous MAGE-11 when p300 was expressed appeared to be cell 
cycle regulated, in agreement with evidence that MAGE-11 is cell cycle regulated in CWR-
R1 prostate cancer cells (6).  
MAGE-11 is monoubiquitinylated at Lys-240 and 245 and undergoes 
polyubiquitinylation in association with its degradation (7). While the E3 ligase that 
ubiquitinates MAGE-11 has not been identified, some evidence suggests that MAGE-11 
itself functions as part of a ubiquitin ligase complex. MAGE-11 contains an F-box similar to 
the F-box in S-phase kinase-associated protein 2 (Skp2) and MAGE-11 interacted with Skp1 
(6). p300 was reported to have E4 ubiquitin ligase activity (47) that could influence the 
ubiquitinylation of MAGE-11. The requirement for the MAGE-11 F-box for p300 NH2-
terminal transcriptional activity suggests a role for a ubiquitin ligase.  
A Primate-Specific AR Transcriptional Scaffold–The evolution of MAGE-11 among 
primates suggests a novel mechanism arose to increase AR signaling by facilitating 
interactions between AR, p300 and TIF2. One potential mechanism is that MAGE-11 
functions as a transcription factor scaffold assembly protein for AR. A similar function as 
transcription factor nucleation site has been attributed to p300 to increase gene expression at 
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select enhancers and function as a bridge between DNA binding nuclear receptors and 
transcription factors to the basal transcriptional machinery (48, 49). Many transcription 
factors, nuclear receptors, and signaling molecules interact with p300, which is thought to be 
rate limiting and redistributes among different classes of transcription factor complexes (50). 
Competition may exist in recruiting p300 to nuclear receptor regulated enhancers. Interaction 
between MAGE-11 and p300 could enhance AR mediated gene regulation through the more 
efficient recruitment of a limiting set of factors that include p300, p160 coactivators and 
components of the general transcriptional machinery.  
p300 and CBP were shown to increase androgen-dependent and ligand-independent 
AR transactivation in prostate cancer (44, 51, 52). However, p300 protein levels decrease in 
prostate cancer cells in response to androgen (53), and p300 mRNA levels were unchanged 
in the CWR22 human prostate cancer xenograft during tumor progression to castration-
recurrent growth, when AR mRNA levels increased ~5 fold (9). In contrast, MAGE-11 
mRNA levels increased ~50 fold in the castration-recurrent CWR22 tumor, and up to 1000 
fold in a subset of castration-recurrent prostate cancer tissue specimens. The increase in 
MAGE-11 in castration-recurrent prostate cancer provides a mechanism for AR to more 
effectively recruit p300 and TIF2 and increase transactivation of AR target genes when 
circulating androgen levels are low.  
MAGE-11 and the Adenovirus Early Protein, E1A–p300 was first identified based on 
its interaction with the adenovirus early oncoprotein E1A that targets p300 during viral 
infection (31, 35, 54, 55). Sequence similarity between the NH2-terminal regions of MAGE-
11 and E1A suggested that MAGE-11 may share properties of E1A and interact with p300. 
Binding to E1A decreased p300 transcriptional activity through the modification of histone 
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acetyltransferase (HAT) activity (35, 56–58). MAGE-11 did not interact with the HAT 
domain of p300, but inhibited p300 acetylation of TIF2. Inhibition of p300 HAT activity was 
also associated with p300 phosphorylation at Ser-89 (59), suggesting that allosteric effects 
extend from the p300 NH2-terminal region and could be influenced by MAGE-11.  
E1A also has a modular structure of interaction motifs for transcriptional regulators 
associated with the induction of S phase of the cell cycle, cell immortalization, cell 
transformation and transcriptional regulation (60–62). Based on evidence that E1A binds 
p300 and promotes cell growth, it was suggested that p300 functions as a tumor suppressor 
(29). The E1A FX(D/E)XXXL motif sequence 
66
FPDSVML
72
 was reported to interact with 
one of several domains in p300/CBP (63). MAGE-11 contains the similar FX(D/E)XXXL 
motif sequence 
66
FREQANL
72
 in the same relative position to the NH2-terminus as in E1A. 
However, single amino acid mutations in the MAGE-11 FX(D/E)XXXL motif did not 
interfere with p300 binding (data not shown), suggesting that other MAGE-11 regions 
possibly homologous to E1A bind p300 (60). Instead, interaction between MAGE-11 and 
p300 depended on the MAGE-11 MXXIF motif sequence 
185
MDAIF
189
, and secondarily on 
the IXXIF sequence 
94
ITQIF
98
, as well as the MAGE-11 F-box and on MAP kinase 
phosphorylation. The MAGE-11 
185
MXXIF
189
 motif and Ser-174 MAP kinase site are in 
close proximity and homologous to a region in E1A. The reported E1A FX(D/E)XXXL 
interaction site for p300 is preceded by 
62
VSQIF
66
 which, based on sequence homology and 
position, could be a previously unrecognized E1A interaction site for p300.  
While there is no known human genomic counterpart for E1A, sequence similarity 
between MAGE-11 and E1A suggests that MAGE-11 may share some of the functional 
properties of E1A. The late evolutionary species-specific expansion of the MAGE gene 
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family among primates suggests that like E1A, MAGE-11 may have hijacked transcription 
factor binding sites required for its function as an AR selective coregulator. 
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Figure 4-1. MAGE-11 and p300 Increase AR Transcriptional Activity. CV1 cells were 
transfected with 5 µg PSA-Enh-Luc and (A) 0.1 µg pCMV-AR, 1.5 µg pSG5-MAGE and 1.5 
µg pSG5-HA-p300 alone and together; (B) 0.1 µg pCMV-AR in the absence and presence of 
1 µg pSG5-MAGE, 2 µg pSG5-TIF2 and 2 µg pSG5-HA-p300; (C) 10 ng pCMV5 empty 
vector (p5) or pCMV-AR-(1–660) with and without 0.5 µg pSG5-MAGE and 2 µg pSG5-
HA-p300; and (D) 10 ng pCMV-AR-(1–660) with and without 0.5 µg pSG5-MAGE, 2 µg 
pSG5-TIF2 and 2 µg pSG5-HA-p300. Cells were incubated in the absence and presence of 1 
nM DHT. 
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Figure 4-2. MAGE-11 Interacts with the p300 NH2-terminal Region. (A) Schematic 
diagram of p300 interaction domains and fragments analyzed for interaction with MAGE-11. 
(B) The indicated GAL-p300 vectors (0.05 µg) were transfected into HeLa cells with 0.1 µg 
5XGAL4Luc3 and 0.05 µg pVP16 empty vector (–) or VP-MAGE. (Lower panel) COS cells 
were transfected with 8 µg GAL-p300 vectors and incubated with 1 µM MG132 for 24 h 
prior to harvest. Cell extracts (50 µg protein/lane) were analyzed on immunoblots using anti-
GAL4 DNA binding domain antibody. (C) The indicated GAL-p300 vectors (0.05 µg) were 
transfected into HeLa cells with 0.1 µg 5XGAL4Luc3 and 0.1 µg pSG5 empty vector (–) or 
pSG5-HA-MAGE-(112–429). (Lower panel) COS cells were transfected with 5 µg GAL-
p300 vectors and incubated with 1 µM MG132 for 24 h and 1 h prior to harvest. Cell extracts 
(60 µg protein/lane) were analyzed on the transblot using GAL4 DNA binding domain 
antibody. 
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Figure 4-3. MAGE-11 Domains Interact with p300. (A) Schematic diagram of MAGE-11 
showing nuclear localization signal (NLS) residues 18–22, phosphorylation sites Ser-174 (6), 
Ser-208 and Thr-360, ubiquitinylation sites Lys-240 and 245 (7), F-box residues 329–369 (6) 
and MAGE-11 fragments. HeLa cells were transfected with 0.1 µg 5XGAL4Luc3 and (B) 
0.05 µg GAL-p300-(2–300) with 0.1 µg VP16 empty vector (–) or VP-MAGE-(2–429), 112–
429, 112–362 or 112–252; (C) 0.05 µg GAL-p300-(2–300) and 0.1 µg pSG5 empty vector (–
) or pSG5-HA-MAGE-(2–429), 112–429, 112–362, 112–307, 112–298 or 112–276; (D) 25 
ng GAL-p300-(2–300) and 0.1 µg pSG5 (–) or wild-type (WT) pSG5-HA-(112–429) or 
indicated F-box mutant; (E) 0.05 µg GAL-p300-(2–300) and 0.1 µg pSG5 (–) or WT pSG5-
HA-MAGE-(112–429) or S174A, S174D, S298A or S298D mutant. (F) In vitro interaction 
between MAGE-11 and p300 was tested using GST-p300-(2–357) and [35S]-labeled MAGE-
11. The input represents 10% of the total reaction. 
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Figure 4-4. Identification of MAGE-11 
185
MDAIF
189
 and 
94
ITQIF
98
 Interaction Sites for 
p300. (A) Schematic diagram of MAGE-11 showing 
94
ITQIF
98
 and 
185
MDAIF
189
 interaction 
motifs for p300, 
260
FPEIF
264
 interaction motif for TIF2, MAGE-11 F-box (residues 329–369) 
interaction site for the AR FXXLF motif (6), nuclear localization signal (NLS), Ser-174 and 
Thr-360 phosphorylation sites, Lys-240 and 245 ubiquitinylation sites, and MAGE-11 
fragments to test the interaction with p300. (Inset) GAL-MAGE fragments were expressed in 
COS cells transfected with 6 µg DNA and incubated with 1 µM MG132 for 24 h and 1 h 
prior to harvest. The transblot of cell extracts (100 µg/lane) was probed using GAL4 DNA 
binding domain antibody. (B) HeLa cells were transfected with 0.1 µg 5XGAL4Luc, 0.05 µg 
GAL-MAGE fragments and 0.15 µg pSG5 empty vector (–) or pSG5-HA-p300. (C) HeLa 
cells were transfected with 0.1 µg 5XGAL4Luc3, 0.05 µg GAL-MAGE fragments and 0.1 
µg pSG5 (–) or pSG5-HA-p300. (Lower panel) GAL-MAGE fragments were expressed in 
COS cells transfected with 5 µg DNA and incubated with 1 µM MG132 for 24 h prior to 
harvest. The transblot of cell extracts (80 µg/lane) was probed using GAL4 DNA binding 
domain antibody. (D) Dependence of AR transcriptional activity on p300 and MAGE-11 
185
MDAIF
189
 motif was performed by transfecting CV1 cells with 0.1 µg pCMV-AR and 3 
µg PSA-Enh-Luc in the absence and presence of 1 µg pSG5-MAGE, 2 µg pSG5-TIF2 and 2 
µg pSG5-HA-p300. Cells were incubated for 48 h in the absence and presence of 1 nM DHT. 
(Inset) Expression was verified in COS cells transfected with 3 µg pSG5 empty vector DNA 
(–) (lane 1), wild-type (WT) pSG5-MAGE (lane 2), and I188A,F189A and I97A,F98A 
mutants (lanes 3 and 4). Cell extracts (10 µg/lane) were probed using FLAG-MAGE 
antibody-1 (0.5 μg/ml). 
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Figure 4-5. Functional Effects of AR and p300 NH2-terminal FXXLF Motifs. (A) AR 
NH2-terminal 
23
FQNLF
27
 and p300 NH2-terminal 
33
FGSLF
37
 FXXLF motifs (red) are flanked 
by basic and acidic residues (cyan). (B) Two hybrid interaction between AR and p300 NH2-
terminal regions was performed in HeLa cells transfected with 0.1 µg 5XGAL4Luc3 and 
0.05 µg GAL0 empty vector (–) or GAL-p300-(2–300), 48–300 or 90–300, and 0.1 µg VP16 
empty vector (–) or wild-type (WT) VP-AR-(1–660) or L26A,F27A (LFAA) mutant. (C) 
HeLa cells were transfected with 0.1 µg/ml 5XGAL4Luc3, 0.05 µg GAL0 empty vector (–), 
GAL-p300-(2–300) or 48–300 with 0.1 µg VP16 empty vector (–) or full-length AR fusion 
vectors VP-AR WT, L26A,F27A (LFAA) or ∆9–28 mutant. Cells were incubated in the 
absence and presence of 10 nM DHT. (D) HeLa cells were transfected with 0.1 µg 
5XGAL4Luc3 and 0.05 µg GAL-p300-(2–300), 48–300 and L26A,F27A (LFAA) with 0.1 
µg pSG5 empty vector (–) or pSG5-TIF2. 
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Figure 4-6. Dependence of GAL-p300-(2–300) Transcriptional Activity on MAGE-11 
and TIF2. (A) Inhibition of MAGE-11 (upper panel) and TIF2 (lower panel) expression by 
siRNA was performed by transfecting COS cells using Lipofectamine 2000 with 1 µg pSG5 
empty vector (lane 1), 1 µg pSG5-MAGE (top panel) or pSG5-TIF2 (bottom panel) in the 
absence and presence of 5 nM MAGE-11 siRNA-2 or 3, TIF2 siRNA-3 and nonspecific (NS) 
siRNA-5. The next day cells were harvested (TIF2) or transferred to fresh serum-free 
medium and harvested 24 h later (MAGE-11). Cell extracts for MAGE-11 (10 µg 
protein/lane) and TIF2 (40 µg protein/lane) were analyzed on transblots probed with MAGE-
Ab-(94–108), TIF2 and β-actin antibodies. (B) HeLa cells (105/well in 12 well plates) were 
transfected using Lipofectamine 2000 with 0.1 µg 5XGAL4Luc3 and 0.05 µg GAL-p300-(2–
300) in the absence and presence of 0.1 µg pSG5 empty vector (–) or pSG5-TIF2 in the 
absence and presence of 5 nM nonspecific siRNA-5 (NS-5), MAGE-11 siRNA-2 or 3, and 
TIF2 siRNA-3. 
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Figure 4-7. MAGE-11 Links p300 to AR N/C Interaction-Mediated Transactivation. (A) 
HeLa cells were transfected with 0.1 µg PSA-Enh-Luc and 50 ng pCMV-AR-(507–919) with 
and without 25 ng wild-type pCMV-AR-(1–503) or the L26A,F27A (LFAA) mutant, 25 ng 
pSG5-MAGE and 25 ng pSG5-HA-p300. (B) COS cells were transfected using 
Lipofectamine 2000 with 2 µg pSG5-HA-p300 and 10 nM nonspecific siRNA-5, 10 nM 
p300 siRNA 1–4 or without siRNA. Cell extracts were prepared in IB lysis buffer and probed 
on a transblot (15 µg protein/lane) using p300 and β-actin antibodies. (C) HeLa cells (1.2 x 
10
5
/well in 6 well plates) were transfected using Lipofectamine 2000 with 0.1 µg PSA-Enh-
Luc, 50 ng pCMV-AR-(507–919), 25 ng pCMV-AR-(1–503) and 25 ng pSG5-MAGE 
without siRNA or with 5 nM nonspecific siRNA-5 (NS5) or p300 siRNA 1–4. Cells were 
incubated for 24 h in serum-free media with and without 10 nM DHT. (D) HeLa cells were 
transfected with 0.1 µg PSA-Enh-Luc, 50 ng pSG5 empty vector (–), wild-type (WT) pSG5-
HA-p300 or D1399Y (DY) acetylation mutant, 15 ng wild-type (WT) or the indicated pSG5-
MAGE mutant, and 0.1 µg GAL-AR-(16–36) or L26A,F27A (LFAA) mutant. 
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Figure 4-8. Dependence of AR Transcription Activity on p300 Acetyltransferase 
Activity. (A) CV1 cells were transfected with 0.1 µg pCMV-AR and 3 µg PSA-Enh-Luc in 
the absence and presence of 1 µg pSG5-MAGE, 2 µg pSG5-TIF2 and 2 µg wild-type (WT) 
pSG5-HA-p300 or D1399Y acetyltransferase mutant (DY). Cells were incubated for 48 h in 
the absence and presence of 1 nM DHT. (B) HeLa cells were transfected with 0.1 µg/ml 
5XGAL4Luc3 and 0.05 µg GAL-MAGE-(85–205) or 140–205 with 0.15 µg pSG5 empty 
vector (–), wild-type (WT) pSG5-HA-p300 or D1399Y mutant (DY). (Lower panel) 
Expression levels were determined in COS cells transfected with 5 µg pSG5 empty vector (–) 
(lane 1), wild-type (WT) pSG5-HA-p300 (lane 2) and D1399Y acetyltransferase mutant (lane 
3). Cell extracts (30 µg/lane) on the transblot were probed using p300 antibody. (C) 
Inhibition of MAGE-11 ubiquitinylation by p300 and p300-D1399Y was demonstrated in 
COS cells transfected with 6 µg FLAG empty vector or FLAG-ubiquitin (Ub) and 3 µg 
pSG5-HA-MAGE-(112–429) in the absence and presence of 5 µg pSG5-HA-p300 or the 
D1399Y acetyltransferase mutant. Cells were incubated in the absence and presence of 0.1 
µg/ml EGF and immunoprecipitated using anti-FLAG M2 affinity resin. The transblot was 
probed with HA antibody. 
 
A 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  B 
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Figure 4-9. MAGE-11 Influences p300 Acetylation of TIF2. (A) Coimmunoprecipitation 
of acetylated TIF2 and p300 with FLAG-MAGE was performed in COS cells transfected 
with 4 µg FLAG empty vector (–) or FLAG-MAGE in the absence and presence of 5 µg 
pSG5 empty vector (–) or pSG5-TIF2, and 5 µg wild-type (WT) pSG5-HA-p300 or D1399Y 
mutant. Cells were incubated with 0.1 µg/ml EGF for 24 h prior to harvest and with 5 mM 
nicotinamide 1 hr prior to harvest. Cell extracts prepared in IP lysis buffer containing 5 mM 
nicotinamide were immunoprecipitated overnight at 4C. Immunoprecipitates and cell 
extracts (50 µg protein/lane) were probed using FLAG, p300, TIF2 and acetylated-lysine 
antibodies. (B) Inhibition of p300-mediated acetylation of TIF2 by MAGE-11 was 
determined by expressing 5 µg FLAG empty vector (–) or FLAG-TIF2 with 5 µg pSG5 
empty vector (–), pSG5-HA-p300 or D1399Y mutant with and without 1 µg pSG5-MAGE. 
Cells were incubated in serum-free media with 0.1 µg/ml EGF for 24 h prior to harvest, and 
with 5 mM nicotinamide and 5 mM sodium butyrate for 1 h prior to harvest in IP lysis buffer 
containing 5 mM nicotinamide and 5 mM sodium butyrate. Immunoprecipitates and cell 
extracts (30 µg protein/lane for p300, 50 µg/lane for acetylated lysine, 70 µg/lane for FLAG-
TIF2 and MAGE-11) were probed on transblots using antibodies for FLAG-MAGE-11, 
FLAG and TIF2, p300 and acetylated-lysine. 
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Figure 4-10. Transient Increase in Endogenous MAGE-11. COS cells were transfected 
with 6 µg pSG5-HA-p300 or pSG5 empty vector. The next day cells were transferred to 
serum-free phenol red-free medium and 24 h later to fresh serum-free medium. Cells were 
harvested at the indicted times, cell extracts prepared in IB lysis buffer and 40 µg 
protein/lane analyzed with the transblot probed using p300 antibody and 10 µg/ml each of 
MAGE-11 antipeptide antibodies 13–26, 59–79 and 94–108. 
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Figure 4-11. Functional Interactions Between AR, MAGE-11, p300 and TIF2. AR 
transcriptional activity is increased through interactions with MAGE-11, p300 and TIF2. AR 
contains a centrally located DNA binding domain (DBD) and activation function 1 (AF1) 
region in the NH2-terminal region. AR NH2-terminal FXXLF motif 
23
FQNLF
27
 interacts with 
the AR activation domain 2 (AF2) region of the ligand binding domain (LBD) in the 
androgen-dependent AR N/C interaction, and with the MAGE-11 F-box residues 329–369 
(6). MAGE-11 contains the MXXIF motif sequence 
185
MDAIF
189 
that interacts with the NH2-
terminal region of p300, and the FXXIF motif 
260
FPEIF
264
 that interacts with TIF2 (6). A 
p300 NH2-terminal FXXLF motif 
33
FGSLF
37
 interacts with TIF2, and TIF2 LXXLL motif 
745
LRYLL
749
 interacts with AF2 in the AR LBD. These motif driven interactions occur in a 
temporal and/or competitive manner that are influenced by the cell cycle and post-translation 
modification that includes phosphorylation, ubiquitinylation and acetylation. The acetylase 
activity of p300 is required for MAGE-11 and TIF2 to increase AR transcriptional activity. 
 
 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 5  
 
SUMMARY AND FUTURE PERSPECTIVES 
 
Molecular Determinants of Testosterone (T) and Dihydrotestosterone (DHT) Binding to the 
Androgen Receptor (AR) 
Based on our research, one can begin to associate how the different physical 
properties of androgens influence the molecular effects of T and DHT on AR mediated gene 
activation. Both T and DHT are 19 carbon steroids that only differ in the presence of a 
double bond in the A-ring of T that is absent in DHT. Our data suggest this subtle difference 
confers more hydrophilic character to T, which is reflected in the fact that T is 10 fold more 
water soluble than DHT, and that DHT is the more potent androgen in vivo. This is 
detrimental to AR activity and activation function 2 (AF2) FXXLF and LXXLF motif 
interactions.  
The ligand binding pocket as well as the AR AF2 surface are hydrophobic in nature 
and thus, AR binding of DHT results in a more stable protein structure conducive for optimal 
AR transcriptional activity and AF2 motif binding. T is positioned in a more planar 
configuration within the AR ligand binding pocket, resulting in reduced inter-atomic 
distances and increased hydrogen bonding potential between a conserved water, the steroid 
A-ring, and AR helix 5 residue Met-745 that lies proximal to the steroid A-ring. Met-745 
projects towards the AF2 surface and potentially interacts with AR residue Leu-712, which 
contacts the FXXLF and LXXLL motifs and is implicated in androgen insensitivity syndrome. 
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The prostate cancer mutant AR-H874Y binds both T and DHT with high affinity yet 
more effectively interacts with the AR FXXLF motif. This is reflected in the slower 
dissociation rate of T as well as increased T-induced AR-H874Y transactivation. While 
crystal structures reveal that the ligand binding pockets of DHT and T bound AR LBD are 
similar, AR-H874Ycompensates by stabilizing the LBD and AF2 via the replacement of a 
water-mediated hydrogen bonding network with a direct-hydrogen bonding network. Protein 
flexibility is increased by structured water molecules involved in multiple H-bonds whereas 
direct protein-mediated H-bonds provide a more rigid foundation. Our findings suggest that 
altered H-bond chemistry may compensate for diminished AR activity and AF2 motif 
interactions, and reveals a possible mechanism for how somatic mutations in castration-
recurrent prostate cancer modulate AR transactivation in the androgen-depleted patient.  
Mechanisms of the Melanoma Antigen Gene Protein-A11 (MAGE-11) Dependent Increase in 
Androgen Receptor Gene Mediated Transcription 
We explored the functional characteristics underlying the MAGE-11 dependent 
increase in androgen receptor (AR) transcriptional activation. The site of interaction in 
MAGE-11 that binds the AR FXXLF motif is a highly conserved F-box within a carboxyl-
terminal MAGE homology domain between residues 329 and 369. This interaction is 
regulated by serum-induced MAP kinase phosphorylation of MAGE-11 Ser-174, which is 
required for the MAGE-11 F-box interaction with the AR FXXLF motif. MAGE-11 also 
increases AR gene mediated activation through direct interactions with transcriptional 
intermediary factor 2 (TIF2) and p300, which possesses histone acetyltransferase activity. 
Our studies suggest that MAGE-11 functions as a bridging factor that recruits AR 
coactivators through interactions involving FXX(L/I)F motifs with F-box containing proteins. 
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Interestingly, Skp1 contains an 
101
FELIL
105
 FXXLF motif within its Skp2 binding region (1), 
further supporting the functional significance of our findings. Thus, our studies also reveal a 
potential regulatory mechanism in which an FXXLF motifs serve as the docking site for F-
box containing proteins.  
The MAGE-11 interaction with AR and associated coregulators provides a 
mechanism for increased AR action in castration-recurrent prostate cancer, when circulating 
androgen levels are low and MAGE-11 levels increase (2,3). This raises an interesting issue 
surrounding the potential relevance and function of F-box proteins in cancer development. 
Wang et al. identified an AR-Skp2 pathway in prostate-cancer cells which promotes 
proliferation independent of differentiation (4), and Skp2 is overexpressed in primary 
prostate cancer samples (5). Additionally, the F-box protein FBXW7 has been detected in 
human malignancies including gastric, pancreatic, and prostate cancer (6). The identification 
of upregulated and/or mutated F-box proteins in human malignancies suggests a universal 
mechanism underlying cancer progression and presents a previously unidentified therapeutic 
target. 
MAGE-11 as a Prostate Cancer Therapeutic Target 
The progression of prostate cancer to a castration-recurrent state is associated with 
AR-mediated signaling, which can be enhanced by overexpressed AR coactivators. Since 
current prostate cancer treatments are not curative, it is vital to identify new prostate cancer 
therapeutic targets to improve the life of the patient. In light of this, it is intriguing that the 
cancer-testis antigens have become the subject of antineoplastic therapy due to their 
restrictive expression profile in normal tissues, high expression in various tumors and their 
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ability to induce an immunogenic response. Recent data suggest that the expression of 
MAGE genes in cancer cells contributes to the malignant phenotype and response to therapy. 
Data from our studies presented here suggest that a vaccine targeting MAGE-11 
might be an effective therapeutic tool to combat prostate cancer progression following 
androgen deprivation therapy. In support of this, a portion of melanoma patients treated with 
an experimental MAGE-A3 peptide in a clinical trial experienced tumor regression (7), while 
a clinical trial evaluating the effectiveness of a MAGE-A4 cancer vaccine in advanced lung 
cancer is scheduled in Japan.  
A detailed investigation into the immunogenicity and effectiveness of a MAGE-11 
prostate cancer vaccine would be validated by human and primate preclinical investigations. 
In the human, an antigen capture enzyme-linked immunosorbent assay (ELISA) could be 
used to examine MAGE-11 antigen levels in serum obtained from prostate cancer patients. In 
support of this, Morrissey et al. developed an antigen capture assay to detect serum clusterin 
levels in prostate cancer patients (8). The immunogenicity of a tumor antigen may also be 
demonstrated from studies in vitro or in primates following challenge with MAGE-11 (9). 
Indeed, human MAGE-A1 overexpression has been reported to confer resistance to tumor 
necrosis factor-mediated cytotoxicity (10).  
Role of MAGE-11 in Infertility 
The Centers for Disease Control estimated that in 2009, approximately 11.8% of 
women in the U.S. between the ages of 15 and 44 presented with infertility. Female factor 
infertility is associated with ovulatory disorders including PCOS, endometriosis, tubal 
factors, and implantation failure (11). The role of implantation failure in infertility is not well 
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defined. Thus, new developments in the evaluation and identification of factors affecting 
endometrial receptivity may lead to the diagnosis of specific implantation defects.  
MAGE-11 should be of particular interest in the search for an intrinsic cause of 
female factor infertility related to implantation since MAGE-11 is temporally expressed 
throughout the menstrual cycle. MAGE-11 regulates AR transcriptional activity through the 
modulation of the AR N/C interaction and direct interaction with p160 coactivators as well as 
p300 (1-3), which are also expressed in human endometrium (12,13). Therefore, one could 
speculate that low levels and/or defects in the MAGE-11 gene exist and play a role in 
impaired endometrial receptivity.  
To study this possibility, researchers could sequence the MAGE-11 gene in genomic 
DNA obtained from patients presenting with infertility. It would also be interesting to 
determine whether MAGE-11 could be used as a screening tool to evaluate for the risk of 
infertility associated with implantation receptivity in the endometrium. This would require 
knowledge of whether or not MAGE-11 levels are altered in females unable to bear children. 
Comparisons of MAGE-11 mRNA and protein expression levels in tissue samples from 
normal and infertile patients would provide necessary preliminary evidence required to 
proceed with broader clinical trials investigating the potential of MAGE-11 as a biomarker 
and screening tool for female factor infertility.  
Studies have also shown a positive correlation between gene therapy and disease 
outcome (14,15). Thus, if studies reveal a relationship between MAGE-11 levels and/or 
MAGE-11 genetic defects and fertility, MAGE-11 could be a therapeutic target for infertility. 
Viral vectors targeted towards MAGE-11 could be used to endogenous levels or replace a 
defective copy during the critical window of endometrial receptivity.  
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